As Filed With the Securities and Exchange Commission on March 13, 2002
Registration No. 333-76190
===============================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------
AMENDMENT NO. 1
TO
FORM S-1
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
----------------
Innovative Drug Delivery Systems, Inc.
(Exact Name of Registrant As Specified In Its Charter)
Delaware 2834 3027473
(State or Other Jurisdiction of (Primary Standard Industrial (I.R.S. Employer
Incorporation or Organization) Classification Code Number) Identification Number)
----------------
787 Seventh Avenue, 48th Floor
New York, New York 10019
(212) 554-4550
(Address, Including Zip Code, and Telephone Number, Including Area Code, of
Registrant's Principal Executive Offices)
----------------
Leonard L. Firestone, M.D.
Chief Executive Officer
787 Seventh Avenue, 48th Floor
New York, New York 10019
(212) 554-4550
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code,
of Agent for Service)
----------------
COPIES TO:
Luci Staller Altman, Esq. Frode Jensen, Esq. Todd Eckland, Esq.
Mark Mandel, Esq. Steven Moore, Esq. Pillsbury Winthrop LLP
Brobeck, Phleger & Harrison LLP Pillsbury Winthrop LLP One Battery Park Plaza
1633 Broadway, 47th Floor Financial Centre New York, New York 10004
New York, New York 10019 695 East Main Street (212) 858-1000
(212) 581-1600 Stamford, Connecticut 06904 Fax: (212) 858-1500
Fax: (212) 586-7878 (203) 348-3200
Fax: (203) 965-8226
----------------
Approximate date of commencement of proposed sale to the public: As soon as
practicable after the effective date of this Registration Statement.
If any of the securities being registered on this form are to be offered on a
delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, check the following box. |_|
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective
registration statement for the same offering. |_|
If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. |_|
If this Form is a post-effective amendment filed pursuant to Rule 462(d)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. |_|
If delivery of the prospectus is expected to be made pursuant to Rule 434,
check the following box. |_|
----------------
CALCULATION OF REGISTRATION FEE
- -----------------------------------------------------------------------------------------------------------------------------------
Proposed Maximum Proposed Maximum
Title of Each Class of Securities Amount to be Offering Price Per Aggregate Offering Amount of
to be Registered(1) Registered(1) Unit Price(2) Registration Fee(3)
- -----------------------------------------------------------------------------------------------------------------------------------
Common Stock, $.001 par value per
share 6,440,000 $10 $64,400,000 $5,925
===================================================================================================================================
(1) Includes shares subject to over-allotment options granted to the
underwriters.
(2) Estimated solely for the purpose of calculating the registration fee in
accordance with Rule 457(o) under the Securities Act of 1933, as amended.
(3) The Registrant previously paid $16,491 in connection with the original
filing of the registration statement.
The registrant hereby amends this registration statement on such date or
dates as may be necessary to delay its effective date until the registrant shall
file a further amendment which specifically states that this registration
statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933 or until the registration statement shall become
effective on such date as the Securities and Exchange Commission, acting
pursuant to said Section 8(a), may determine.
===============================================================================
- --------------------------------------------------------------------------------
The information in this prospectus is not complete and may be changed. We may
not sell these securities until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus is not an offer
to sell these securities, and it is not soliciting offers to buy these
securities, in any state in which the offer or sale is not permitted.
- --------------------------------------------------------------------------------
SUBJECT TO COMPLETION, DATED MARCH 13, 2002
PROSPECTUS
[LOGO]
[LOGO][IDDS]
Innovative Drug Delivery Systems, Inc.
5,600,000 Shares
Common Stock
- -------------------------------------------------------------------------------
We are selling 5,600,000 shares of our common stock. We have granted the
underwriters a 30-day option to purchase up to an additional 840,000 shares to
cover over-allotments, if any.
This is an initial public offering of our common stock. We currently expect
the initial public offering price to be between $8.00 and $10.00 per share. We
have applied for approval for quotation of our common stock on the Nasdaq
National Market under the symbol "IDDS."
- -------------------------------------------------------------------------------
INVESTING IN OUR COMMON STOCK INVOLVES RISKS. SEE "RISK FACTORS" BEGINNING
ON PAGE 7.
- -------------------------------------------------------------------------------
Per Share Total
Public offering price $ $
Underwriting discount $ $
Proceeds, before expenses, to us $ $
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a
criminal offense.
- -------------------------------------------------------------------------------
Thomas Weisel Partners LLC
Wells Fargo Securities, LLC
Jefferies & Company, Inc.
The date of this prospectus is , 2002
[LOGO][IDDS]
TABLE OF CONTENTS
Page
----
Prospectus Summary ...................................................... 1
Risk Factors ............................................................ 7
Information Regarding Forward-Looking Statements ........................ 18
Use of Proceeds ......................................................... 19
Dividend Policy ......................................................... 19
Capitalization .......................................................... 20
Dilution ................................................................ 21
Selected Financial Data ................................................. 23
Management's Discussion and Analysis of Financial Condition and Results
of Operations.......................................................... 25
Business ................................................................ 30
Management .............................................................. 51
Relationships and Related Party Transactions ............................ 61
Principal Stockholders .................................................. 63
Description of Capital Stock ............................................ 65
Shares Eligible for Future Sale ......................................... 68
United States Federal Income Tax Consequences to Non-U.S. Holders ....... 70
Underwriting ............................................................ 72
Legal Matters ........................................................... 75
Experts ................................................................. 75
Where You Can Find More Information ..................................... 75
Index to Financial Statements ........................................... F-1
PROSPECTUS SUMMARY
This summary highlights information contained elsewhere in this prospectus.
You should read the entire prospectus carefully, including the "Risk Factors"
section.
Our Company
We are a specialty pharmaceutical company that applies proprietary
technologies to develop new drugs and improved formulations of existing drugs
for the prescription pain management market. We believe that our product
candidates address unmet medical needs for breakthrough cancer pain,
postoperative pain, lower-back pain, pain due to orthopedic injury, dental pain
and other indications. We believe our product candidates offer a combination of
enhanced pain relief, improved side effect profiles and faster onset of pain
relief compared to currently available treatments. Our lead product candidates
have demonstrated safety and effectiveness in early- and mid-stage clinical
trials and we expect to begin late-stage clinical trials in the second half of
2002.
Our Opportunity
Drugs are a key element in the treatment of pain. The worldwide market for
therapeutics to manage pain is expected to grow from $22 billion in 2000 to $30
billion in 2007 according to Frontline Strategic Management Consulting, Inc. Our
product candidates target a $3.4 billion subsegment of the worldwide pain
management market.
Our Product Candidates
We are developing prescription drugs for the treatment of a variety of acute
and chronic moderate-to-severe pain syndromes. We selected our product
candidates based on our belief that they offer significantly lower clinical,
regulatory and commercial risk profiles as compared to new chemical entities, or
NCEs. All of our product candidates contain drugs approved for other uses by the
U.S. Food and Drug Administration, or FDA. We are developing proprietary
formulations for these drugs in order to deliver therapeutic levels into the
bloodstream through fast and effective routes of administration.
Our current product candidates according to clinical indication and their
stages of clinical development in the United States and the United Kingdom are:
Product Candidate Clinical Indication Development Stage
----------------- ----------------------- -----------------
Intranasal Ketamine Acute Pain and Acute Episodes of Phase II
Chronic Moderate-to-Severe Pain
Intranasal Morphine Acute Pain and Acute Episodes of Phase II
Chronic Moderate-to-Severe Pain
Intravenous Diclofenac Acute Moderate-to-Severe Pain Phase II
Intranasal Fentanyl Acute Episodes of Chronic Preclinical
Moderate-to-Severe Pain
Intranasal Ketamine
Our intranasal ketamine product candidate is in clinical development for the
treatment of syndromes associated with acute and chronic moderate-to-severe
pain. Ketamine is an FDA-approved drug that has been in clinical use for over 25
years for general anesthesia. At lower doses than that approved for use as an
anesthetic, ketamine has been reported to be an effective analgesic for the
treatment of breakthrough pain, postoperative pain and pain associated with
emergency medical procedures. We have licenses to two U.S. patents and their
foreign counterparts directed towards the use of ketamine to manage pain and the
administration of ketamine through the nasal route.
1
In the third quarter of 2001, we successfully completed three Phase II
clinical trials evaluating the safety and effectiveness of intranasal ketamine
for the treatment of acute and chronic moderate-to-severe pain following dental
surgery and for breakthrough episodes of chronic malignant pain. The results of
these studies demonstrated that intranasal ketamine provides rapid onset of pain
relief with dose-related effectiveness and duration of effect, and appears to be
well-tolerated. Based on the results of these studies, we believe that
intranasal ketamine may offer a safe, non-opioid alternative for the treatment
of moderate-to-severe postoperative pain and breakthrough pain. To date, we have
enrolled a total of 118 patients in our intranasal ketamine clinical trials. We
expect to file the data from our Phase II clinical trials and our proposed Phase
III clinical trial designs with the FDA in the first half of 2002.
Intranasal Morphine
Our intranasal morphine product candidate is in clinical development for the
treatment of syndromes associated with acute pain and acute episodes of chronic
pain. Morphine is a strong opioid analgesic that is used for the relief of acute
and chronic moderate-to-severe pain and is the drug of choice for pain
associated with cancer. Orally delivered morphine products may not provide rapid
relief of pain and demonstrate considerable patient-to-patient variability in
absorption. Injectable formulations of morphine provide rapid and effective pain
relief, but administration often requires professional assistance or
hospitalization. We believe our intranasal morphine product candidate would
provide significant medical benefit over oral and injectable formulations as it
combines patient convenience and ease of use with the rapid onset of pain relief
and the well-accepted potency of injectable delivery routes. We have licenses to
two U.S. patents and their foreign counterparts directed towards the use of
intranasal morphine.
Based on the results of both single- and multiple-dose Phase I clinical
trials, conducted on behalf of our licensor, in the third quarter of 2001 we
initiated a Phase II clinical trial to evaluate the safety and effectiveness of
intranasal morphine for the management of acute postoperative pain. This study
will compare two different doses of intranasal morphine with placebo and with
both intravenous and oral morphine in a total of 225 patients suffering from
moderate-to-severe pain following dental surgery. Our Phase I clinical trials
demonstrated that intranasal morphine is rapidly absorbed, achieving blood
levels typically associated with analgesic effectiveness in as early as five to
ten minutes following administration. We expect to complete our Phase II
clinical trials in the first quarter of 2002 and to present the data from our
clinical trials and proposed Phase III clinical trial design to the FDA in the
first half of 2002.
Intravenous Diclofenac
Our intravenous diclofenac product candidate is in clinical development for
the management of acute postoperative pain in the hospital setting. Diclofenac
belongs to the class of nonsteroidal anti-inflammatory drugs, or NSAIDs, and is
widely prescribed as an anti-inflammatory agent due to its combination of
effectiveness and tolerability. While currently approved for use in the U.S. in
a variety of oral formulations, as well as a topical and an ophthalmic
formulation, its poor solubility in water and susceptibility to breakdown has
precluded the development of an injectable formulation of diclofenac. We believe
that our intravenous diclofenac product candidate has the potential to overcome
these issues and satisfy the unmet medical need for a safe and effective
injectable NSAID in the hospital setting. We have licenses to one U.S. patent
and its foreign counterparts directed towards intravenous diclofenac
formulations and methods of preparing the same.
Our intravenous diclofenac product candidate has been evaluated in over 270
human subjects in Phase I clinical trials performed in South Africa and Phase II
clinical trials performed in the United Kingdom, with both sets of trials
conducted on behalf of a third party. Based on the encouraging results of these
clinical trials, combined with the extensive published literature on the safety
and effectiveness of diclofenac, the FDA has indicated that Phase I and single
dose Phase II clinical trials in the United States may be initiated concurrently
upon allowance of an Investigational New Drug Application, or IND. We anticipate
filing an IND for our intravenous diclofenac product candidate in the first half
of 2002 in order to initiate a U.S. clinical development program.
2
Intranasal Fentanyl
Our intranasal fentanyl product candidate is currently in preclinical
development for the treatment of acute episodes of chronic moderate-to-severe
pain. Fentanyl is a widely prescribed and effective short-acting opioid
analgesic that is 75-100 times more potent than morphine and is used for
treating chronic moderate-to-severe pain, including cancer pain. When
administered using a transdermal patch that provides a controlled rate of
delivery, fentanyl is effective in controlling the chronic pain associated with
cancer. An oral, transmucosal formulation of fentanyl was approved by the FDA in
1998 specifically for the treatment of breakthrough pain in cancer patients and
is used as an adjunct to the fentanyl patch to control these flare-up pain
episodes.
We believe that our intranasal fentanyl product candidate could also be used
to complement the fentanyl transdermal patch, as well as controlled-release
formulations of oral opioids, to effectively treat episodes of breakthrough
pain. Our intranasal fentanyl product candidate may offer several advantages
over existing fentanyl-based products for the management of breakthrough pain,
including rapid and consistent onset of action, coupled with certain cost and
safety advantages. In addition, intranasal fentanyl could have advantages for
patients who are unable to swallow, or those with oral ulcerations resulting
from cancer chemotherapy.
Our Strategy
Our goal is to become a leading specialty pharmaceutical company that
develops and commercializes new drugs for the management of pain in order to
fulfill unmet medical needs. Key elements of our strategy to accomplish this
goal are to:
o develop new products with reduced clinical and regulatory risk,
o focus on large markets where our product candidates can address unmet
clinical needs,
o focus on clinical development and late-stage product candidates,
o retain significant rights to our product candidates,
o use our technology platforms to develop new product candidates and
o outsource key functions.
--------------------
Our predecessor, Pain Management, Inc., was formed in February 1998.
Innovative Drug Delivery Systems, Inc. was incorporated in Delaware in April
1999 and was merged with Pain Management in September 2000. Our principal
executive office is located at 787 Seventh Ave, 48th Floor, New York, New York
10019. Our telephone number at this location is (212) 554-4550. Our corporate
web site is www.idds.com. We do not intend the reference to our web address to
constitute incorporation by reference of the information contained at that site.
The information found on our site is not intended to be part of this prospectus
and should not be relied upon by you when making a decision to invest in our
common stock.
"IDDS" and our logo are trademarks of Innovative Drug Delivery Systems, Inc.
This prospectus also contains trademarks and tradenames of other parties.
3
The Offering
Common stock offered by us.................... 5,600,000 shares
Common stock outstanding after this offering.. 20,645,327 shares
Use of proceeds............................... For research and development
activities, including clinical
studies, milestone and other
payments payable under our
strategic agreements, working capital and
other general corporate purposes.
Proposed Nasdaq National Market symbol........ IDDS
The above information is based on 9,960,427 shares of common stock outstanding
as of December 31, 2001 and excludes:
o 1,367,101 shares of common stock issuable upon exercise of options then
outstanding at a weighted average exercise price of $3.93 per share,
o 406,456 shares of common stock issuable upon exercise of options granted on
February 25, 2002 at a weighted average exercise price of $5.46,
o 925,000 shares of common stock issuable upon exercise of options to be
granted on or prior to the closing of this offering at an exercise price
equal to the initial public offering price,
o 624,146 shares of common stock issuable upon exercise of warrants then
outstanding at a weighted average exercise price of $2.58 per share, and
o 442,395 shares of common stock issuable upon the exercise and assumed
conversion of 15.83 unit purchase options, which entitle the holders to
purchase 395,788 shares of our series A convertible preferred stock
(convertible into 402,177 shares of common stock) at $4.40 per share and a
warrant to purchase 40,218 shares of common stock at $3.94 per share.
Unless otherwise noted, this prospectus:
o assumes no exercise of the underwriters' over-allotment,
o assumes an initial public offering price of $9.00 per share,
o gives effect to an approximate 1.0161-for-one stock split in the form of a
stock dividend on our common stock to be effected in connection with this
offering, and
o reflects the automatic conversion, on approximately a 1.0161-for-one basis,
of 5,004,116 shares of our outstanding series A and series B convertible
preferred stock into 5,084,900 shares of our common stock upon the closing
of this offering.
4
Summary Financial Data
Period from Period from
February 23, February 23,
1998 Year Ended 1998
(inception) to December 31, (inception) to
December 31, ------------------------------- December 31,
1998 1999 2000 2001 2001
-------------- ------- -------- -------- --------------
(in thousands, except per share data)
Statement of Operations Data:
Revenues:
Government grants............................................ $ -- $ -- $ 306 $ 882 $ 1,188
------ ------- -------- -------- --------
Operating expenses:
Research and development (1)(2).............................. 207 665 21,833 7,009 29,714
General and administrative (3)............................... 257 312 1,353 2,286 4,208
Depreciation................................................. -- -- 1 3 4
------ ------- -------- -------- --------
Total operating expenses..................................... 464 977 23,187 9,298 33,926
------ ------- -------- -------- --------
Interest (expense) income, net................................ (6) (229) (143) 349 (29)
------ ------- -------- -------- --------
Net loss...................................................... (470) (1,206) (23,024) (8,067) (32,767)
Deemed dividend related to beneficial conversion feature of
series B convertible preferred stock........................ -- -- -- (3,560) (3,560)
------ ------- -------- -------- --------
Net loss attributable to common stockholders.................. $ (470) $(1,206) $(23,024) $(11,627) $(36,327)
====== ======= ======== ======== ========
Net loss per share attributable to common stockholders:
Basic and diluted............................................ $(0.11) $ (0.28) $ (3.93) $ (1.20)
====== ======= ======== ========
Weighted average shares...................................... 4,236 4,310 5,859 9,725
====== ======= ======== ========
Pro forma net loss per share attributable to common
stockholders: (4)
Basic and diluted............................................ $ (0.84)
========
Weighted average shares...................................... 13,807
========
- ---------------
(1) Includes non-cash expense of $3 for the period from February 23, 1998
(inception) to December 31, 1998, $29 for the year ended December 31, 1999,
$18,614 for the year ended December 31, 2000 and $72 for the year ended
December 31, 2001.
(2) For the year ended December 31, 2000, includes costs associated with the
acquisition of a license agreement valued at approximately $18.6 million in
connection with our merger with Pain Management.
(3) Includes non-cash expense of $87 for the period from February 23, 1998
(inception) to December 31, 1998, $220 for the year ended December 31,
1999, $857 for the year ended December 31, 2000 and $409 for the year ended
December 31, 2001.
(4) Pro forma net loss per share data presented above assume that the
historical per share data are adjusted to reflect the conversion of all
outstanding shares of series A and series B convertible preferred stock
into common stock, on a weighted average basis, as if they had been
converted on the respective dates of issuance. Pro forma net loss per share
data for the period from February 23, 1998 (inception) to December 31, 1998
and the years ended December 31, 1999 and 2000 have been intentionally
omitted.
5
As of December 31, 2001
-----------------------------------
Pro Forma
Actual Pro Forma as Adjusted
-------- --------- -----------
(in thousands)
Balance Sheet Data:
Cash and cash equivalents...................... $ 7,744 $7,744 $51,616
Working capital................................ 6,805 6,805 50,677
Total assets................................... 8,845 8,845 52,717
Convertible preferred stock.................... 18,795 -- --
Stockholders' (deficit) equity................. (11,142) 7,653 51,525
The preceding table presents a summary of our balance sheet data as of December
31, 2001:
o on an actual basis,
o on a pro forma basis to reflect the conversion of all of our outstanding
shares of series A and series B convertible preferred stock into common
stock.
o on a pro forma as adjusted basis to give effect to:
o the sale by us of 5,600,000 shares of common stock in this offering at an
assumed initial public offering price of $9.00 per share, after deducting
the estimated underwriting discount and estimated offering expenses, and
o the payment by us of a minimum of $1.0 million and a maximum of $2.0
million in the aggregate to Shimoda Biotech (Proprietary) Ltd. and
Farmarc Netherlands B.V. (Registration No. 2807216) upon the closing of
this offering in connection with a license agreement. Assuming an
initial public offering price of $9.00 per share, the payment to Shimoda
and Farmarc will be $1.0 million, in the aggregate.
6
RISK FACTORS
An investment in our common stock involves significant risks. You should
carefully consider the following risk factors before you decide to buy our
common stock.
Risks Related To Our Company
We have no product revenues and may need to raise additional capital to operate
our business.
We are a development-stage company focused on product development and have
not generated any product revenues to date. Until, and if, we receive approval
from the FDA and other regulatory authorities for our product candidates, we
cannot sell our drugs and will not have product revenues. Therefore, for the
foreseeable future, we will have to fund all of our operations and capital
expenditures from the net proceeds of this offering, cash on hand and grants. We
expect that the assumed net proceeds of $43.9 million from this offering and
cash on hand will be sufficient to meet our working capital and capital
expenditure needs for at least the next 12 months. However, our actual capital
requirements will depend on many factors. If we experience unanticipated cash
requirements, we may need to seek additional sources of financing, which may not
be available on favorable terms, if at all. If we do not succeed in raising
additional funds on acceptable terms, we may be unable to complete planned
preclinical studies and clinical trials or obtain approval of our product
candidates from the FDA and other regulatory authorities. In addition, we could
be forced to discontinue product development, reduce or forego sales and
marketing efforts and attractive business opportunities or discontinue
operations.
We have a history of losses and we may never achieve or sustain profitability.
We have incurred substantial losses since our inception, and we may not
achieve profitability for the foreseeable future, if at all. We incurred a net
loss attributable to our common stockholders of approximately $470,000 for the
period from February 23, 1998 (inception) to December 31, 1998, $1.2 million in
1999, $23.0 million in 2000 and $11.6 million in 2001. As of December 31, 2001,
we had an accumulated net loss attributable to our common stockholders of $36.3
million. Even if we succeed in developing and commercializing one or more of our
product candidates, we expect to incur substantial net losses and negative cash
flows for the foreseeable future due in part to increasing research and
development expenses, including clinical trials, and increasing expenses from
leasing additional facilities and hiring additional personnel. As a result, we
will need to generate significant revenues in order to achieve and maintain
profitability. We may not be able to generate these revenues or achieve
profitability in the future. Even if we do achieve profitability, we may not be
able to sustain or increase profitability.
We have a limited operating history upon which to base an investment decision.
We commenced operations in 1998. Our limited operating history may limit your
ability to evaluate our prospects due to our limited historical financial data
and our unproven potential to generate profits. You should evaluate the
likelihood of financial and operational success in light of the risks,
uncertainties, expenses and difficulties associated with an early-stage
business, many of which may be beyond our control, including:
o our potential inability to continue to undertake preclinical studies and
clinical trials,
o our potential inability to obtain regulatory approvals, and
o our potential inability to manufacture, sell and market our products.
Our operations have been limited to organizing and staffing our company,
acquiring, developing and securing our proprietary technology and undertaking
preclinical studies and clinical trials of our principal product candidates.
These operations provide a limited basis for you to assess our ability to
commercialize our product candidates and the advisability of investing in our
common stock.
7
If we fail to obtain or maintain necessary regulatory approvals for our
products, or if approvals are delayed or withdrawn, we will be unable to
commercialize our product candidates.
Government regulation in the United States and other countries has a
significant impact on our business and affects the research and development,
manufacture and marketing of our products. In the United States, the FDA has
broad authority to regulate the distribution, manufacture and sale of drugs.
Foreign sales of drugs are subject to foreign governmental regulation and
restrictions, which vary from country to country. In order to obtain FDA
approval of any of our product candidates, we must submit to the FDA a New Drug
Application, or NDA, demonstrating that the product candidate is safe for humans
and effective for its intended use. This demonstration requires significant
research and animal tests, which are referred to as preclinical studies, as well
as human tests, which are referred to as clinical trials. The process of
obtaining FDA and other regulatory clearances and approvals is lengthy and
expensive. We may not be able to obtain or maintain necessary approvals for
clinical trials or for the manufacturing or marketing of our products. Failure
to comply with applicable regulatory approvals can, among other things, result
in fines, suspension or withdrawal of regulatory approvals, product recalls,
operating restrictions, and criminal prosecution. In addition, governmental
regulations may be established which could prevent, delay, modify or rescind
regulatory approval of our products. Any of these actions by the FDA, or any
changes in FDA regulations, would adversely impact our business and financial
condition.
Our product candidates are in early stages of clinical testing.
Our three principal product candidates, intranasal ketamine, intranasal
morphine and intravenous diclofenac, are still in the early- to mid-stages of
clinical testing on a limited number of patients. We will need to commit
substantial time and additional resources to conducting further preclinical
studies and clinical trials before we can submit an NDA with respect to any of
these product candidates. Our other product candidate, intranasal fentanyl, is
at a much earlier stage of development and may require extensive preclinical
testing before we can proceed to clinical trials. In addition, before we can
commence clinical trials in the United States on intravenous diclofenac and
intranasal fentanyl, we will have to submit an IND to the FDA. We cannot predict
with any certainty if or when we might submit an NDA for regulatory approval of
any of our product candidates.
If the clinical trials of our product candidates fail, we will not be able to
market our product candidates.
To receive the regulatory approvals necessary for the sale of our product
candidates, we must demonstrate through human clinical trials that each product
candidate is safe and effective. Positive results from preclinical studies and
early clinical trials do not ensure positive results in clinical trials designed
to permit application for regulatory approval. We may suffer significant
setbacks in clinical trials, even after earlier clinical trials show promising
results. Any of our product candidates may produce undesirable side effects in
humans that could cause us or regulatory authorities to interrupt, delay or halt
clinical trials of a product candidate.
We, the FDA and foreign or other regulatory authorities may suspend our
clinical trials at any time if we or they believe the trial participants face
unacceptable health risks or if the FDA finds deficiencies in our IND
submissions.
Even if we obtain FDA approval to market our product candidates, they may not be
accepted by physicians and patients.
Our drugs will not be commercially accepted products unless physicians and
patients determine that our drugs are clinically useful, cost-effective and
safe. Acceptance and use of our drugs will also depend upon a number of factors
including:
o the cost of our drugs as compared to competing products,
o the availability of adequate coverage and reimbursement levels from
government health administration authorities, private or other health
insurers and other organizations, and
8
o the effectiveness of our and our licensees' marketing and distribution
efforts.
Because we expect sales of our current product candidates, if approved, to
generate substantially all of our product revenues for the foreseeable future,
the failure of any of these drugs to find market acceptance would harm our
business and could require us to seek additional financing.
Our product candidates contain controlled substances, the supply of which may be
limited by U.S. government policy and the use of which may generate public
controversy.
The active ingredients in our current product candidates, including morphine,
ketamine and fentanyl, are listed by the U.S. Drug Enforcement Agency, or DEA,
as Schedule II or III substances under the Controlled Substances Act of 1970.
The DEA regulates chemical compounds as Schedule I, II, III, IV or V substances,
with Schedule I substances considered to present the highest risk of substance
abuse and Schedule V substances the lowest risk. These product candidates are
subject to DEA regulations relating to manufacturing, storage, distribution and
physician prescription procedures. For example, all regular Schedule III drug
prescriptions must be signed by a physician and may not be refilled.
Furthermore, the amount of Schedule III substances we can obtain for clinical
trials and commercial distribution is limited by the DEA and our quota may not
be sufficient to complete clinical trials or meet commercial demand, if any.
Products containing controlled substances may generate public controversy.
Opponents of these products may seek restrictions on marketing and withdrawal of
any regulatory approvals. In addition, these opponents may seek to generate
negative publicity in an effort to persuade the medical community to reject
these products. Political pressures and adverse publicity could lead to delays
in, and increased expenses for, and limit or restrict the introduction and
marketing of our product candidates. The FDA may require us to develop a
comprehensive risk management program to reduce the inappropriate use of our
products and product candidates, including the manner in which they are marketed
and sold, so as to reduce the risk of improper patient selection and diversion
or abuse of the product. Developing such a program in consultation with the FDA
may be a time-consuming process and could delay approval of any of our product
candidates. Such a program or delays of any approval from the FDA could limit
market acceptance of the product.
International commercialization of our product candidates faces significant
obstacles.
We may plan to commercialize some of our products internationally through
collaborative relationships with foreign partners. We have limited foreign
regulatory, clinical and commercial resources. Future partners are critical to
our international success. We may not be able to enter into collaboration
agreements with appropriate partners for important foreign markets on acceptable
terms, or at all. Future collaborations with foreign partners may not be
effective or profitable for us.
We will need to obtain approvals from the appropriate regulatory, pricing and
reimbursement authorities to market any of our proposed products
internationally, and we may be unable to obtain foreign regulatory approvals.
Pursuing foreign regulatory approvals will be time-consuming and expensive. The
regulations can vary among countries and foreign regulatory authorities may
require different or additional clinical trials than we conducted to obtain FDA
approval for our product candidates. In addition, adverse clinical trial
results, such as death or injury due to side effects, could jeopardize not only
foreign regulatory approval, but may also lead to marketing restrictions in the
United States. Our product candidates may also face foreign regulatory
requirements applicable to controlled substances.
Our drug-development programs depend upon third-party researchers who are
outside our control.
We depend upon third parties, such as independent investigators,
collaborators and medical institutions, to conduct our preclinical studies and
clinical trials under agreements with us. These third parties are not our
employees and we cannot control the amount of time or resources that they devote
to our programs. These investigators may not assign as great a priority to our
programs or pursue them as diligently as we would if we were undertaking such
programs ourselves. If outside collaborators fail to devote sufficient time and
resources to our drug-development programs, or if their performance is
substandard, the approval of our FDA applications, if any, and our introduction
of new drugs, if any, will be delayed. These collaborators may also
9
have relationships with other commercial entities, some of whom may compete with
us. If our collaborators assist our competitors at our expense, our competitive
position would be harmed.
We rely exclusively on one party to formulate and supply some of our product
candidates and the loss of this party could harm our business.
We currently rely on a single supplier, West Pharmaceutical Services, Inc.,
to supply intranasal morphine for our clinical trials. Our agreement with West
Pharmaceutical will expire on September 21, 2002. The parties meet regularly to
discuss the status of the development programs and we submit to West
Pharmaceutical biannual revised product plans, the scope and detail of which we
believe are consistent with industry standards. Although we believe that we can
obtain morphine from alternative suppliers, we may be unable to obtain it on
favorable terms, or at all. If we are unable to obtain sufficient supplies of
morphine, our business would be seriously harmed. If any of our product
candidates receives FDA approval, we expect to rely on one or more third-party
contractors to supply our drugs. If our current or future third-party suppliers
cease to supply the drugs in the quantity and quality we need to manufacture our
drug candidates or if they are unable to comply with good manufacturing practice
and other government regulations, the qualification of additional or replacement
suppliers could be a lengthy process and there may not be adequate alternatives
to meet our needs, which would negatively affect our business. We may not be
able to obtain the necessary drugs used in our products in the future on a
timely basis, if at all.
If our sole supplier of chitosan fails to provide us sufficient quantities, we
may not be able to obtain an alternative supply on a timely or acceptable basis.
We currently rely on a sole source for our supply of chitosan, a principal
component of our intranasal morphine product candidate. Under our agreement with
West Pharmaceutical, which will expire on September 21, 2002, we are required to
purchase from West Pharmaceutical all of the chitosan required for use in our
intranasal morphine clinical trials, subject to West Pharmaceutical's ability to
supply the full amount we require. There are relatively few alternative sources
of supply for chitosan and we may not be able to obtain a sufficient supply of
chitosan from West Pharmaceutical or other suppliers, or at all. We may also not
be able to find alternative suppliers in a timely manner that would provide
chitosan at acceptable quantities and prices. Any interruption in the supply of
chitosan would disrupt our ability to manufacture intranasal morphine and could
have a material adverse effect on our business.
We have no experience selling, marketing or distributing products and no
internal capability to do so.
We currently have no sales, marketing or distribution capabilities. In order
to commercialize our products, if any are approved, we intend to develop
internal sales, marketing and distribution capabilities to target particular
markets for our products, as well as make arrangements with third parties to
perform these services for us with respect to other markets for our products. We
may not be able to establish these capabilities internally or hire marketing and
sales personnel with appropriate expertise to market and sell our products, if
approved. In addition, even if we are able to identify one or more acceptable
collaborators to perform these services for us, we may not be able to enter into
any collaborative arrangements on favorable terms, or at all.
If we enter into any collaborative arrangements for the marketing or sale of
our products, our product revenues are likely to be lower than if we marketed
and sold our products ourselves. In addition, any revenues we receive would
depend upon the efforts of our collaborators, which may not be adequate due to
lack of attention or resource commitments, management turnover, change of
strategic focus, business combinations, their inability to comply with
regulatory requirements or other factors outside of our control. Depending upon
the terms of our collaboration, the remedies we have against an under-
performing collaborator may be limited. If we were to terminate a relationship,
it may be difficult or impossible to find a replacement collaborator on
acceptable terms, if at all.
10
We are faced with intense competition and rapid technological change, which may
make it more difficult for us to achieve significant market penetration. If we
cannot compete successfully for market share against other drug companies, we
may not achieve sufficient product revenues and our business will suffer.
The market for our product candidates is characterized by intense competition
and rapid technological advances. If our product candidates receive FDA
approval, they will compete with a number of existing and future drugs and
therapies developed, manufactured and marketed by others which use opioids and
NSAIDs as pain management. If our competitors' existing products or new products
are more effective than or considered superior to our future products, the
commercial opportunity for our product candidates will be reduced or eliminated.
Existing or future competing products may provide greater therapeutic
convenience or clinical or other benefits for a specific indication than our
products, or may offer comparable performance at a lower cost. We face
competition from fully integrated pharmaceutical companies and smaller companies
that are collaborating with larger pharmaceutical companies, academic
institutions, government agencies and other public and private research
organizations. If we are successful in penetrating the market for pain treatment
with our product candidates, other companies may be attracted to the market.
Many of our competitors have opioid or NSAID painkillers already approved or in
development. In addition, many of these competitors, either alone or together
with their collaborative partners, are larger than we are and have substantially
greater financial, technical, research, marketing, sales, distribution and other
resources than we do. Our competitors may develop or market products that are
more effective or commercially attractive than any that we are developing or
marketing. Our competitors may obtain regulatory approvals, and introduce and
commercialize products before we do. These developments could have a significant
negative effect on our financial condition. Even if we are able to compete
successfully, we may not be able to do so in a profitable manner.
If we fail to adequately protect or enforce our intellectual property rights or
secure rights to patents of others, we may be unable to compete effectively.
Our success, competitive position and future revenues will depend in part on
our ability and the abilities of our third-party licensors to obtain and
maintain patent protection for our products, methods, processes and other
technologies and to preserve our trade secrets.
To date, we have licenses to certain patent rights, including rights under
U.S. patents and U.S. patent applications and under foreign patents and patent
applications, related to our product candidates. We anticipate filing additional
patent applications both in the United States and in other countries, as
appropriate. The procedures for obtaining an issued patent in the United States
and in most foreign countries are complex. These procedures require an analysis
of the scientific technology related to the invention and many legal issues.
Accordingly, we expect that the examination of our patent applications will be
complex and time consuming. We do not know when, or if, we will obtain
additional issued patents for our technologies.
We cannot predict whether or not:
o any additional patents will issue and the degree and range of protection
they will afford us against competitors,
o others will obtain patents claiming aspects similar to those covered by
our patents and patent applications,
o we will need to initiate litigation or administrative proceedings
regarding our patents, which may be costly whether we win or lose or
o third parties will find ways to challenge, invalidate or otherwise
circumvent our patent rights that we currently hold or license.
The degree and range of protection afforded by any of our licensed patents,
as with all patents, is defined by the breadth of the claims of the patent. As
the components of our product candidates are commercially available to third
parties, it is possible that competitors may design formulations, propose
dosages, or develop methods or routes of administration with respect to these
components that would be
11
outside the scope of the claims of one or more, or of all, of our licensed
patents. This would enable their products to effectively compete with our
product candidates.
We may have to institute costly legal action to protect our intellectual
property rights. We may not be able to afford the costs of enforcing our
intellectual property rights. Consequently, we do not know how much, if any,
protection our patents will provide. A third party might request a court to rule
that our patents are invalid or unenforceable. In such a case, even if the
validity and enforceability of our patents were upheld, a court might hold that
the third party's actions do not infringe our patent.
The laws of some countries may not protect our intellectual property rights
to the same extent as U.S. laws. For example, methods of treating humans are not
patentable subject matter in many countries outside of the United States. It may
be necessary or useful for us to participate in proceedings to determine the
validity of our foreign patents or those of our competitors, which could result
in substantial cost and divert our efforts and attention from other aspects of
our business. These and other issues may limit the patent protection we will be
able to secure outside of the United States.
Our success also depends upon the skills, knowledge and experience of our
scientific and technical personnel, our consultants and advisors as well as our
licensors and contractors. To help protect our proprietary know-how and our
inventions, we also rely on trade secret protection and confidentiality
agreements, in addition to patents. However, trade secrets are difficult to
protect. To this end, we require all of our employees, consultants, advisors and
contractors to enter into agreements that prohibit the disclosure of our trade
secrets and other confidential information and, where applicable, require
disclosure and assignment to us of the ideas, developments, discoveries and
inventions important to our business. These agreements may not provide adequate
protection for our trade secrets, know-how or other proprietary information in
the event of any unauthorized use or disclosure or the lawful development by
others of such information. If any of our trade secrets, know-how or other
proprietary information is disclosed, or if third parties independently discover
our trade secrets or proprietary information, the value of our trade secrets,
know-how and other proprietary rights would be significantly impaired and our
business and competitive position would suffer.
Technology licensed to us by others, or in-licensed technology, is important
to our business. We may not control the patent prosecution, maintenance or
enforcement of some of our in-licensed technology. Accordingly, we may be unable
to exercise the same degree of control over this intellectual property as we
would over our internally developed technologies. Moreover, our rights to
in-licensed technology could be terminated under the terms of our license
agreements, including upon a default by us. If such a default were to occur
under any of these agreements, we could lose our rights to the in-licensed
technologies or other products that are the subject of that agreement, including
our rights to continue to develop that technology. The loss of these
technologies, products or rights could harm our business.
A dispute regarding the infringement or misappropriation of our proprietary
rights or the proprietary rights of others could be costly and result in delays
in our research and development activities.
Our success, competitive position and future revenues will also depend in
part on our ability to operate without infringing on or misappropriating the
proprietary rights of others. Since our product candidates contain components
that are well known and that have been in use by other companies, our product
candidates could infringe the proprietary rights of third parties. We are aware
of one third party who could allege that certain uses of our product candidates
infringe its proprietary rights. We do not intend to market our products for
such uses, nor are we aware of any such uses currently in practice, but we may
not be able to avoid claims or liability with respect thereto because we cannot
prevent others from using our products for such uses in the future.
Many of our employees and consultants were, and many of our consultants may
currently be, parties to confidentiality agreements with other companies. While
our confidentiality agreements with these employees and consultants require that
they do not bring to us, or use without proper authorization, any third party's
proprietary technology, if they violate their agreements, we could suffer claims
or liabilities.
If our products, methods, processes and other technologies infringe the
proprietary rights of other parties, we could incur substantial costs and we may
have to:
12
o obtain licenses, which may not be available on commercially reasonable
terms, if at all,
o redesign our products or processes to avoid infringement,
o stop using the subject matter claimed in the patents held by others,
o pay damages or
o defend litigation or administrative proceedings which may be costly whether
we win or lose, and which could result in a substantial diversion of our
valuable management resources.
We may not successfully manage our growth.
Our success will depend upon the expansion of our operations and the
effective management of our growth. We expect to experience significant growth
in the scope of our operations and the number of our employees. If we grow
significantly, such growth will place a significant strain on our management and
on our administrative, operational and financial resources. To manage this
growth, we must expand our facilities, augment our operational, financial and
management systems and hire and train additional qualified personnel. Our future
success is heavily dependent upon growth and acceptance of our future products.
If we are unable to scale our business appropriately or otherwise adapt to
anticipated growth and new product introduction, our business and financial
condition will be harmed.
We depend upon Paramount Capital Investments, LLC for all of our current
infrastructure-related administrative services and office support and equipment.
Paramount Capital Investments, LLC, an affiliate of one of our principal
stockholders, currently provides all of our office space, some members of our
management and employees and certain administrative and legal assistance at no
cost to us. Paramount also provides us with computer hardware and software and
services related to the development, management and maintenance of our internal
data and file storage, as well as office equipment. The estimated fair value of
the assistance provided by Paramount to us totaled $481,299 for the twelve
months ended December 31, 2001, which has been reflected in the accompanying
financial statements as an expense in that period with a corresponding deemed
capital contribution. We currently do not have an agreement in place with
Paramount governing all aspects of this relationship. We do, however, have an
agreement in place with Paramount under which Paramount has waived any claim for
reimbursement for such assistance, and will continue to waive any claim for
reimbursement for any assistance provided to us through the end of the third
quarter of 2002. If Paramount fails to provide assistance to us, we will need to
obtain similar services from a third party or develop an internal infrastructure
for similar services in order to operate our business. We also have an agreement
with Paramount under which Paramount assigned to us all rights in all
proprietary technology and information developed with the assistance of
Paramount. In addition, we have an agreement stating that Paramount will
maintain our proprietary information in confidence for a period of ten years
from the date they receive such proprietary information. Due to the existing
arrangements, Paramount may be able to exert influence over our business and
affairs.
We currently have no permanent facilities.
We currently share office space with Paramount Capital Investments on a
rent-free and informal basis. We do not have any contractual rights to continue
that arrangement. We currently have an agreement in place with Paramount under
which Paramount has waived any claim for reimbursement for any payments
regarding this arrangement, and will continue to waive any claim for
reimbursement for any similar payments through the end of the third quarter of
2002. In order to succeed, we will need to lease our own facilities at some
point in the future. If we are unable to acquire these facilities on acceptable
terms, or at all, our business will be harmed.
We may be exposed to liability claims associated with the use of hazardous
materials and chemicals.
Our research and development activities involve the controlled use of
hazardous materials and chemicals. Although we believe that our safety
procedures for using, storing, handling and disposing of these materials comply
with federal, state and local laws and regulations, we cannot completely
eliminate the risk of
13
accidental injury or contamination from these materials. In the event of such an
accident, we could be held liable for any resulting damages and any liability
could materially adversely affect our business, financial condition and results
of operations. In addition, the federal, state and local laws and regulations
governing the use, manufacture, storage, handling and disposal of hazardous or
radioactive materials and waste products may require us to incur substantial
compliance costs that could materially adversely effect our business and
financial condition.
We rely on key executive officers and scientific and medical advisors, and their
knowledge of our business and technical expertise would be difficult to replace.
We are highly dependent on Dr. Leonard Firestone, our Chief Executive Officer
and Chief Medical Officer, as well as other executive officers, including
Douglas A. Hamilton, our Chief Operating Officer and Chief Financial Officer,
Dr. Fred Mermelstein, our President, and Dr. Randi Albin, our Chief Scientific
Officer. We have entered into an employment agreement with Dr. Firestone. In
addition, Dr. Mermelstein devotes only 80% of his business time to us and the
remainder to Paramount Capital Investments. We do not have "key person" life
insurance policies for any of our officers. The loss of the technical knowledge
and management and industry expertise of any of our key personnel could result
in delays in product development, loss of customers and sales, if any, and
diversion of management resources, which could adversely affect our operating
results.
In addition, we rely on members of our scientific advisory board and clinical
advisors to assist us in formulating our research and development strategy. All
of the members of our scientific advisory board and our clinical advisors have
other jobs and commitments that may limit their availability to work with us.
If we are unable to hire additional qualified personnel, our ability to grow our
business may be harmed.
We will need to hire additional qualified personnel with expertise in
preclinical studies, clinical research and trials, government regulation,
formulation and manufacturing and sales and marketing. We compete for qualified
individuals with numerous biopharmaceutical companies, universities and other
research institutions. Competition for such individuals, particularly in the New
York City area, is intense, and we may not be able to hire sufficient personnel
to support our efforts.
We may incur substantial liabilities and may be required to limit
commercialization of our products in response to product liability lawsuits.
The testing and marketing of medical products entail an inherent risk of
product liability. Although side effects from our clinical trials thus far have
been limited to symptoms known to be associated with these medications, such as
dysphoria, which is a feeling of malaise, and nausea, we may be held liable if
any more serious adverse reactions from the use of our product candidates
occurs. Our product candidates involve a new method of delivery for potent drugs
that require greater precautions to prevent unintended use, especially since
they are designed for patients' self-use rather than being administered by
medical professionals. For example, the FDA may require us to develop a
comprehensive risk management program for our product candidates to reduce the
risk of improper patient selection, diversion and abuse. The failure of these
measures could result in harmful side effects or death. As a result, consumers,
regulatory agencies, pharmaceutical companies or others might make claims
against us. If we cannot successfully defend ourselves against product liability
claims, we may incur substantial liabilities or be required to limit
commercialization of our product candidates. Our inability to obtain sufficient
product liability insurance at an acceptable cost to protect against potential
product liability claims could prevent or inhibit the commercialization of
pharmaceutical products we develop, alone or with corporate collaborators. We
currently carry clinical trial insurance but do not carry product liability
insurance. We, or any corporate collaborators, may not be able to obtain
insurance at a reasonable cost, if at all. Even if our agreements with any
future corporate collaborators entitle us to indemnification against losses,
such indemnification may not be available or adequate if any claim arises.
14
Risks Related To The Offering
Our stock price could be volatile and the value of your investment could
decline.
After this offering, you may not be able to resell your shares at or above
the initial public offering price. The trading price for our common stock is
likely to be highly volatile and could be subject to wide fluctuations in price
in response to various factors, many of which are beyond our control, including:
o publicity regarding actual or potential clinical results relating to
products under development by our competitors or us,
o delay or failure in initiating, completing or analyzing preclinical studies
or clinical trials or unsatisfactory design or results of these tests,
o achievement or rejection of regulatory approvals by our manufacturers,
suppliers, distributors, competitors or us,
o announcements of technological innovations or new commercial products by
our competitors or us,
o developments concerning proprietary rights, including patents,
o developments concerning our collaborations,
o regulatory developments in the United States and foreign countries,
o economic or other crises and other external factors,
o period-to-period fluctuations in our revenue and other results of
operations,
o changes in financial estimates by securities analysts, and
o sales of our common stock.
We will not be able to control many of these factors, and we believe that
period-to-period comparisons of our financial results will not necessarily be
indicative of our future performance. If our revenues, if any, in any particular
period do not meet expectations, we may not be able to adjust our expenditures
in that period, which could cause our operating results to suffer further. If
our operating results in any future period fall below the expectations of
securities analysts or investors, our stock price may fall by a significant
amount.
In addition, the stock market in general, and the Nasdaq National Market and
the market for biotechnology companies in particular, has experienced extreme
price and volume fluctuations that may have been unrelated or disproportionate
to the operating performance of individual companies. These broad market and
industry factors may seriously harm the market price of our common stock,
regardless of our operating performance.
We are at risk of securities class action litigation due to our expected stock
price volatility.
In the past, securities class action litigation has often been brought
against companies following periods of volatility in the market price of their
securities. Due to the expected volatility of our stock price, we may be the
target of securities litigation in the future. Securities litigation could
result in substantial costs and divert management's attention and resources from
our business.
An active trading market for our common stock may not develop.
Before this offering, there was no public market for our common stock. An
active public market for our common stock may not develop or be sustained after
this offering. We will determine the initial public offering price of our common
stock based on negotiations between the representatives of the underwriters and
our management concerning the valuation of our common stock, and this price may
not be indicative of future market prices. The public market may not agree with
or accept this valuation. The factors to be considered in determining the
initial public offering price of our common stock, in addition to prevailing
market conditions, include:
o estimates of our business potential and earnings prospects,
15
o an assessment of our management, and
o the consideration of these factors in relation to market valuations of
companies in related businesses.
Because our directors, management and affiliates will retain significant control
over us after this offering, they could control our actions in a manner that
conflicts with our interests and the interests of our stockholders.
We anticipate that our officers, directors and individuals or entities
affiliated with our directors, including our largest stockholder, will
beneficially own approximately 40.1% of our outstanding common stock as a group
after this offering closes. Acting together, these stockholders would be able to
exercise significant influence over all matters that our stockholders vote upon,
including the election of directors and the approval of significant corporate
transactions. This concentration of ownership may also delay, deter or prevent a
change in our control and may make some transactions more difficult or
impossible to complete without the support of the stockholders.
We will be subject to the anti-takeover provisions of the Delaware General
Corporation Law, which regulates corporate acquisitions and we have other
anti-takeover provisions that may make it difficult for a third party to acquire
us.
Delaware law will prevent us from engaging, without the approval of our board
of directors, or two-thirds of our stockholders, in transactions with any
stockholder that controls, together with its affiliates, 15% or more of our
outstanding common stock for three years following the date on which the
stockholder first acquired 15% or more of our outstanding common stock. The
anti-takeover provisions of our charter documents, including our board's ability
to issue up to 5,000,000 shares of preferred stock, and of the Delaware General
Corporation Law are likely to discourage potential acquisition proposals and
delay or prevent a transaction resulting in a change in control.
If a large number of shares of our common stock are sold after this offering,
the market price of our common stock could decline.
If our stockholders sell substantial amounts of common stock in the public
market, including shares that we may issue upon the exercise of outstanding
options and warrants, the market price of our common stock could decline. This
could also impair our ability to raise additional capital through the sale of
our equity securities. After this offering, we will have 20,645,327 shares of
common stock outstanding or, if the underwriters exercise their over-allotment
option in full, 21,485,327 shares of common stock outstanding. Of these shares,
the shares sold in this offering will be freely tradeable. The remaining
15,045,327 shares are "restricted shares" and will become eligible for sale in
the public market at various times after 180 days after the date of this
prospectus, subject to the limitations and other conditions of Rule 144 under
the Securities Act.
In addition, after this offering, the holders of approximately 7,281,725
shares of common stock and warrants to purchase common stock will have
registration rights with respect to these shares, allowing these stockholders to
sell these shares in the market simultaneously with any further public offerings
by us of our equity securities.
You will suffer immediate and substantial dilution because the net tangible book
value of shares purchased in this offering will be substantially lower than the
initial public offering price.
The initial public offering price of the shares of common stock in this
offering will significantly exceed the pro forma as adjusted net tangible book
value per share of our common stock. Any shares of common stock that investors
purchase in this offering will have a pro forma as adjusted net tangible book
value per share of $6.50 per share less than the initial public offering price
paid, assuming an initial public offering price per share of $9.00. Accordingly,
if you purchase common stock in this offering, you will incur immediate and
substantial dilution of your investment.
16
You may suffer additional dilution if current options or warrants are exercised.
We have issued options and warrants to acquire our common stock at prices
significantly below the initial public offering price of our common stock in
this offering. When any of these options or warrants are exercised, you will
incur additional dilution. Upon the completion of certain milestones and upon
mutual agreement of the parties, Dr. Stuart Weg, one of our licensors, and West
Pharmaceutical may receive a cash or stock payment from us. If West
Pharmaceutical receives our stock, we will be required to issue the stock at its
then fair market value. If Dr. Weg receives our stock, we will be required to
issue the stock at the average closing price for our shares of common stock for
the ten consecutive trading days immediately preceding the achievement of such
milestones. In addition, upon the completion of certain milestones, Shimoda
Biotech (Proprietary) Ltd. and Farmarc Netherlands B.V. (Registration No.
2807216) may elect to receive a cash or stock payment from us. If Shimoda and
Farmarc receive our stock, we will be required to issue the stock at the initial
public offering price. If any of these stock payments occur, you will incur
additional dilution. To the extent we raise additional capital by issuing equity
securities in the future, you and our other stockholders may experience dilution
and future investors may be granted rights superior to those of our current
stockholders.
17
INFORMATION REGARDING FORWARD-LOOKING STATEMENTS
This prospectus contains forward-looking statements. The forward-looking
statements are principally contained in the sections entitled "Prospectus
Summary," "Business" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations." These statements involve known and unknown
risks, uncertainties and other factors that may cause our actual results,
performance or achievements to differ, perhaps materially, from any future
results, performance or achievements expressed or implied by the forward-looking
statements. Forward-looking statements include, but are not limited to,
statements about:
o our product development efforts,
o anticipated operating losses and capital expenditures,
o anticipated regulatory filing dates and clinical trial initiation dates,
o our estimates regarding our capital requirements and our needs for
additional financing,
o our estimates for future revenues and profitability,
o our selection and licensing of product candidates,
o our ability to attract partners with acceptable development, regulatory
and commercialization expertise,
o the benefits to be derived from corporate collaborations, license
agreements and other collaborative efforts, including those relating to the
development and commercialization of our product candidates, and
o sources of revenues and anticipated revenues, including contributions from
corporate collaborations, license agreements and other collaborative
efforts for the development and commercialization of our product
candidates, and the continued viability and duration of those agreements
and efforts.
In some cases, you can identify forward-looking statements by terms such as
"may," "will," "should," "could," "would," "expect," "plan," "anticipate,"
"believe," "estimate," "project," "predict," "intend," "potential" and similar
expressions intended to identify forward-looking statements. These statements
reflect our current views with respect to future events and are based on
assumptions and subject to risks and uncertainties. Given these uncertainties,
you should not place undue reliance on these forward-looking statements. We
discuss many of these risks in greater detail under the heading "Risk Factors."
Also, these forward-looking statements represent our estimates and assumptions
only as of the date of this prospectus.
Market data and forecasts used in this prospectus, including, for example,
estimates of the size and growth rates of the pain management market, have been
obtained from independent industry sources. We have not independently verified
the data obtained from these sources and we cannot assure you of the accuracy or
completeness of the data. Forecasts and other forward-looking information
obtained from these sources are subject to the same qualifications and the
additional uncertainties accompanying any estimates of future market size.
You should read this prospectus and the documents that we reference in this
prospectus and have filed as exhibits to the registration statement, of which
this prospectus is part, completely and with the understanding that our actual
future results may be materially different from what we expect. We may not
update these forward-looking statements, even though our situation may change in
the future, unless we have obligations under the federal securities laws to
update and disclose material developments related to previously disclosed
information. We qualify all of our forward-looking statements by these
cautionary statements.
18
USE OF PROCEEDS
We estimate that the net proceeds we will receive from the sale of 5.6
million shares of common stock, before payments to Shimoda Biotech (Proprietary)
Ltd. and Farmac Netherlands B.V. (Registration No. 2807216), will be
approximately $44.9 million, or approximately $51.9 million if the underwriters
fully exercise their over- allotment option, in each case assuming an initial
public offering price of $9.00 per share and after deducting the estimated
underwriting discount and estimated offering expenses payable by us.
The principal purposes of this offering are to increase funds available for:
o research and development activities, including clinical trials, which we
estimate could approximate $35.0 million,
o milestone and other payments payable under our strategic agreements,
including a minimum of $1.0 million and a maximum of $2.0 million in the
aggregate payable to Shimoda and Farmarc upon the closing of this offering,
which payment will be $1.0 million assuming an initial public offering
price of $9.00 per share,
o working capital, and
o other general corporate purposes.
The amount and timing of our actual expenditures will depend on numerous
factors, including the progress of our research and development activities and
clinical trials, the number and breadth of our product development programs, our
ability to establish and maintain corporate collaborations and other
arrangements and the amount of cash, if any, generated by our operations. In
addition, a portion of the net proceeds may be used for the acquisition of
businesses, products and technologies that are complementary to our own. We are
not currently engaged in any negotiations to acquire any other company. We will
retain broad discretion in the allocation and use of the net proceeds of this
offering. Pending application of the net proceeds as described above, we intend
to invest the remaining net proceeds from this offering in short-term,
investment-grade, interest-bearing securities.
DIVIDEND POLICY
We have never declared nor paid any cash dividends on our common stock. We do
not intend to pay cash dividends on our common stock in the foreseeable future.
We presently intend to retain future earnings, if any, to finance the expansion
and growth of our business. Any future determination to pay dividends will be at
the discretion of our board of directors and will depend on our financial
condition, results of operations, capital requirements and other factors that
our board of directors deems relevant.
19
CAPITALIZATION
The following table describes our capitalization as of December 31, 2001:
o on an actual basis,
o on a pro forma basis to give effect to the automatic conversion, on
approximately a 1.0161-for-one basis, of 5,004,116 shares of our
outstanding series A and series B convertible preferred stock into
5,084,900 shares of our common stock upon the closing of this offering,
o on a pro forma as adjusted basis to give effect to:
o the sale of 5,600,000 shares of common stock by us in this offering at an
assumed initial offering price of $9.00 per share, after deducting the
estimated underwriting discount and estimated offering expenses payable
by us,
o the payment by us of a minimum of $1.0 million and a maximum of $2.0
million to Shimoda and Farmarc upon the closing of this offering in
connection with a licensing agreement, which payment will be $1.0 million
assuming an initial public offering price of $9.00 per share.
As of December 31, 2001
-----------------------------------
Pro Forma
Actual Pro Forma as Adjusted
-------- --------- -----------
(in thousands, except share and per
share data)
Convertible preferred stock, $0.001 par value per share, 6,500,000 shares authorized,
5,004,116 shares issued and outstanding, actual, no shares issued and outstanding, pro
forma and pro forma as adjusted........................................................... $ 18,795 $ $
-------- -------- --------
Stockholders' (deficit) equity:
Undesignated preferred stock, $0.001 par value per share, _________ shares authorized,
none issued and outstanding..............................................................
Common stock, $0.001 par value per share, 21,500,000 shares authorized,
9,960,427 shares issued and outstanding, actual, 15,045,327 shares issued and
outstanding, pro forma, 20,645,327 shares issued and outstanding, pro forma
as adjusted.............................................................................. 10 15 21
Additional paid-in capital................................................................ 21,615 40,405 84,271
Deficit accumulated during the development stage.......................................... (32,767) (32,767) (32,767)
-------- -------- --------
Total stockholders' (deficit) equity..................................................... (11,142) 7,653 51,525
-------- -------- --------
Total capitalization.................................................................... $ 7,653 $ 7,653 $ 51,525
======== ======== ========
The above table excludes:
o 1,367,101 shares of common stock issuable upon exercise of options
outstanding as of December 31, 2001 at a weighted average exercise price of
$3.93 per share,
o 406,456 shares of common stock issuable upon exercise of options granted on
February 25, 2002 at a weighted average exercise price of $5.46,
o 925,000 shares of common stock issuable upon exercise of options to be
granted on or prior to the closing of this offering at an exercise price
equal to the initial public offering price,
o 624,146 shares of common stock issuable upon exercise of warrants
outstanding as of December 31, 2001 at a weighted average exercise price of
$2.58 per share, and
o 442,395 shares of common stock issuable upon the exercise and assumed
conversion of 15.83 unit purchase options, which entitle each holder to
purchase 395,788 shares of our series A convertible preferred stock
(convertible into 402,177 shares of common stock) at $4.40 per share and a
warrant to purchase 40,218 shares of our common stock at $3.94 per share.
20
DILUTION
The historical net tangible book value (deficit) as of December 31, 2001 was
approximately $(11.9) million, or $(1.20) per share of common stock. Historical
net tangible book value (deficit) represents the amount of our total assets less
the aggregate of prepaid offering costs, convertible preferred stock and total
liabilities. Historical net tangible book value (deficit) per share represents
historical net tangible book value (deficit) divided by the number of shares of
our common stock outstanding at December 31, 2001. After giving effect to the
automatic conversion of all of our series A and series B convertible preferred
stock into an aggregate of 5,084,900 shares of our common stock, which will
occur upon the closing of this offering, and the issuance and sale by us of the
shares of common stock offered by this prospectus at an assumed initial public
offering price of $9.00 per share and after deducting the estimated underwriting
discount and estimated offering expenses and an estimated payment by us of
$1.0 million due to Shimoda and Farmarc upon completion of this offering in
connection with a licensing agreement, our pro forma as adjusted net tangible
book value as of December 31, 2001 would have been approximately $51.5 million,
or approximately $2.50 per share. This represents an immediate increase in the
historical net tangible book value of $3.70 per share to existing stockholders
and immediate dilution of $6.50 per share to new investors participating in this
offering, which is illustrated by the following table:
Assumed initial public offering price per share ............. $9.00
-----
Historical net tangible book value (deficit) per share as
of December 31, 2001...................................... $(1.20)
------
Increase per share attributable to this offering ........... 3.70
------
Pro forma as adjusted net tangible book value per share
after this offering ........................................ 2.50
-----
Dilution per share to new investors participating in this
offering ................................................... $6.50
=====
Assuming the exercise in full of the underwriters' over-allotment option, our
pro forma as adjusted net tangible book value as of December 31, 2001 would have
been approximately $58.5 million, or approximately $2.72 per share. This
represents an immediate increase in the historical net tangible book value
(deficit) of $3.92 per share to existing stockholders and immediate dilution of
$6.28 per share to new investors participating in this offering.
The following table sets forth, on a pro forma as adjusted basis as of
December 31, 2001, the differences between the total cash consideration paid and
the average price per share paid by existing stockholders and new investors
participating in this offering with respect to the number of shares of our
common stock purchased from us based on an assumed initial public offering price
of $9.00 per share:
Shares Purchased Total Consideration
-------------------- --------------------- Average Price
Number Percent Amount Percent Per Share
---------- ------- ----------- ------- -------------
Existing Stockholders ................................ 15,045,327 73% $21,561,210 30% $1.43
New Investors ........................................ 5,600,000 27 50,400,000 70 9.00
---------- --- ----------- ---
Totals ........................................... 20,645,327 100% $71,961,210 100%
========== === =========== ===
The foregoing discussion and tables assume no exercise of any stock options
or warrants and no issuance of shares reserved for future issuance under our
equity plans. As of December 31, 2001, there were 9,960,427 shares outstanding,
which excludes:
o 1,367,101 shares of common stock issuable upon exercise of options then
outstanding at a weighted average exercise price of $3.93 per share,
o 406,456 shares of common stock issuable upon exercise of options granted on
February 25, 2002 at a weighted average exercise price of $5.46,
o 925,000 shares of common stock issuable upon exercise of options to be
granted on or prior to the closing of this offering at an exercise price
equal to the initial public offering price,
21
o 624,146 shares of common stock issuable upon exercise of warrants then
outstanding at a weighted average exercise price of $2.58 per share, and
o 442,395 shares of common stock issuable upon the exercise and assumed
conversion of 15.83 unit purchase options, which entitle each holder to
purchase 395,788 shares of our series A convertible preferred stock
(convertible into 402,177 shares of common stock) at $4.40 per share and a
warrant to purchase 40,218 shares of common stock at $3.94 per share.
To the extent that any of these options or warrants is exercised, your
investment will be further diluted. In addition, we may grant additional options
or warrants or issue other equity securities in the future that may be dilutive
to investors in this offering.
22
SELECTED FINANCIAL DATA
You should read the following selected financial data in conjunction with
"Management's Discussion and Analysis of Financial Condition and Results of
Operations" and the financial statements and related notes included elsewhere in
this prospectus. The selected financial data presented below as of December 31,
2000 and 2001, for each of the three years in the period ended December 31, 2001
and for the period from February 23, 1998 (inception) to December 31, 2001 are
derived from our financial statements, which are included elsewhere in this
prospectus and which have been audited by PricewaterhouseCoopers LLP. The
selected financial data presented below as of December 31, 1998 and 1999 and for
the period from February 23, 1998 (inception) to December 31, 1998 have been
derived from our audited financial statements that are not included in this
prospectus.
Period from Period from
February 23, Year Ended February 23,
1998 December 31, 1998
(inception) to ------------------------------- (inception) to
December 31, December 31,
1998 1999 2000 2001 2001
-------------- ------- -------- -------- --------------
(in thousands, except per share data)
Statement of Operations Data:
Revenues:
Government grants............................................ $ -- $ -- $ 306 $ 882 $ 1,188
------ ------- -------- -------- --------
Operating expenses:
Research and development (1)(2).............................. 207 665 21,833 7,009 29,714
General and administrative (3)............................... 257 312 1,353 2,286 4,208
Depreciation................................................. -- -- 1 3 4
------ ------- -------- -------- --------
Total operating expenses..................................... 464 977 23,187 9,298 33,926
------ ------- -------- -------- --------
Operating loss............................................... (464) (977) (22,881) (8,416) (32,738)
Interest (expense) income, net................................ (6) (229) (143) 349 (29)
------ ------- -------- -------- --------
Net loss...................................................... (470) (1,206) (23,024) (8,067) (32,767)
Deemed dividend related to beneficial conversion feature of
Series B convertible preferred stock........................ -- -- -- (3,560) (3,560)
------ ------- -------- -------- --------
Net loss attributable to common stockholders.................. $ (470) $(1,206) $(23,024) $(11,627) $(36,327)
====== ======= ======== ======== ========
Net loss per share attributable to common stockholders:
Basic and diluted............................................ $(0.11) $ (0.28) $ (3.93) $ (1.20)
====== ======= ======== ========
Weighted average shares...................................... 4,236 4,310 5,859 9,725
====== ======= ======== ========
Pro forma net loss per share attributable to common
stockholders: (4)
Basic and diluted............................................ $ (0.84)
========
Weighted average shares...................................... 13,807
========
- ---------------
(1) Includes non-cash expense of $3 for the period from February 23, 1998
(inception) to December 31, 1998, $29 for the year ended December 31, 1999,
$18,614 for the year ended December 31, 2000, and $72 for the year ended
December 31, 2001.
(2) For the year ended December 31, 2000, includes costs associated with the
acquisition of a license agreement valued at approximately $18.6 million in
connection with our merger with Pain Management.
(3) Includes non-cash expense of $87 for the period from February 23, 1998
(inception) to December 31, 1998, $220 for the year ended December 31,
1999, $857 for the year ended December 31, 2000 and $409 for the year ended
December 31, 2001.
(4) Pro forma net loss per share data presented above assume that the
historical per share data are adjusted to reflect the conversion of all
outstanding shares of series A and series B convertible preferred stock
into common stock, on a weighted average basis, as if they had been
converted on the respective dates of issuance. Pro forma net loss per share
data for the period from February 23, 1998 (inception) to December 31, 1998
and the years ended December 31, 1999 and 2000 have been intentionally
omitted.
23
As of December 31,
--------------------------------------
1998 1999 2000 2001
----- ------- ------- --------
(in thousands)
Balance Sheet Data:
Cash and cash equivalents........................................................... $ 49 $ 253 $10,084 $ 7,744
Working capital (deficit)........................................................... (379) (1,268) 10,175 $ 6,805
Total assets........................................................................ 49 398 10,498 $ 8,845
Convertible preferred stock......................................................... -- -- 13,775 $ 18,795
Stockholders' (deficit)............................................................. (379) (1,136) (3,556) $(11,142)
24
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following discussion in conjunction with our financial
statements, the related notes and other financial information appearing
elsewhere in this prospectus. This discussion may contain forward-looking
statements based upon current expectations that involve risks and uncertainties.
Our actual results and the timing of selected events could differ materially
from those anticipated in these forward-looking statements as a result of many
factors, including those set forth under "Risk Factors" and elsewhere in this
prospectus.
Overview
We have devoted substantially all of our resources since we began our
operations in February 1998 to the development of proprietary pharmaceutical
products for the treatment of pain. We are a development stage pharmaceutical
company and have not generated any revenues from product sales. We have not been
profitable and, since our inception, we have incurred an accumulated net loss
attributable to our common stockholders of approximately $36.3 million through
December 31, 2001. These losses have resulted principally from costs incurred in
research and development activities, including acquisition of technology rights
and general and administrative expenses. We expect to incur additional operating
losses until such time as we generate sufficient revenue to offset expenses and
may never achieve profitable operations.
Research and development, manufacturing and marketing costs will continue to
increase as we advance our product candidates and prepare for the
commercialization of our products pending regulatory approval.
Since our inception, we have incurred approximately $29.7 million of research
and development costs. The major research projects undertaken by us include
intranasal ketamine, morphine and fentanyl and intravenous diclofenac. Total
research and development costs incurred to date for each of these products was
approximately $3.1 million, $6.6 million and $0.8 million, respectively. In
addition, there was approximately $0.6 million of research and development costs
incurred since inception which do not relate to our major research projects and
we incurred a charge of approximately $18.6 million related to our merger with
Pain Management, Inc. and the acquisition of a licensing agreement. For various
reasons, many of which are outside our control, including timing and results of
our clinical trials, obtaining regulatory approval and dependence on third
parties, we cannot estimate the total remaining costs to be incurred to
commercialize our products, nor is it possible to estimate when, if ever, any of
our products will be approved by regulatory agencies for commercial sale. In
addition, we may experience adverse results in the development of our products
which could result in significant delays in obtaining approval to sell our
products, additional costs to be incurred to obtain regulatory approval and/or
failure to obtain regulatory approval. In the event any of our product
candidates were to experience setbacks, it would have a material adverse effect
on our financial position and operating results. Even if we successfully
complete developments and obtain regulatory approval of one or more of our
products, failure of physicians and patients to accept our products as a safe,
cost-effective alternative compared to existing products would have a material
adverse effect on our business.
In June 2000, we issued 5,080,717 shares of our common stock to our founders.
In September 2000, in connection with our merger with Pain Management, Inc., we
issued an aggregate of 4,648,220 shares of our common stock for the outstanding
shares of Pain Management's common stock. At the time of the merger, the only
asset held by us was a license agreement with West Pharmaceutical Services, Inc.
We remained dormant until the merger and the execution of the license agreement.
The merger was accounted for financial reporting purposes as the acquisition of
a license agreement by the predecessor company and a reorganization with
Innovative Drug Delivery Systems, Inc. as the surviving entity. As a result, our
assets, liabilities and historic operating results prior to September 2000 are
those of Pain Management. The fair value of the license agreement was determined
to be approximately $18.6 million based on the then fair value of the common
stock we issued. Since the licensed technology had not reached technological
feasibility and had no alternative future use, the fair value of the
consideration issued to obtain the license agreement was expensed as research
and development at the time the merger closed.
As of December 31, 2001, if certain defined events occur, we would be
required to pay West Pharmaceutical in the future an aggregate of $11.25 million
for research and development milestones, which
25
include the filing of an NDA with the FDA for intranasal morphine, the approval
of an NDA by the FDA and the first commercial sale of a licensed product. As of
December 31, 2001, we had paid West $4.8 million in cash. The timing of the
remaining milestones is dependent upon factors that are beyond our control,
including our ability to recruit patients, the outcome of future clinical trials
and any requirements imposed on our clinical trials by the FDA. If the FDA
imposes more stringent requirements on our clinical trials, the length and
number of such trials may be increased resulting in additional research and
development expenses.
In addition, as of December 2001, under the license agreement with Shimoda
Biotech (Proprietary) Ltd., we are obligated to pay a license fee of $1.5
million to Shimoda, of which $550,000 was paid as of December 31, 2001. In
addition, following completion of this offering, we are obligated to pay Shimoda
and Farmarc Netherlands B.V. (Registration No. 2807216) an aggregate of 2% of
the net proceeds from this offering, subject to a minimum payment of $1.0
million and a maximum payment of $2.0 million. Under this agreement, we are also
obligated to make certain payments to Shimoda upon the occurrence of specified
developmental milestones, which include the filing of an NDA with the FDA for
diclofenac, the approval of an NDA by the FDA and the first commercial sale of a
licensed product and pay a royalty based upon our and our sublicensees' sales of
products. The timing of the remaining milestones, which total approximately $6.0
million, is dependent upon factors that are beyond our control, including our
ability to recruit patients, the outcome of future clinical trials and any
requirements imposed on our clinical trials by the FDA. If the FDA imposes more
stringent requirements on our clinical trials, the length and number of such
trials may be increased resulting in additional research and development
expenses.
In addition, under the license agreement with Dr. Weg, we are obligated to
make aggregate milestone payments of approximately $1.6 million, of which
$300,000 was paid as of December 31, 2001, upon the earlier of certain defined
dates ranging from August 2003 to November 2004 or satisfaction of certain
clinical and regulatory milestones, which include the filing of an NDA with the
FDA for ketamine, the approval of an NDA by the FDA and the first commercial
sale of a licensed product. The timing of the remaining milestones, which total
approximately $1.3 million, is dependent upon factors that are beyond our
control, including our ability to recruit patients, the outcome of future
clinical trials and any requirements imposed on our clinical trials by the FDA.
If the FDA imposes more stringent requirements on our clinical trials, the
length and number of such trials may be increased resulting in additional
research and development expenses.
Non-Cash Expense, Beneficial Conversion Feature and Financial Support Provided
by a Principal Stockholder
Since our inception, we have issued stock or granted stock options or
warrants to non-employee lenders and consultants for which we recorded non-cash
expense of approximately $93,000 in 1999, $708,000 in 2000 and none in 2001.
In December 2001, we issued 989,991 shares of series B preferred stock in
consideration of gross proceeds of approximately $5.5 million. The series B
conversion price represented a discount from the estimated fair value of our
common stock at the time of issuance. Accordingly, the discount amount is
considered incremental yield to the preferred stockholders and has been
accounted for as a deemed dividend to preferred stockholders. Based on the
conversion terms of the series B stock, a deemed dividend of approximately $3.6
million has been added to the net loss applicable to common stockholders in the
year ended December 31, 2001.
Since our inception, Paramount Capital Investments, LLC has provided us with
office space, industry expertise, financial support and certain administrative
and legal assistance at no cost to us. Paramount Capital Investments is an
affiliate of Paramount Capital, Inc., which, in turn, is affiliated with one of
our principal stockholders. Paramount Capital is an integrated, privately held,
full-service investment banking firm specializing in private placements of
equity and debt securities for publicly traded and privately held biotechnology
and biopharmaceutical companies. Paramount's assistance has allowed us to focus
our available cash resources almost exclusively on product development and has
reduced our cash burn rate through in-kind overhead contributions.
The estimated fair value of Paramount's assistance has been reflected in the
accompanying financial statements as an expense in the period benefited with a
corresponding deemed capital contribution. The estimated fair value of the
financial assistance totaled $89,531 for the period from February 23, 1998
26
(inception) to December 31, 1998, $155,917 for the year ended December 31, 1999,
$163,376 for the year ended December 31, 2000 and $481,299 for the year ended
December 31, 2001.
Results of Operations
Revenues. With the exception of revenues derived from government grants, we
have generated no operating revenues since our inception and do not expect
operating revenues for the foreseeable future. In the second half of 2000, we
were awarded a $1.2 million research and development grant for intranasal
ketamine from the Department of Defense, or DOD, payable monthly from October 1,
2000 to October 31, 2003. Also in 2000, we were awarded a $298,000 research and
development grant from the National Institutes of Health, or NIH, for intranasal
ketamine. The DOD and NIH grants are billed monthly as costs are incurred.
Research and Development Expenses. Research and development expenses consist
primarily of salaries and related expenses for personnel, materials and supplies
used to develop our product candidates. Other research and development expenses
include compensation paid to consultants and outside service providers and the
costs to license acquired technologies that have no alternative future use. We
expense research and development costs as incurred. We expect that we will
continue to incur significant research and development expenses in the future.
General and Administrative Expenses. General and administrative expenses
consist primarily of salaries and other related costs for personnel in
executive, finance, accounting, information technology and human resource
functions. Other costs include facility costs and professional fees for legal
and accounting services.
Interest Income and Expense. Interest income consists of interest earned on
our cash and cash equivalent balances. Interest expense consists of interest
incurred on loans.
Years Ended December 31, 2000 and 2001
Revenues. Grant revenue increased from $306,035 for the year ended December
31, 2000 to $882,358 for the year ended December 31, 2001. The increase is
attributable to grant revenue resulting from an increase in resources dedicated
to fulfilling our obligations under the DOD and NIH grants.
Research and Development Expenses. Research and development expenses
decreased from approximately $21.8 million for the year ended December 31, 2000
to approximately $7.0 million for the year ended December 31, 2001. The decrease
in research and development expense resulted primarily from an $18.6 million
noncash charge we recorded for the year ended December 31, 2000 for the fair
value of the license agreement purchased in connection with the merger with Pain
Management. Excluding the non-cash charge, research and development expenses
increased from approximately $3.2 million for the year ended December 31, 2000
to $7.0 million for the year ended December 31, 2001.
This increase resulted from increased costs associated with the clinical
development of our lead product candidates, intranasal ketamine and intranasal
morphine. Four human clinical trials were active during the period, including
two intranasal ketamine Phase II clinical trials and two intranasal morphine
Phase I clinical trials. Our consulting expenses also increased as a result of
increased clinical activity associated with protocol development, regulatory
management and report finalization.
General and Administrative Expenses. General and administrative expenses
increased from approximately $1.4 million for the year ended December 31, 2000
to approximately $2.3 million for the year ended December 31, 2001. This
increase resulted from the hiring of additional personnel and increased
professional service fees. We expect general and administrative expenses to
increase further as we hire additional personnel, lease our own facilities and
separate our operations from Paramount.
Interest Expense. Interest expense decreased from $320,533 for the year ended
December 31, 2000 to zero for the year ended December 31, 2001. The decrease in
interest expense was due to the repayment of $475,000 of bank notes and $1.0
million of bridge notes during 2000 from the net proceeds of our September 2000
series A convertible preferred stock financing. We had no debt outstanding
during 2001.
Interest Income. Interest income increased from $177,490 for the year ended
December 31, 2000 to $348,475 for the year ended December 31, 2001. The increase
in interest income was primarily due to interest earned on the net proceeds
raised from our September 2000 series A convertible preferred stock financing.
27
The Period from February 23, 1998 (inception) to December 31, 1998 and the Years
Ended December 31, 1999 and 2000
Revenues. We generated no operating revenues during 1998 and 1999. We
generated revenues of $306,035 in 2000 due to the commencement of projects
funded by grants from the DOD in July 2000 and the NIH in September 2000.
Research and Development Expenses. Research and development expenses
increased from $206,618 in 1998 to $664,636 in 1999 and to $21.8 million in
2000. The increase in research and development expense from 1998 to 1999
resulted primarily from the license fee paid to West Pharmaceutical for entering
into a license agreement for intranasal morphine and subsequent costs associated
with initiation of the intranasal morphine development program. The increase in
research and development expenses from 1999 to 2000 resulted primarily from
costs associated with acquisition of a license agreement valued at approximately
$18.6 million in connection with the merger with Pain Management.
General and Administrative Expenses. General and administrative expenses
increased from $256,980 in 1998 to $312,079 in 1999 and increased to $1.4
million in 2000. The increase in general and administrative expenses resulted
primarily from the hiring of additional personnel, including senior level
management, and costs associated with business development, consulting services
related to market research, fundraising and travel. The increase in general and
administrative expenses from 1998 to 1999 was due to the hiring of additional
personnel. The increase in general and administrative expenses from 1999 to 2000
resulted primarily from non-cash compensation expenses of approximately $708,000
relating to options granted to non-employees and from an increase in the number
of personnel from three employees in the first quarter of 1999 to seven
employees in the fourth quarter of 2000 and related expenses necessary to
support our growth.
Interest Expense. Interest expense increased from $6,602 in 1998 to $239,092
in 1999 and $320,533 in 2000. The increase in interest expense from 1998 to 1999
and from 1999 to 2000 resulted from interest accrued on the bridge notes.
Between April 1999 and July 2000, the bridge notes accrued interest at a rate of
12% per annum for the first 12 months and 15% per annum thereafter.
Interest Income. Interest income increased from zero in 1998 to $10,572 in
1999 and $177,490 in 2000. The increase in interest income from 1998 to 1999
reflected interest earned from proceeds raised from $1.0 million of our bridge
notes issued from April through July 1999. The increase in interest income from
1999 to 2000 reflected higher invested balances during 2000 due primarily to
interest earned on the proceeds of our September 2000 series A convertible
preferred stock financing.
Liquidity and Capital Resources
As of December 31, 2001, we had cash and cash equivalents of approximately
$7.7 million, and working capital was approximately $6.8 million.
From inception through December 31, 2001, net cash used in operating
activities was approximately $11.2 million. From inception through December 31,
2001, net cash used in investing activities was $75,702, primarily due to the
acquisition of products, furniture and fixtures and office equipment, and the
purchase of short-term investments. From inception through December 31, 2001,
net cash provided by financing activities was $19.0 million. The principal
source of cash was from equity and debt financings.
We expect that our operating expenses and capital expenditures will increase
in future periods as a result of increased preclinical studies and clinical
trial activity, research and development and the anticipated commercialization
of our product candidates, assuming we receive the necessary regulatory
approvals. The initiation of commercial activities will require the hiring of
additional staff to coordinate contract manufacturing services at multiple
locations. Research and development expenditures, including clinical trials, are
expected to increase as we continue to develop new product candidates.
We also intend to hire additional research and development, clinical and
administrative staff. Our capital expenditure requirements will depend on
numerous factors, including the progress of our research and development
programs, the time required to file and process regulatory approval
applications, the ability to obtain additional licensing arrangements, and the
demand for our product candidates, if and when approved by the FDA or other
regulatory authorities. Our expenditures would also increase if we are required
to pay Paramount or other third parties for administrative and other costs,
including rent.
28
We believe that our current cash and investment position will be sufficient
to fund our operations and capital expenditures at least through the next 12
months.
Income Taxes
As of December 31, 2001, we had approximately $12.6 million of net operating
loss carryforwards available to offset future taxable income. These
carryforwards will begin to expire in 2018.
Recent Accounting Pronouncements
In July 2001, the Financial Accounting Standards Board issued Statement No.
141, "Business Combinations," and Statement No. 142, "Goodwill and Other
Intangible Assets." FAS 141 requires that all business combinations be accounted
for under the purchase method and that certain acquired intangible assets in a
business combination be recognized as assets apart from goodwill. FAS 142
requires that ratable amortization of goodwill and certain intangible assets be
replaced with periodic tests of the goodwill's impairment and that other
intangible assets be amortized over their useful lives. FAS 141 is effective for
all business combinations initiated after June 30, 2001. The provisions of FAS
142 will be effective for fiscal years beginning after December 15, 2001 and
will be adopted by us in 2002. We do not expect the adoption of FAS 141 or 142
to have any material impact on our financial statements.
In July 2001, The Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 143, "Accounting for Obligations Associated
with the Retirement of Long-Lived Assets." The objective of FAS 143 is to
provide accounting guidance for legal obligations associated with the retirement
of tangible long-lived assets. The retirement obligations included within the
scope of FAS 143 are those that an entity cannot avoid as a result of either the
acquisition, construction or normal operation of a long-lived asset. Components
of larger systems also fall under FAS 143, as well as tangible long-lived assets
with indeterminable lives. FAS 143 is required to be adopted on January 1, 2003.
We do not expect the adoption of FAS 143 to have any material impact on our
financial statements.
The Financial Accounting Standards Board issued FASB Statement No. 144,
"Accounting for the Impairment or Disposal of Long-Lived Assets." The objectives
of FAS 144 are to address significant issues relating to the implementation of
FASB Statement No. 121, "Accounting for the Impairment of Long-Lived Assets and
for Long-Lived Assets to Be Disposed Of," and to develop a single accounting
model, based on the framework established in FAS 121, for long-lived assets to
be disposed of by sale, whether previously held and used or newly acquired. The
provisions of FAS 144 are effective for financial statements issued for fiscal
years beginning after December 15, 2001. We do not expect the adoption of FAS
144 to have any material impact on our financial statements.
Disclosure About Market Risk
Our exposure to market risk is principally confined to our cash equivalents,
all of which currently have maturities of less than three months. We maintain a
non-trading investment portfolio of investment grade, liquid debt securities
that limits the amount of credit exposure to any one issue, issuer or type of
instrument. The fair value of these securities approximates their cost.
The primary objective of our investment activities is to preserve principal
while at the same time maximizing the income we receive from investments without
significantly increasing risk. Some of the securities that we may invest in may
be subject to market risk. This means that a change in prevailing interest rates
may cause the value of the investment to fluctuate. For example, if we purchase
a security that was issued with a fixed interest rate and the prevailing
interest rate later rises, the value of our investment will probably decline. To
minimize this risk, we intend to maintain our portfolio of cash equivalents and
short-term investments in a variety of securities, including commercial paper,
money market funds and government and non-government debt securities. In
general, money market funds are not subject to market risk because the interest
paid on such funds fluctuates with the prevailing interest rate. As of December
31, 2001, we neither had any holding of derivative financial or commodity
instruments, nor any foreign currency denominated transactions, and all of our
cash and cash equivalents were in money market and checking funds.
29
BUSINESS
We are a specialty pharmaceutical company that applies proprietary
technologies to develop new drugs and improved formulations of existing drugs
for the prescription pain management market. We believe that our product
candidates address unmet medical needs for breakthrough cancer pain,
postoperative pain, lower-back pain, pain due to orthopedic injury, dental pain
and pain due to other indications. We believe our product candidates offer a
combination of enhanced pain relief, improved side effect profiles and faster
onset of pain relief compared to currently available treatments.
Definition of Pain
Pain is an unpleasant sensory and emotional experience. The sensation of pain
can be caused by actual or potential tissue damage, such as that resulting from
an injury or trauma, or may be the result of a disease.
Classifications of Pain
How an individual feels pain is a complicated process that is carried out by
the central nervous system. Each individual's perception of pain is a subjective
and personal experience. In order to prescribe the appropriate medications for
treatment, clinicians evaluate pain according to duration, intensity and cause.
Duration describes the period of time over which pain impacts a patient's life
before it is resolved. The intensity of pain directly impacts a patient's
ability to perform routine, everyday activities, ranging from daily work to
self-care. The cause of pain is linked to its underlying origin, whether it be
the consequence of direct injury or an inflammatory process. The overall
experience of pain is a combination of these three factors. Clinicians consider
each of these factors, individually and collectively, when developing the
therapeutic regimen most effective for patients.
Pain Categories
The duration of pain can be categorized as either acute or chronic depending
on its origin.
Acute pain is typically brief in duration and eases of its own accord or
after successful treatment of the underlying problem. Acute pain usually results
from trauma or surgery.
Episodic flare-ups of acute pain occurring on a background of treated,
persistent pain may complicate chronic pain. These flare-ups are referred to as
"breakthrough pain" and may be frequent and unpredictable.
Chronic pain persists or recurs for prolonged periods and may last for a
patient's lifetime despite the healing process. Some of the more common types of
chronic pain are associated with cancer and other long-term conditions,
including lower-back pain.
Pain Intensity
The intensity of pain can be described as mild, moderate or severe.
Mild pain generally does not affect the routines of daily life. Common
examples of mild pain include muscular aches and mild headaches. Mild pain
almost always responds to over-the-counter medications such as NSAIDs, including
aspirin and acetaminophen.
Moderate pain can affect an individual's daily life and can be debilitating.
Common examples of moderate pain include pain from minor surgery or orthopedic
injury. Such pain may require treatment with prescription pain medicines,
typified by opioids, including morphine, and stronger NSAIDs, including
ketorolac.
Severe pain drastically interferes with even the simplest daily activities
and undermines an individual's quality of life. Common examples of severe pain
include pain resulting from serious underlying conditions, including cancer,
major surgery or trauma. Treatment of severe pain requires the most potent
medications, typically prescription opioid narcotics, including morphine and
fentanyl, at very high doses.
30
Causes of Pain
The causes of pain are classified as somatic, visceral and neuropathic. Each
of these causes is differentiated by the tissue affected.
Somatic pain results from injuries to skin, muscle, bone, or joint and is
typically characterized as a sharp pain that is localized to an injured area.
Somatic pain may be mild, moderate or severe in intensity, depending on the
extent of the injury.
Visceral pain is produced by injury, inflammation or stretching of internal
organs and is typically characterized by diffuse, poorly localized, dull and
vague pain. Visceral pain is usually moderate-to-severe in intensity, such as
abdominal pain accompanying appendicitis or the passing of a kidney stone.
Neuropathic pain is produced by injuries or inflammation of nerves and is
typically characterized by diffuse, burning pain. Cancer pain is one of the most
common examples of neuropathic pain.
The following table gives examples of how common indications of pain can be
described using the classifications set forth above:
Indication Category Intensity Cause
- ---------- --------- ---------- -----
Breakthrough Cancer Pain Acute Moderate-to-Severe Neuropathic
Episodes of
Chronic Pain
Postoperative Pain Acute Pain Mild-to-Severe Somatic, Visceral, or Neuropathic
Lower-Back Pain Acute Pain Mild-to-Severe Somatic
and Acute
Episodes of
Chronic Pain
Orthopedic Injury Acute Pain Mild-to-Severe Somatic
Dental Pain Acute Pain Mild-to-Severe Somatic
Pain Management Market
Pain is a serious health and economic problem. According to Front Line
Strategic Management Consulting, Inc., the worldwide market for therapeutics to
manage pain is expected to grow from $22 billion in 2000 to $30 billion in 2007.
Over the past ten years, the healthcare industry has taken active measures that
focus on the importance of pain management as a component of patient care. These
measures include:
o The designation of pain management as a recognized subspecialty for
physicians by the American Board of Medical Specialties in 1991.
o The 1994 publication by the Agency for Health Care Policy and Research,
U.S. Department of Health and Human Services, or AHCPR, of guidelines for
the treatment of breakthrough cancer pain recommending the administration
of regularly scheduled analgesic doses as well as additional doses of
breakthrough pain medication.
o The requirement, as of 1999, for all U.S. hospitals and healthcare
facilities to assess the adequacy of pain treatment for each patient on a
regular basis in order to achieve accreditation by the Joint Commission on
Accreditation of Healthcare Organizations.
o The recommendation by the World Health Organization to increase the
availability of opioids in order to meet demand for treatment of patients
in pain.
31
Because of the increasing awareness of the importance of pain management by the
healthcare industry, growth in the pain management market has been significant
in recent years and is expected to continue. Additional factors that are
contributing to the growth of the pain management market include:
o population demographic shifts growing the target market population,
o new therapies that have increased survival times for patients with
chronic conditions,
o increasing recognition of the therapeutic and economic benefits of
effective pain management by physicians, healthcare providers and payors,
o rapid market acceptance of new products with novel mechanisms of action,
and
o targeted markets that permit cost-effective selling and marketing.
Left unmanaged, pain can significantly compromise an individual's quality of
life. Drugs are a key element in the treatment of pain. The drugs most commonly
used to treat acute, moderate-to-severe pain include strong opioids, such as
morphine, and in the case of moderate pain, weaker opioids such as hydrocodone
and oxycodone or stronger NSAIDs, such as ketorolac. Patients suffering from
chronic, moderate-to-severe pain syndromes, such as cancer pain, often require
long-term use of opioids that are typically prescribed in sustained-or
extended-release formulations. Chronic pain is often treated with a combination
of drugs, including sustained-release products, such as the fentanyl patch or
sustained-release morphine, to treat the underlying baseline pain and
immediate-release products, such as transmucosal fentanyl, or immediate release
or intravenous morphine to treat episodic breakthrough pain.
Based on information from The Analytica Group, the table below shows the
total predicted market for several key pain indications, in order of total
annual market size, that we believe our product candidates will address. These
market projections are based on the estimated U.S. presenting population, which
is the subset of the total population that seeks medical attention for the
respective indication, for the year 2000. The cost of therapy for each
indication is calculated by multiplying the estimated average daily cost of
prescription pain medication for our product candidates by the number of therapy
days. The total market for each indication is calculated by multiplying the U.S.
presenting population by the cost of therapy.
U.S. Presenting Cost of Drug Therapy per
Indication Population Patient per Year Total Annual Market
--------------------------------------- --------------- ------------------------ -------------------
(in millions)
Breakthrough Cancer Pain................. 792,690 $1,500 $1,189
Postoperative Pain....................... 14,692,706 60 882
Lower-Back Pain.......................... 627,654 906 569
Orthopedic Injury........................ 4,676,761 84 393
Dental Pain.............................. 21,600,000 18 389
---------- ------ ------
Total................................. 42,389,811 2,568 3,422
Breakthrough Cancer Pain
The 2000 U.S. incidence rate of breakthrough cancer pain as determined by The
Analytica Group and the American Cancer Society was estimated to be
approximately 793,000 patients per year. It is estimated that more than 70% of
cancer patients with advanced disease suffer from moderate-to-severe
breakthrough pain and are treated for their conditions with a combination of
short and long acting analgesics. On average, patients suffering from
breakthrough pain experience three to four breakthrough episodes per day and
require therapy for their condition for an average of 150 days per year. The
current standard of care for breakthrough pain is the administration of as-
needed, immediate-release oral opioids.
Most patients with advanced cancer experience pain, and one out of five of
such patients experience uncontrolled pain. The World Health Organization has
established guidelines that recommend the appropriate medications that
physicians should prescribe for the management of cancer pain. However, these
guidelines do not address the limited treatment options available for patients
who have uncontrolled, or breakthrough, pain.
32
Breakthrough cancer pain is characterized by acute episodes of chronic
moderate-to-severe, neuropathic pain that suddenly flares-up and does not
respond to standard pain management treatments. This type of pain is
particularly difficult to treat due to its severity, rapid onset and the
unpredictable nature of its occurrence. Breakthrough pain may be further
classified into three types: incident pain, spontaneous pain or pain occurring
when the background pain management medication reaches the limits of its
effectiveness. This latter type of breakthrough pain is also referred to as end
of dose failure. Incident pain is usually precipitated by a voluntary action,
such as movement. By comparison, an episode of breakthrough pain that is
spontaneous in its origin is not associated with a precipitating event.
Breakthrough pain associated with end of dose failure occurs more frequently
near the end of a dosing interval for the standard pain management drug that the
patient is using to control background pain.
We believe that our product candidates, if approved, will provide an
effective, alternative treatment for breakthrough pain.
Postoperative Pain
Postoperative pain is typically attributable to acute, mild-to-severe pain,
can be somatic, visceral or neuropathic in cause, and is the direct result of a
surgical procedure.
The need for postoperative pain management depends in large part on the
magnitude of the surgical trauma. Generally, the greater the magnitude of the
surgery, the greater the postoperative discomfort. The choice of analgesic can
be based on the invasiveness of the surgical procedure. Minor surgical
procedures such as arthroscopy and breast biopsy are minimally invasive and
produce minimal surgical trauma. These types of procedures are usually performed
on an out-patient basis. Postoperative pain following minor surgical procedures
is usually provided with oral or parenteral NSAIDs or a weak oral opioid for the
management of breakthrough pain episodes.
More invasive surgical procedures of an intermediate nature, such as
hysterectomy, appendectomy and total joint replacement, require hospitalization
for the management of postoperative pain. Intravenous patient-controlled
analgesia, or PCA, with opioids is the therapy of choice for treating this
patient population prior to discharge from the hospital. PCA allows a patient to
receive drugs on demand by using an infusion pump that is programmed by the
physician to intermittently administer drugs when the patient pushes a button.
The addition of parenteral or oral NSAIDs to this regimen is gaining broader use
as these have been demonstrated to decrease the requirement for opioids.
Major surgery, such as heart surgery, produces major trauma and requires
hospitalization. Treatment of postoperative pain following major surgery often
requires epidural infusion of the strongest opioids supplemented by PCA with
opioids and oral or parenteral NSAIDs to manage breakthrough pain episodes.
We believe our product candidates will be effective for the management of
pain following minor surgical procedures, offer a readily acceptable alternative
to intravenous PCA for the management of moderate-to-severe postoperative pain
following intermediate procedures, and have utility for the treatment of
breakthrough pain associated with major surgical procedures.
Lower-Back Pain
Lower-back pain is the most common medical complaint in developed countries.
As a result, the patient population is extremely large. Our product candidates
are designed for individuals whose lower-back pain is severe enough to limit
their activities. According to the Centers for Disease Control, in 1998 there
were approximately 7.9 million individuals whose chronic back problems were
activity limiting.
Lower-back pain is typically acute, mild-to-severe, somatic pain, although a
substantial percentage of sufferers develop chronic symptoms. Episodes of
breakthrough lower-back pain are treated with both over-the-counter and
prescription medications, depending on the severity of symptoms. The most severe
episodes may require the use of opioids.
We believe that our product candidates, if approved, will provide an
effective, alternative treatment for patients experiencing breakthrough lower-
back pain.
33
Orthopedic Injury
Orthopedic injuries are associated with acute, somatic pain that varies in
intensity from mild to severe depending on the extent of the trauma. Those
injuries that are the result of a fracture or dislocation are usually associated
with mild-to-severe pain. Many patients with fractures or dislocations are
treated by an orthopedist in the emergency department of a hospital or clinic
and are discharged the same day.
Treatment of fractures can involve the realignment of bones, a procedure
referred to as reduction. Although fractures and dislocations are generally due
to minor injuries, the time leading up to and during reduction of a fracture or
the correction of a dislocation is often associated with acute,
moderate-to-severe, somatic pain. Pain due to orthopedic injury is generally
under-treated or untreated in the emergency department.
Our product candidates may be effective in treating pain associated with
procedures that are the result of orthopedic injury, such as pin removal. Pin
removal is a painful process that follows certain types of setting procedures
that require external fixtures. In these types of surgical procedures, pins are
placed into the broken bone above and below the fracture site in order to allow
the orthopedic surgeon to reposition the bone fragments. The pins may
subsequently be connected to an external frame that immobilizes the bone and is
kept in place until the fracture heals. Analgesia is often necessary at the time
of removal of this external stabilizing device.
We believe that emergency departments have an economic incentive to use any
therapy that can speed patient discharge from the hospital and avoid expenses
associated with administration of intravenous drugs. We also believe that our
product candidates satisfy the unmet medical need for agents that are fast
acting, safe and easily titrated to treat moderate-to-severe pain associated
with orthopedic injury in the emergency department setting.
Dental Pain
The 2000 U.S. incidence rate of dental pain as determined by The Analytica
Group was estimated to be approximately 21.6 million patients per year. Dental
pain is typically acute, mild-to-severe, somatic pain. Dental pain associated
with oral surgery, including wisdom tooth extraction and periodontal procedures,
frequently requires short-term management with opioid analgesics or strong
NSAIDs.
The treatment of dental pain with analgesics is complicated by the inherent
difficulties in swallowing following dental surgery and the unusual intensity of
its symptoms. Pain originating in the tooth pulp or surrounding gums is
instantly worsened by even the slightest changes in temperature, humidity or
pressure and, as a result, dental pain has been described as excruciating.
Relief from pain of this quality requires substantial doses of the strongest
opioids.
We believe our product candidates will provide an effective, rapidly acting,
non-oral alternative for the treatment of pain resulting from oral surgery.
Limitations of Current Pain Management
Despite advances in medicine and the development of new drugs, we believe
pain management remains a critical area of unmet medical need. Increasingly,
patients, advocacy groups and the media are highlighting the shortcomings of
pain management and are demanding changes to the current standards of care
provided by the medical system. To address these inadequacies, clinicians and
the pharmaceutical industry are creating a variety of different pain control
products that can provide the flexibility and versatility required to close the
gap in the current practice of pain management. These gaps include:
o Slow onset of action. Commercially available oral pain medications can take
20 to 40 minutes to provide detectable levels of pain relief. Drugs
delivered through a transdermal patch can take several hours to reach
effective blood levels, and prolonged drug absorption can occur after patch
removal.
o Insufficient dose-to-intensity control. It is difficult to match the doses
of drugs that are administered orally or by transdermal patch to the
patient's level of pain. This mismatch can result in either under-
treatment or over-treatment.
34
o Costly to administer. Although intravenous administration provides rapid
entry of drugs into the bloodstream, delivery by this route requires both
trained personnel and, in some cases, specialized equipment. This adds to
the overall cost of therapy.
o Invasive route of delivery. Intravenous or intramuscular delivery of drugs
can cause pain to patients when administered. Consequently, some patients
are adverse to receiving injections.
o Poor side-effect profile. Opioids, such as morphine, are associated with a
number of side effects, including nausea, vomiting, constipation,
respiratory depression and sedation. In addition, some patients are unable
to use opioid medications.
Our Solution
We believe that our product candidates, if approved, address many of the
limitations of existing pain treatment therapies by providing one or all of the
following characteristics:
o Rapid onset of pain relief. Our intranasal ketamine and morphine product
candidates rapidly enter the bloodstream following administration and
generally provide detectable pain relief within two to five minutes after
administration.
o Appropriate dose-to-intensity control. Our intranasal product candidates
allow the patient to administer an amount of drug that is appropriate for
that individual's level of pain and to discontinue administration once a
desired level of pain relief is obtained. This ability to self-regulate the
dose of drugs avoids doses that are higher than necessary to achieve safe
and effective management of pain.
o Low cost to administer. Our intranasal product candidates permit patients
to self-administer and self-regulate the dose of drugs. This eliminates the
need for the personnel and equipment necessary to establish an intravenous
line and is more affordable for hospitals and home care settings.
o Non-invasive route of delivery. Our intranasal product candidates are
non-invasive, eliminating the need for injections. In addition, a non-
invasive route of delivery reduces the incidence of needle stick injuries
and the potential for transmission of blood-borne viruses.
o Improved side-effect profile. Our intranasal ketamine and intravenous
diclofenac product candidates have improved side-effect profiles over
comparable products in their category. For example, they are non-sedating
and do not affect a patient's blood pressure or heart rate. In addition,
when used in combination with other opioids, ketamine and diclofenac have
been reported to reduce the amount of opioids required to produce an equal
level of pain relief, which reduces the requirement for narcotics. This
reduction in the requirement for opioids can enhance the patient's overall
quality of life.
Product Candidates
Our product candidates are comprised of a number of well-known analgesic
drugs that, in combination with our chosen routes of administration, are under
development for the treatment of a variety of acute and chronic moderate-to-
severe pain syndromes. We selected our product candidates for development based
on our belief that they offer significantly lower clinical, regulatory and
commercial risk profiles as compared to NCEs.
We are evaluating each of our product candidates in several clinical models
of pain in order to seek approval by the FDA for use in the treatment of acute
and chronic moderate-to-severe pain indications. The guidelines established by
the FDA recommend that we demonstrate effectiveness in more than one clinical
model of pain. Acceptable clinical models of pain include dental pain,
postoperative pain, cancer pain and pain due to various types of trauma.
Typically, our clinical trials are designed as randomized, double-blind,
placebo-controlled and, where appropriate, comparator-controlled studies. A
randomized study is one in which the patient is randomly assigned to receive a
study drug or placebo based on a pre-determined ratio. A double-blind study is
one in which the patient, the physician and the sponsor are unaware if the
patient is receiving a placebo or drug in order to preserve the integrity of the
trial and prevent observer bias. A placebo-controlled study is one in which a
subset of patients is purposefully not administered the study drug.
35
A comparator-controlled study is one in which a subset of patients is
administered a medication that is currently prescribed to treat the condition in
order to directly compare the study drug to approved therapies.
All of our product candidates offer the ability to deliver an approved drug
into the bloodstream through a fast and effective route of administration. Three
of our product candidates are administered by a nasal spray, and one is
administrated intravenously. Nasal delivery is an ideal route for drug
administration as it does not require intravenous or intramuscular injections.
The large surface area, uniform temperature, high permeability and high density
of blood vessels in the lining of the nasal cavity all contribute to the rapid
absorption of drugs into the bloodstream. The nasal route of delivery is also a
good alternative for patients who have difficulty swallowing oral products.
Drugs that are administered orally are absorbed from the blood vessels that
line the stomach and pass through the liver where they may be metabolized to an
inactive form. This process is referred to as first pass metabolism. By
contrast, our product candidates enter the bloodstream directly through
intravenous administration or through the blood vessels of the nasal cavity and
avoid the phenomenon of first pass metabolism. By avoiding first pass
metabolism, it is possible to achieve higher concentrations of the active drug
circulating in the bloodstream.
The following table identifies our current product candidates according to
clinical indication and stage of development in the United States and the United
Kingdom:
Product Candidate Clinical Indication Development Stage
----------------- ------------------- -----------------
Intranasal Ketamine Acute Pain and Acute Episodes of Chronic Phase II
Moderate-to-Severe Pain
Intranasal Morphine Acute Pain and Acute Episodes of Chronic Phase II
Moderate-to-Severe Pain
Intravenous Diclofenac Acute Moderate-to-Severe Pain Phase II
Intranasal Fentanyl Acute Episodes of Chronic Preclinical
Moderate-to-Severe Pain
Intranasal Ketamine
Background
Ketamine is a non-opiate, N-methyl-D-aspartate, or NMDA, receptor antagonist
that has been in clinical use for over 25 years as a general anesthetic. Since
its approval by the FDA, ketamine has been safely used for anesthesia in tens of
thousands of patients. NMDA receptors are located in the central nervous system
and play a role in the perception of pain. Ketamine blocks NMDA receptors, and
therefore it is a logical drug candidate for use as an analgesic for syndromes
associated with acute pain, including breakthrough pain. A large body of
clinical literature describes the off-label use and effectiveness of lower doses
of ketamine than that approved for use as an anesthetic in providing pain relief
for postoperative pain, emergency medical procedures and neuropathic pain,
cancer pain, including breakthrough pain, and other acute pain. In addition,
several of these publications report the ability of ketamine to increase the
potency of the analgesic effects, as well as reduce the overall requirement of,
co-administered opioid pain relievers.
The use of ketamine as an analgesic is gaining acceptance by clinicians in
view of its effectiveness and minimal impact on cardiovascular and respiratory
functions. Since ketamine is not approved for use as a pain reliever, physicians
have resorted to using the drug off-label. We believe that an FDA-approved
formulation of ketamine for the treatment of moderate-to-severe pain will
provide physicians with an accepted and regulated alternative to off-label use.
In addition, in 1999 ketamine was labeled by the Drug Enforcement Agency, or
DEA, as a Schedule III controlled substance. The scheduling of ketamine by the
DEA provides additional protection with respect to controlling potential misuse
by placing restrictions on the ability to prescribe and distribute the drug.
36
Clinical Results
Our intranasal ketamine product is in clinical development for the treatment
of a heterogeneous group of syndromes associated with acute pain and acute
episodes of chronic pain. To obtain the information that will be required by the
FDA to demonstrate safety and effectiveness in these two pain categories, we are
pursuing a development program of intranasal ketamine along two clinical paths.
The first path focuses on the development of intranasal ketamine for acute
indications, including postoperative pain. The second path focuses on the
development of intranasal ketamine for acute episodes of chronic pain, including
breakthrough cancer pain.
All of our clinical trials for intranasal ketamine are being performed in the
U.S. under a company-sponsored IND. We have successfully completed three Phase
II clinical trials and one Phase I clinical trial of intranasal ketamine in a
total of 118 patients and volunteers. In these trials, a total of 98 patients
and volunteers have received doses of intranasal ketamine. Seventy-eight of
these patients and volunteers received intranasal ketamine in our Phase I and
two of our Phase II acute pain trials. Twenty patients and volunteers received
intranasal ketamine in our Phase II breakthrough pain trial. Based on the
results of these completed trials, we expect to complete final reports and to
file the data from our Phase II clinical trials and our Phase III clinical
designs with the FDA in the first half of 2002. At our subsequent End-of-Phase
II meeting, we will seek feedback from the FDA regarding the trial design of our
future clinical trials. We anticipate initiating Phase III clinical trials
shortly thereafter.
Acute Indications
In the second quarter of 2001, we completed a placebo-controlled Phase II
randomized, double-blind trial evaluating the safety and effectiveness of three
dose levels of intranasal ketamine for the treatment of moderate-to-severe
postoperative pain in 40 patients undergoing the removal of two to four wisdom
teeth. In this trial, we demonstrated the following results:
o compared to a placebo, all three dose levels of intranasal ketamine
provided significant postoperative pain relief,
o intranasal ketamine is fast-acting, with onset of pain relief generally
occurring within two to ten minutes following administration,
o both analgesic effectiveness and duration of effect depended on the dose
of intranasal ketamine, and
o intranasal ketamine appears to be safe and well-tolerated by patients.
Patients enrolled in this trial received either placebo or one of three doses
of intranasal ketamine upon the onset of moderate-to-severe pain following
dental surgery. Both pain intensity and pain relief were evaluated at specific
time intervals over a three-hour period following the administration of
intranasal ketamine. These evaluations were performed using several categorical
and visual scales that are well established and widely used in evaluating drugs
for the treatment of pain. Patient vital signs, including heart rate and blood
pressure, were measured throughout the study, and physical examinations and
nasal examinations were performed prior to treatment and after completion of the
study. Patients who did not receive adequate pain relief within an hour were
administered a "rescue" medication to treat their pain.
As illustrated in the graph, each dose level of intranasal ketamine
demonstrated pain relief, with the highest dose having the fastest onset,
highest peak and longest duration of effect. Pain relief was calculated as the
difference between baseline pain and the pain intensity measured at specified
timepoints over the initial 60 minute observation phase. In this trial, the
onset of pain relief was rapid in each of the three dose groups of intranasal
ketamine. Maximum pain relief was attained 30 minutes following dose
administration. No harmful effects on heart rate or blood pressure were found
and assessment of patient vital signs and the results of physical and nasal
examinations indicated that intranasal ketamine was well-tolerated. Based on the
results of this study, we believe that intranasal ketamine may offer a safe,
non-opioid alternative for the treatment of moderate-to-severe postoperative
pain.
37
Effectivness of Intranasal Ketamine for
the Treatment of Postoperative Pain
[LINE GRAPH]
In the third quarter of 2001, we initiated, and successfully completed, a
second 40-patient Phase II clinical trial of intranasal ketamine for the
treatment of acute pain. This trial was designed to confirm the safety and
effectiveness and determine the minimum effective dose of intranasal ketamine
required by patients suffering from moderate-to-severe postoperative pain.
Patients enrolled in this study received either placebo or one of three doses of
intranasal ketamine upon the onset of moderate-to-severe pain following dental
surgery. The parameters used to evaluate safety and effectiveness of intranasal
ketamine in this second Phase II clinical trial were identical to that of the
previous Phase II clinical trial. However in this study, the highest dose of
intranasal ketamine tested was equal to the lowest dose tested in the earlier
Phase II clinical trial.
In this trial, we demonstrated the following results:
o intranasal ketamine generally provides pain relief within two to ten
minutes following administration,
o the amount and duration of pain relief depends on the dose of intranasal
ketamine,
o intranasal ketamine appears to be safe and well-tolerated by patients,
and
o at very low doses, intranasal ketamine provides minimum and limited pain
relief.
Our clinical trial results suggest that intranasal ketamine provides rapid
onset of pain relief with dose-related effectiveness and duration of effect. In
the fourth quarter of 2001, we initiated a Phase II clinical trial conducted at
multiple clinical sites of intranasal ketamine for the treatment of
moderate-to-severe pain associated with orthopedic injury. We began enrolling
patients for this study during the first half of 2002.
Acute Episodes of Chronic Pain
In the fourth quarter of 2001, we completed a Phase II clinical trial
conducted at multiple clinical sites that evaluated the safety and effectiveness
of intranasal ketamine for the treatment of moderate-to-severe episodes of
breakthrough pain. Patients who enrolled in this trial had a documented history
of chronic debilitating malignant pain and most were considered opioid tolerant.
The trial was designed as a placebo-controlled, double-blind crossover trial in
20 patients experiencing severe breakthrough pain episodes. In this trial, we
demonstrated the following results:
o compared to placebo, intranasal ketamine provided statistically
significant relief for breakthrough pain,
o intranasal ketamine is fast-acting with measurable pain relief obtained
within five minutes of administration,
38
o intranasal ketamine provided significant pain relief over the one-hour
treatment period, and
o intranasal ketamine appears to be safe and well tolerated by patients.
Patients enrolled in this trial were given either placebo or intranasal
ketamine upon inception of their first breakthrough pain episode and instructed
to administer a fixed dose of up to five sprays until adequate pain relief was
achieved. The alternate substance was administered in an identical fashion for
the second breakthrough pain episode. For each breakthrough episode, a rating of
the patient's pain intensity was measured using a numerical scale at the onset
of the breakthrough pain episode and at specific time intervals over a one-hour
period following the administration of intranasal ketamine or placebo. The use
of a numeric pain intensity scale is a well-established and widely used tool for
evaluating drugs for the treatment of pain. Patient vital signs, including heart
rate and blood pressure, were measured throughout the study, and physical
examination and nasal examinations were performed prior to treatment and after
completion of the study. Patients who did not receive adequate pain relief
within 7.5 minutes were administered the "rescue" medication they routinely used
to treat their breakthrough pain.
The results of our clinical trial suggests that intranasal ketamine provides
rapid onset of relief for breakthrough pain syndromes. As illustrated in the
graph, as compared to placebo, intranasal ketamine demonstrated a significant
reduction in breakthrough pain intensity over the duration of the breakthrough
pain episode. The onset of action of intranasal ketamine was rapid and
statistically different from the placebo, occurring within four minutes after
administration of the fifth, and final, spray. No harmful effects on heart rate
or blood pressure were found and assessment of patient vital signs and the
results of physical and nasal examinations indicated that intranasal ketamine
was well-tolerated. Based on the results of this study, we believe that
intranasal ketamine may offer a safe, non-opioid alternative for the treatment
of moderate-to-severe breakthrough pain.
Effectivness of Intranasal Ketamine for
the Treatment of Breakthrough Pain
[BAR GRAPH]
Intranasal Morphine
Background
Morphine, the analgesic standard to which all other opioids are usually
compared, is a potent agonist of the mu-opioid receptor. When morphine binds to
its receptor, it inhibits the transmission of pain signals from nerve endings to
the central nervous system. The ability of morphine to reduce pain places it
among the most important naturally occurring compounds. Morphine is a strong
analgesic used for the relief of acute and chronic moderate-to-severe pain,
preoperative sedation and as a supplement to anesthesia. It is the drug of
39
choice for pain associated with myocardial infarction and cancer. The calming
effect produced by morphine is also used to protect the system against
exhaustion in traumatic shock, internal hemorrhage, congestive heart failure and
other debilitating conditions.
Chitosan Delivery Platform
We have licensed a proprietary drug delivery technology that allows us to
achieve therapeutic blood levels of drugs that were previously unattainable when
administered through the nasal route. The key to this technology is chitosan, a
naturally occurring carbohydrate polymer that, while pharmaceutically inert by
itself, enhances the absorption of compounds across mucosal membranes, such as
those found in the nasal cavity, and provides the potential to deliver drugs
through alternative routes. This is particularly important for compounds such as
morphine that are poorly absorbed across mucosal barriers and, in particular,
the nasal membrane. The contribution of chitosan to enhancing mucosal drug
absorption appears to be due to several factors, including its potent
mucoadhesive property, which we believe prevents drug washout.
The following graph illustrates the increase in the nasal absorption of
morphine associated with chitosan in our intranasal morphine product candidate.
Data from published, historical studies report that effective pain relief is
often associated with a patient attaining or exceeding morphine blood levels of
19 nanograms per milliliter. Data from our study demonstrated that our
formulation of intranasal morphine rapidly delivers and exceeds this threshold
within five minutes following administration.
Contribution of Chitosan and Nasal Absorption of Morphine
[LINE GRAPH]
Conventional oral formulations of morphine do not provide rapid relief of
pain in many patients. Aside from its slow and variable onset of action, oral
morphine demonstrates considerable patient-to-patient variability in absorption
and has relatively low blood levels of active drug. Clinicians must therefore
often rely on injectable types of morphine preparations to assure rapid and
effective pain relief. Administration of injectable morphine often requires
professional assistance or hospitalization. Therefore, alternative formulations
of morphine that are easy to administer by a patient or caregiver and afford
rapid onset of action and high blood levels of active drug would provide
significant medical benefit. We believe that intranasal morphine represents an
alternative formulation that combines the promise of patient convenience, ease
of use and cost-effectiveness with the rapid onset of pain relief and the
well-accepted potency of injectable delivery routes.
Clinical Results
Our intranasal morphine product candidate is in clinical development for the
treatment of a heterogeneous group of syndromes associated with acute pain and
acute episodes of chronic pain. We have
40
completed two Phase I clinical trials and have initiated a Phase II clinical
trial of our intranasal morphine product candidate.
In the third quarter of 2001, we initiated enrollment in a 225-patient Phase
II clinical trial of intranasal morphine. This trial is designed to compare the
safety and effectiveness of two different doses of intranasal morphine with
placebo and with both intravenous and oral morphine in patients suffering from
moderate-to-severe postoperative pain. We expect to complete this clinical trial
in the first quarter of 2002 and present the data from our clinical trials and
proposed Phase III clinical trial designs to the FDA in the first half of 2002.
We have successfully completed both single-and multiple-dose Phase I
clinical trials in the U.S. and the United Kingdom, evaluating the tolerability
and resulting blood levels of three dose levels of intranasal morphine in normal
patients. In both trials, we demonstrated the following results:
o all three dose levels of intranasal morphine are rapidly absorbed and
achieve blood levels typically associated with analgesic effectiveness of
morphine generally in as early as five to ten minutes following
administration,
o the safety profile of intranasal morphine was comparable to other
formulations of morphine,
o blood levels of intranasal morphine varied depending on the dose
administered, and
o intranasal morphine was well tolerated by the mucous membranes of the
nasal cavity.
The following graph illustrates the blood levels obtained with our intranasal
morphine product candidate as compared to an identical dose of immediate release
oral morphine and an infusion dose of intravenous morphine. The steep slope of
the plasma concentration curve at the initial times following drug
administration, suggests that the intranasal morphine product candidate is
rapidly delivered to the bloodstream. By contrast to oral morphine, the plasmal
concentration curves for intravenous morphine and intranasal morphine are very
similar, suggesting similar onset of action and duration of pain relief.
Plasma Concentration of Morphine Following Nasal Administration
[LINE GRAPH]
Intravenous Diclofenac
Background
In December 2001, we acquired the rights to develop a novel, proprietary
intravenous formulation of diclofenac from Shimoda and Farmarc. Diclofenac is
one of the most potent NSAIDs known clinically for both inflammation and pain.
It is also one of the world's most prescribed anti-inflammatory agents due to a
combination of efficacy and tolerability.
41
The exact mechanism of action of diclofenac and other NSAIDs has not been
fully determined but appears to be associated with inhibiting the body's ability
to synthesize prostaglandins. Prostaglandins are a family of hormone-like
chemicals, some of which are made in response to tissue injury and produce
inflammation and pain. In particular, diclofenac inhibits the synthesis of the
enzyme cyclooxygenase, or COX, that is necessary for the formation of
prostaglandins during tissue injury. COX enzymes exist in two forms known as
COX-1 and COX-2. COX-1 protects the stomach lining and intestines and COX-2 is
involved in making the prostaglandins that are responsible for inflammation and
pain. NSAIDs that preferentially inhibit COX-1, such as aspirin, are associated
with undesirable gastric side-effects, including stomach irritation and ulcers.
NSAIDs that preferentially inhibit COX-2, such as diclofenac, have a more
desirable side-effect profile than COX-1 inhibitors.
Cyclodextrin Delivery Platform
The key to the intravenous formulation of diclofenac that we have in-
licensed is hydroxypropyl-beta-cyclodextrin, or HPBCD. Cyclodextrins, such as
HPBCD, are donut-shaped carbohydrate molecules that can improve the solubility
of poorly soluble drugs such as diclofenac. By improving the solubility of
diclofenac, HPBCD provides a means to create an intravenous formulation that can
efficiently deliver the drug to the patient's bloodstream. While there are many
types of cyclodextrins, only modified cyclodextrins such as HPBCD are regarded
as safe for injection.
NSAIDs offer several advantages over the more traditional opioid narcotics
for the management of postoperative pain. NSAIDs have limited effect on the
central nervous system, do not depress respiration and are non-sedating. This
latter attribute is of special importance in intermediate, ambulatory surgery
since NSAIDs can provide analgesia without delaying discharge from the hospital
or outpatient setting. In addition, NSAIDs are also useful in patients who
cannot take opioids.
There exists an unmet medical need for a safe and effective injectable NSAID
in the hospital setting. Diclofenac is currently approved for use in the U.S. in
a variety of oral formulations as well as a topical and ophthalmic formulation.
An intramuscular formulation of diclofenac is commercially available in Europe.
The development of injectable formulations of diclofenac have been limited by
the drug's poor solubility in water and susceptibility to breakdown. We believe
that the proprietary formulation of diclofenac that we have in-licensed has the
potential to overcome these issues and may provide an effective and safe
treatment of moderate-to-severe acute pain.
Clinical Results
Our intravenous diclofenac product candidate has been evaluated in Phase I
clinical trials performed in South Africa and a Phase II clinical trial
performed in the United Kingdom, with both sets of trials being conducted on
behalf of a third party with a relationship with our licensor. We anticipate
filing an IND for our formulation of intravenous diclofenac in the first half of
2002 in order to initiate a U.S. clinical development program. Based on the
results of the Phase I and Phase II clinical trials that have already been
conducted outside of the U.S., combined with the extensive published literature
on the safety and effectiveness of diclofenac, the FDA has indicated that Phase
I and single-dose Phase II clinical trials may be initiated concurrently upon
allowance of an IND.
A 269-patient Phase II clinical trial has been completed in the United
Kingdom evaluating the safety and effectiveness of intravenous diclofenac for
the treatment of acute postoperative pain. This trial was conducted on behalf of
a third party with a relationship with our licensor and was a randomized,
double-blind, placebo-controlled study conducted at multiple clinical sites to
evaluate the safety, effectiveness and tolerability of three dose levels of
intravenous diclofenac for the treatment of pain following removal of one or
more impacted wisdom teeth. This trial demonstrated the following:
o compared to placebo, all three dose levels of intravenous diclofenac
provided statistically significant pain relief and delayed the need for
rescue medication, and
o at all three dose levels, intravenous diclofenac appears to be safe and
well-tolerated.
42
The following graph illustrates the effect of all three dose levels of
intravenous diclofenac compared to placebo on pain intensity following dental
surgery. Pain intensity was measured on a 100 point scale, with zero
representing no pain and 100 representing the most intense pain imaginable. Upon
onset of moderate to severe pain following surgery, patients were treated with
either intravenous diclofenac or placebo. By comparison to placebo, there was a
rapid drop in pain intensity with all three dose levels of intravenous
diclofenac. This drop in pain intensity is characteristic of effective pain
medications when delivered by the intravenous route.
Effectivness fo Intravenous Diclofenac for the
Treatment of Postoperative Dental Pain
[LINE GRAPH]
Intranasal Fentanyl
Fentanyl is a synthetic opioid that was originally approved by the FDA in
1968 and is commercially available in formulations for transdermal, transmucosal
and injectable delivery. Fentanyl has a similar effect on the body as morphine.
The actions of fentanyl are similar to those of morphine, although fentanyl is
much more potent and has a more rapid onset of action. By comparison, while the
analgesic potency of fentanyl is some 75 to 100 times that of morphine, its
duration of effect is shorter.
Fentanyl is a widely-used and effective opioid analgesic for treating chronic
moderate-to-severe pain, including cancer pain. When administered using a
transdermal patch that provides a controlled rate of delivery, fentanyl is
effective in controlling the chronic pain associated with cancer. A fentanyl
drug matrix in a lollipop format, Actiq, was approved in 1998 for the treatment
of breakthrough pain in cancer patients who are already receiving and tolerating
opioid therapy for their pain. This oral, transmucosal formulation of fentanyl
is the first opioid approved specifically for this indication and is frequently
used as an adjunct to the fentanyl patch to control these flareup pain episodes.
We believe that an intranasal formulation of fentanyl could also be used to
complement the fentanyl transdermal patch, as well as oral morphine
controlled-release formulations, to effectively treat episodes of breakthrough
pain. Intranasal fentanyl may offer several advantages over existing fentanyl-
based products for the management of breakthrough pain, including rapid and
consistent onset of action, coupled with certain cost and safety advantages.
Nasal delivery of fentanyl could provide an advantage for cancer patients who,
as a side effect of chemotherapy, have difficulty swallowing due to oral
ulcerations.
Intranasal fentanyl is currently in preclinical development using our
chitosan delivery platform technology.
43
Our Strategy
Our goal is to become a leading specialty pharmaceutical company that
develops and commercializes new drugs for the management of pain in order to
fulfill unmet medical needs. Our strategies to accomplish this goal include the
following:
o Develop New Products with Reduced Clinical and Regulatory Risk. We intend
to develop drugs that we believe have lower clinical and regulatory risks
compared to the development of new chemical entities. Our current product
candidates, intranasal ketamine, intranasal morphine, intravenous
diclofenac and intranasal fentanyl, combine drugs and natural compounds
whose safety and pharmacology are well established and have been
independently approved by the FDA.
o Focus on Large Markets Where Our Product Candidates Can Address Unmet
Medical Needs. We intend to maintain a portfolio of product candidates that
address important medical needs in large markets. All of our current
product candidates address the management of moderate-to-severe pain in
several indications that we believe are underserved by current therapeutic
treatment options. Pharmaceuticals for the treatment of pain represent one
of the largest drug categories in terms of sales, and this market segment
is continuing to expand due to a combination of factors, including the
increased focus on the importance of effective pain management by the
healthcare industry.
o Focus on Clinical Development and Late-Stage Product Candidates. We will
continue to devote significant effort toward designing and managing
clinical trials for late stage product candidates we acquire or in-
license. Three of our current product candidates are in Phase II clinical
trials. The conduct of human trials is a complex, highly regulated and
highly specialized effort. We believe that our clinical development focus
will enable us to create successful therapeutic products more rapidly and
more efficiently than if we were developing new chemical entities.
o Retain Significant Rights to Our Product Candidates. We currently retain
exclusive worldwide commercialization rights to all of our pain management
product candidates in all markets and indications. In general, we intend to
independently develop our product candidates through late-stage clinical
trials. As a result, we expect to capture a greater percentage of the
profits from drug sales than we would if we out-licensed our drugs earlier
in the development process.
o Use Our Technology Platforms to Develop New Product Candidates. We believe
our proprietary formulation technologies are broadly applicable to pain
management. We intend to leverage these technologies to develop treatments
across multiple indications.
o Outsource Key Functions. We will continue to outsource components of
preclinical studies, clinical trials, formulation and manufacturing. We
intend to both contract with outside sales organizations and enter into
distribution agreements with pharmaceutical partners to sell our products.
We believe that outsourcing these functions will enable us to focus our
resources on developing existing and new product candidates and to quickly
commercialize these products. We may enter markets that demand highly
specialized sales and marketing efforts. In such cases, we may seek sales
and marketing alliances with third parties. We believe that such alliances
will enable us to commercialize our future products in a more rapid and
cost-effective manner.
Competitive Grants
We have received the following grants that provide both financial and
development support for several of our clinical programs:
U.S. Military
We were awarded a grant of approximately $1.2 million in the third quarter of
2000 to be paid over a three-year period from the U.S. Department of Defense to
develop intranasal ketamine for the treatment of acute moderate-to-severe pain
associated with traumatic orthopedic injury. This award, entitled "A Non-Opiate,
Nasally Administered Alternative to Injection of Morphine Sulfate For the
Treatment of Pain in Military Casualties," is based on the desire of the
military for a fast-acting, non-invasive and non-sedating
44
alternative to the intravenous and oral medications commonly used today for
treating combat related injuries such as burns, bullet wounds and blunt trauma
associated with mass casualty management. We initiated patient enrollment in the
first quarter of 2002.
National Institutes of Health/National Cancer Institute
In the third quarter of 2000, we were awarded a Phase I grant from the
National Institutes of Health/National Cancer Institute Small Business
Innovation Research Award for "The Development of Transnasal Ketamine for
Breakthrough Pain." This award provided approximately $298,000 of funding for a
period of one year from the National Cancer Institute for the development of
intranasal ketamine as an analgesic for intractable malignant pain, such as
breakthrough cancer pain, based on its potential to provide a substantial
medical benefit in an area of unmet medical need.
Strategic Agreements
We have entered into a number of strategic agreements with West
Pharmaceutical related to its proprietary chitosan intranasal delivery
technology for the administration of morphine, fentanyl and other compounds and
an agreement with Shimoda and the Farmarc companies.
West Pharmaceutical Agreements
In the third quarter of 2000, we entered into a license agreement, which has
been further amended, with West Pharmaceutical under which we have a worldwide
exclusive right to develop and commercialize products, including intranasal
morphine and intranasal fentanyl under patents held by West Pharmaceutical, for
the transmucosal delivery to humans and animals of morphine and fentanyl for the
treatment of pain. Most of these patents expire between 2013 and 2016, although
two expire in 2010. As consideration for the license, we paid West
Pharmaceutical up-front license fees and under a development milestone and
option agreement, we are obligated to pay West Pharmaceutical milestone payments
in cash, or, if agreed by both parties, in stock, upon the successful completion
of certain defined events. We are also required to pay West Pharmaceutical a
portion of any up-front license fees that we may receive from our sublicensees,
a royalty based upon our or our sublicensees' sales of products and minimum
annual royalty payments for each licensed product that receives regulatory
approval in specified countries.
The term of the license agreement expires in 2016, unless terminated earlier
by the parties. The license agreement can be terminated by either party upon
default by the other party under any one of several of our agreements with West
Pharmaceutical, but only if the breaching party fails to remedy the default
within 30 days of receiving notice from the non-defaulting party. We can also
terminate the license agreement with respect to specific compounds if the FDA
does not allow chitosan in the products contemplated by the agreement. If the
license agreement is terminated for any reason other than West Pharmaceutical's
breach, we must grant to West Pharmaceutical perpetual, exclusive, worldwide,
royalty-free rights to what we develop under the agreement. The development
milestone and option agreement remains in effect until our intranasal morphine
product is launched in all specified major country markets, unless earlier
terminated for failure of a defaulting party to remedy its breach within 30
days' notice by the non-defaulting party, or within 5 days' notice from West
Pharmaceutical to us in the event we breach the payment terms in that agreement.
In the third and fourth quarters of 2000, we entered into agreements, which
have been further amended, with West Pharmaceutical for the development of a
product for the intranasal administration of morphine and a product for the
intranasal administration of fentanyl, each based upon the chitosan-based
intranasal delivery technology licensed from West Pharmaceutical. Under these
agreements, West Pharmaceutical will conduct development activities related to
intranasal morphine and intranasal fentanyl, and we will make milestone payments
to West Pharmaceutical in an aggregate amount of $13.5 million payable in cash,
or if agreed by both parties, in stock, upon the attainment of specified
clinical and regulatory milestones. As of December 31, 2001, $2.25 million of
this amount had been paid in cash. Additionally, we have granted to West
Pharmaceutical a right of first negotiation with respect to the manufacturing
and packaging of commercial quantities of the licensed intranasal morphine and
fentanyl products. Each of the agreements remains in effect until our product
covered by that agreement is launched in all specified major country markets.
Each of the
45
agreements, however, may be terminated earlier for failure of a defaulting party
to remedy its breach within 30 days' notice by the non-defaulting party, or
within 5 days' notice from West Pharmaceutical to us in the event we breach the
payment terms in that agreement.
In the third quarter of 2000, we entered into a clinical manufacturing
agreement with West Pharmaceutical requiring us to purchase from West
Pharmaceutical, for a period of two years, all of the intranasal morphine
required for use in our intranasal morphine clinical trials, subject to West
Pharmaceutical's ability to supply the full amount we require. The agreement
requires West Pharmaceutical to manufacture the product according to applicable
clinical product specifications. The agreement remains in effect for its
two-year term, unless terminated earlier for failure of a defaulting party to
remedy its breach within 30 days' notice by the non-defaulting party, or within
5 days' notice from West Pharmaceutical to us in the event we breach the payment
terms in the agreement. The parties meet regularly to discuss the status of the
development programs and we submit to West Pharmaceutical biannual revised
product plans, the scope and detail of which we believe are consistent with
industry standards.
Shimoda Agreement
In the fourth quarter of 2001, we entered into a license agreement with
Shimoda and its wholly-owned subsidiaries, Farmarc N.A.N.V. (Netherlands
Antilles) and Farmarc, under which we received certain worldwide exclusive
rights to develop and commercialize products related to a proprietary
formulation of the intramuscular and intravenous delivery of diclofenac. Under
the terms of this agreement, we agreed to use our commercially reasonable
efforts to bring to market products that use the technology we licensed from
Farmarc and Shimoda, continue active marketing efforts for those products and
comply with the commercialization timelines imposed on Shimoda by the company
that licensed certain of this technology to Shimoda. Shimoda agreed that, during
the first three years of the agreement, it will not grant to any third party any
right or license under any of Shimoda's intellectual property rights involving
the use of any cyclodextrin product related to pain management, anesthesia or
sedation without first offering us the right on the same terms and conditions.
Upon entering into the agreement with Shimoda and its subsidiaries, we made
certain payments on Shimoda's behalf to third parties. We are obligated to pay
to Shimoda and Farmarc, and on Shimoda's behalf, to certain third parties, other
milestone and reimbursement payments and if we commercialize products using the
technology under this agreement, we are obligated to pay Shimoda and Farmarc, on
a country-by-country basis, a royalty on the sales, net of various customary
cash discounts, attributable to these products.
Shimoda may terminate our agreement upon 15 days' written notice if we fail
to maintain a minimum amount of certain types of insurance and do not produce to
Shimoda written proof of any such insurance within 14 days of Shimoda's request,
and Shimoda or Farmarc may terminate the agreement upon 60 days' written notice
if we fail to make royalty payments on a timely basis. We and Shimoda have the
right to terminate the agreement upon 60 days' written notice if the other party
materially breaches the agreement in any other way. In each case, however, the
defaulting party has the opportunity to cure the payment default or breach of
the agreement in order to prevent termination of the agreement. We also have the
right to terminate the agreement upon 90 days' written notice to the Shimoda
parties. If we terminate under this provision, or if the agreement is terminated
due to our breach, we have agreed to assign to Shimoda (at no cost to Shimoda)
all clinical information and other data developed by us in furtherance of the
development of the products licensed to us.
Competition
Our success will depend, in part, upon our ability to achieve market share at
the expense of existing and established and future products in our target
markets. Existing and future products, therapies, technological innovations and
delivery systems will compete directly with our products. Competing products and
technologies may provide greater therapeutic benefit for a specific indication,
or may offer comparable performance at a lower cost. Alternative technologies
are being developed to improve the delivery of drugs
46
within the pain management industry, several of which may be in the clinical
trials stage or are awaiting FDA approval.
We compete with fully integrated pharmaceutical companies, smaller companies
that are collaborating with larger pharmaceutical companies, academic
institutions, government agencies and other public and private research
institutions. We believe that our competitors include, but are not limited to,
Cephalon, Inc., Merck & Co., Inc., Nastech Pharmaceutical Company Inc., Pain
Therapeutics, Inc and Pharmacia Corporation. Such competitors may also have
access to more resources, financial and otherwise, which may allow these
institutions to develop and market competing products more rapidly and more
effectively than we do.
Intellectual Property
Our goal is to obtain, maintain and enforce patent protection for our
products, formulations, processes, methods and other proprietary technologies,
preserve our trade secrets, and operate without infringing on the proprietary
rights of other parties, both in the United States and in other countries. Our
policy is to actively seek to obtain, where appropriate, the broadest
intellectual property protection possible for our product candidates,
proprietary information and proprietary technology through a combination of
contractual arrangements and patents, both in the United States and elsewhere in
the world.
We currently have licenses to five U.S. patents and a number of foreign
counterpart patents and applications, as described below. We have licensed two
U.S. patents and their foreign counterparts from Dr. Stuart Weg, M.D., which are
directed toward the use of ketamine to manage pain and the administration of
ketamine through the nasal route. We have licensed two U.S. patents and their
foreign counterparts from West Pharmaceutical, which are directed toward the use
of chitosan and pectin for the transmucosal delivery of morphine and fentanyl.
We have licensed one U.S. patent and its foreign counterparts under the Shimoda
license agreement, which are directed toward intravenous diclofenac formulations
and methods of preparing the same.
The term of a patent is typically 20 years from filing date, subject to any
statutory extension. If any application contains a specific reference to earlier
filed application(s), the term of the patent is 20 years from the date on which
the earliest application was filed, subject to any statutory extension. In the
United States for applications filed prior to June 8, 1995, the term of a patent
is the longer of 17 years from the date of grant of the patent or 20 years from
the earliest effective U.S. filing date of the application, subject to any
statutory extension. Because the time from filing to issuance of medical patent
applications is often more than three years, patent protection, if any, on
patented medical technologies, such as our products, may be substantially less
than 17 years.
We also depend upon the skills, knowledge and experience of our scientific
and technical personnel, as well as that of our advisors, consultants and other
contractors, none of which is patentable. To help protect our proprietary
know-how that is not patentable, and for inventions for which patents may be
difficult to enforce, we rely on trade secret protection and confidentiality
agreements to protect our interests. To this end, we require all employees,
consultants, advisors and certain other contractors to enter into
confidentiality agreements which prohibit the disclosure of confidential
information and, where applicable, require disclosure and assignment to us of
the ideas, developments, discoveries and inventions important to our business.
Additionally, these confidentiality agreements require that our employees,
consultants and advisors do not bring to us, or use without proper
authorization, any third party's proprietary technology.
Manufacturing
We own no manufacturing facilities. However, we contract with qualified third
parties for the manufacture of bulk active pharmaceutical ingredients and
production of clinical supplies. The ingredients and supplies comply with
current good manufacturing practices procedures reviewed by the FDA. We have
entered into an agreement with West Pharmaceutical to manufacture our clinical
supplies for both intranasal ketamine and morphine.
47
Government Regulation
The FDA and comparable regulatory agencies in state and local jurisdictions
and in foreign countries impose substantial requirements upon the clinical
development, manufacture and marketing of pharmaceutical products. These
agencies and other federal, state and local entities regulate research and
development activities and the testing, manufacture, quality control, safety,
effectiveness, labeling, storage, record keeping, approval, advertising and
promotion or our products.
The process required by the FDA under the drug provisions of the federal
Food, Drug and Cosmetics Act before our initial products may be marketed in the
United States generally involves the following:
o preclinical laboratory and animal tests,
o submission of an IND which must become effective before human clinical
trials may begin,
o adequate and well-controlled human clinical trials to establish the
safety and efficacy of the product candidate in our intended use,
o submission to the FDA of an NDA, and
o FDA approval of an NDA.
The testing and approval process requires substantial time, effort, and
financial resources and we cannot be certain that any approval will be granted
on a timely basis, if at all.
Preclinical studies include laboratory evaluation of the product candidate,
its chemistry, formulation and stability, as well as animal studies to assess
the potential safety and efficacy of the product candidate. We then submit the
results of the preclinical studies, together with manufacturing information and
analytical data, to the FDA as part of an IND, which must become effective
before we may begin human clinical trials. The IND automatically becomes
effective 30 days after receipt by the FDA, unless the FDA, within the 30-day
time period, raises concerns or questions about the conduct of the trials as
outlined in the IND and imposes a clinical hold. In such a case, the IND sponsor
and the FDA must resolve any outstanding concerns before clinical trials can
begin. Our submission of an IND may not result in FDA authorization to commence
clinical trials. Further, an independent Institutional Review Board at each
medical center proposing to conduct the clinical trials must review and approve
any clinical study.
Human clinical trials are typically conducted in three sequential phases that
may overlap:
o Phase I: The drug is initially introduced into healthy human subjects or
patients and tested for safety, dosage tolerance, absorption, metabolism,
distribution and excretion.
o Phase II: The drug is studied in a limited patient population to identify
possible adverse effects and safety risks, to determine the efficacy of the
product for specific targeted diseases and to determine dosage tolerance
and optimal dosage.
o Phase III: When Phase II evaluations demonstrate that a dosage range of the
drug is effective and has an acceptable safety profile, Phase III clinical
trials are undertaken to further evaluate dosage, clinical efficacy and to
further test for safety in an expanded patient population, often at
geographically dispersed clinical study sites.
We cannot be certain that we will successfully complete Phase I, Phase II or
Phase III testing of our product candidates within any specific time period, if
at all. Furthermore, the FDA or the Institutional Review Board or the IND
sponsor may suspend clinical trials at any time on various grounds, including a
finding that the subjects or patients are being exposed to an unacceptable
health risk.
The results of product development, preclinical studies and clinical trials
are submitted to the FDA as part of an NDA for approval of the marketing and
commercial shipment of the product. The FDA reviews each NDA submitted, and may
request additional information, before accepting the NDA for filing. Once the
FDA accepts the NDA for filing, the FDA has 12 months in which to review the NDA
and respond to the applicant. The review process may be significantly extended
by FDA requests for additional information or clarification regarding
information already provided. The FDA may deny an NDA if the applicable
regulatory
48
criteria are not satisfied or may require additional clinical data. Even if
these data are submitted, the FDA may ultimately decide that the NDA does not
satisfy the criteria for approval. Once issued, the FDA may withdraw product
approval if compliance with regulatory standards is not maintained or if safety
problems occur after the product reaches the market. In addition, the FDA
requires surveillance programs to monitor approved products that have been
commercialized, and the agency has the power to require changes in labeling or
to prevent further marketing of a product based on the results of these post-
marketing programs.
Satisfaction of the above FDA requirements or similar requirements of state,
local and foreign regulatory agencies typically takes several years and the
actual time required may vary substantially, based upon the type, complexity and
novelty of the pharmaceutical product. Government regulation may delay or
prevent marketing of potential products for a considerable period of time and
impose costly procedures upon our activities. We cannot be certain that the FDA
or any other regulatory agency will grant approval for any of our products under
development on a timely basis, if at all. Success in preclinical studies or
early-stage clinical trials does not assure success in later-stage clinical
trials. Data obtained from preclinical and clinical activities are not always
conclusive and may be susceptible to varying interpretations that could delay,
limit or prevent regulatory approval. Even if a product receives regulatory
approval, the approval may be significantly limited to specific indications.
Further, even after regulatory approval is obtained, later discovery of
previously unknown problems with a product may result in restrictions on the
product or even complete withdrawal of the product from the market. Delays in
obtaining, or failures to obtain regulatory approvals, would have a material
adverse effect on our business.
Any products manufactured or distributed by us pursuant to FDA clearances or
approvals are subject to pervasive and continuing regulation by the FDA,
including record-keeping requirements and reporting of adverse experiences with
the drug. Drug manufacturers and their subcontractors are required to register
their facilities with the FDA and state agencies, and are subject to periodic
unannounced inspections by the FDA and state agencies for compliance with good
manufacturing practices, which impose procedural and documentation requirements
upon us and our third-party manufacturers. Failure to comply with these
regulations could result, among other things, in suspension of regulatory
approval, recalls, injunctions or civil or criminal sanctions. We cannot be
certain that we or our present or future subcontractors will be able to comply
with these regulations and other FDA regulatory requirements.
The FDA regulates drug labeling and promotion activities. The FDA has
actively enforced regulations prohibiting the marketing of products for
unapproved uses. Under the FDA Modernization Act of 1997, the FDA will permit
the promotion of a drug for an unapproved use in certain circumstances, but
subject to very stringent requirements. We and our product candidates are also
subject to a variety of state laws and regulations in those states or localities
where our products are or will be marketed. Any applicable state or local
regulations may hinder our ability to market our products in those states or
localities. In addition, whether or not FDA approval has been obtained, approval
of a pharmaceutical product by comparable governmental regulatory authorities in
foreign countries must be obtained prior to the commencement of clinical trials
and subsequent sales and marketing efforts in those countries. The approval
procedure varies in complexity from country to country, and the time required
may be longer or shorter than that required for FDA approval. We may incur
significant costs to comply with these laws and regulations now or in the
future.
The FDA's policies may change and additional government regulations may be
enacted which could prevent or delay regulatory approval of our potential
products. Moreover, increased attention to the containment of health care costs
in the U.S. and in foreign markets could result in new government regulations
that could have a material adverse effect on our business. We cannot predict the
likelihood, nature or extent of adverse governmental regulation that might arise
from future legislative or administrative action, either in the U.S. or abroad.
Other Regulatory Requirements
The Controlled Substances Act imposes various registration, record-keeping
and reporting requirements, procurement and manufacturing quotas, labeling and
packaging requirements, security controls and a restriction on prescription
refills on certain pharmaceutical products. A principal factor in determining
the
49
particular requirements, if any, applicable to a product is its actual or
potential abuse profile. A pharmaceutical product may be "scheduled" as a
Schedule I, II, III, IV or V substance, with Schedule I substances considered to
present the highest risk of substance abuse and Schedule V substances the
lowest. Ketamine, morphine and fentanyl are classified as Schedule II and III
substances. In addition, any of our products that contain one of our product
candidates in combination with narcotics will be subject to DEA regulations
relating to manufacturing, storage, distribution and physician prescribing
procedures.
We are also subject to numerous federal, state and local laws relating to
such matters as safe working conditions, manufacturing practices, environmental
protection, fire hazard control and disposal of hazardous or potentially
hazardous substances. We may incur significant costs to comply with these laws
and regulations now or in the future. The regulatory framework under which we
currently operate may change and any change could have a material adverse effect
on our current and anticipated operations.
Employees
As of March 12, 2002, we had nine full-time employees, including five
employees with Ph.D. or M.D. degrees. Most members of our senior management have
had prior experience in pharmaceutical or biotechnology companies. None of our
employees is covered by collective bargaining agreements. We believe that our
relations with our employees are good.
Facilities
We presently maintain our executive offices on a rent-free basis in premises
of approximately 2,500 square feet that we share with Paramount Capital
Investments. We do not have a lease agreement with Paramount Capital Investments
and consequently our use of this space may be terminated at any time. We
currently have an agreement in place with Paramount under which Paramount has
waived any claim for reimbursement for any payments for this arrangement and
will continue to waive any claim for reimbursement for any similar payments
through the end of the third quarter of 2002. We believe that our existing
facilities are adequate for our current needs and that suitable additional or
alternative space will be available without material disruption of our business
and that such space will be available to us in the future on commercially
reasonable terms.
Legal Proceedings
We are not a party to any legal proceedings.
50
MANAGEMENT
Directors and Executive Officers
The following table provides information regarding our directors and
executive officers as of March 12, 2002:
Name Age Title
- ---- --- -----
Leonard L. Firestone, M.D................ 50 Chief Executive Officer, Chief Medical Officer and Director
Fred H. Mermelstein, Ph.D................ 43 President, Secretary and Director
Douglas A. Hamilton...................... 36 Chief Operating Officer and Chief Financial Officer
Randi Albin, Ph.D........................ 43 Chief Scientific Officer
Mark C. Rogers, M.D...................... 56 Chairman of the Board
Michael Weiser, M.D., Ph.D............... 38 Director
Edward Miller, M.D....................... 58 Director
Mark S. Siegel........................... 50 Director
Peter M. Kash............................ 40 Director
Douglas G. Watson(1)..................... 56 Director
- ---------------
(1) Mr. Watson has been appointed to our board of directors effective April 1,
2002.
Leonard L. Firestone, M.D. Dr. Firestone has served as a member of our board
of directors and as our Chief Executive Officer since January 2001 and as our
Chief Medical Officer since August 2001. Prior to joining us, Dr. Firestone
served as Chief Executive Officer and Chair of University Anesthesiology and
Critical Care Medicine Foundation, an anesthesiology, critical care and pain
management clinical practice, from 1996 to 2001, as well as Chair of University
Anesthesiology and Critical Care Medicine Foundation's Pension Trustees. Dr.
Firestone served as an endowed Professor at University of Pittsburgh School of
Medicine from 1996 to 2001, as an Associate Professor at University of
Pittsburgh School of Medicine from 1994 to 1996, as an Assistant Professor at
Harvard Medical School from 1985 to 1987, as a National Institutes of Health
Postdoctoral Fellow in molecular pharmacology at Harvard Medical School's
Department of Pharmacology from 1980 to 1985 and as a Research and Clinical
Fellow at Yale School of Medicine from 1979 to 1980. Dr. Firestone held a
competitive National Institutes of Health Principal Investigatorship from 1985
to 2001 and served as a permanent member of the National Institutes of Health's
Anesthesiology Review Committee, Division of Research Grants, from 1997 to 2001.
Dr. Firestone holds an M.D. from the Yale School of Medicine and is certified by
the American Board of Anesthesiology.
Fred H. Mermelstein, Ph.D. Dr. Mermelstein has served as a member of our
board of directors and as our President since inception. Dr. Mermelstein
concurrently serves as Director of Venture Capital at Paramount Capital
Investments, LLC, a biotechnology, biomedical and biopharmaceutical merchant
banking firm, since April 1996. Dr. Mermelstein is also a member of Orion
Biomedical GP, LLC. Dr. Mermelstein has concurrently served as a director and
the Chief Science Officer of PolaRx BioPharmaceuticals, an oncology based
biopharmaceutical company, from February 1997 until January 2000. Dr.
Mermelstein holds a dual Ph.D. in Pharmacology and Toxicology from Rutgers
University and University of Medicine and Dentistry of New Jersey (UMDNJ)
Robert Wood Johnson Medical School. He completed his post-doctoral training
supported by two grant awards, a National Institutes of Health fellowship and
a Howard Hughes Medical Institute fellowship in the Department of Biochemistry
at UMDNJ Robert Wood Johnson Medical School.
Douglas A. Hamilton. Mr. Hamilton has served as our Chief Financial Officer
since March 1999 and also as our Chief Operating Officer since April 2001. Mr.
Hamilton concurrently served as Chief Financial Officer and a Project Manager
for Trisenox at PolaRx BioPharmaceuticals from March 1999 to October 2000.
From October 1997 to March 1999, Mr. Hamilton served as a Project Manager for
Zithromax and Voriconazole at Pfizer, Inc. From August 1993 to October 1997,
Mr. Hamilton served as a Project Manager for EPOGEN, Aranesp and Stemgen,
among other products, at Amgen, Inc. Mr. Hamilton holds an M.B.A. from the
Richard Ivey School of Business.
51
Randi Albin, Ph.D. Dr. Albin has served as our Chief Scientific Officer
since inception. From August 1998 to December 2001, Dr. Albin also served as
an Investment Strategist at Paramount Capital Investments. From August 1988 to
August 1998, Dr. Albin held positions of increasing responsibility at the
Schering-Plough Research Institute of Schering-Plough Corporation. Dr. Albin
holds an M.S. and a Ph.D. in Molecular Biology from Albert Einstein College of
Medicine. She completed her post-doctoral training as a Visiting Research
Fellow in the Department of Molecular Biology at Princeton University where
she was supported by grants from the National Institutes of Health and the
Leukemia Society of America.
Mark C. Rogers, M.D. Dr. Rogers has served as the Chairman of our board of
directors since August 1999. Since July 1998, Dr. Rogers has served as
President and Chief Executive Officer of Paramount Capital, Inc., Paramount
Capital Investments and Paramount Capital Asset Management, Inc. Paramount
Capital Asset Management serves as the general partner of each of the Aries
Domestic Fund, L.P. and the Aries Domestic Fund II, L.P., and as the managing
member of each of Aries Select I, LLC, Aries Select II, LLC, Aries Select
Domestic, LLC and Aries Select Domestic II, LLC. Dr. Rogers is also a member
of Orion Biomedical GP, LLC, which serves as the general partner to The Orion
BioMedical Funds. In addition, Dr. Rogers also serves as a director of Genta
Incorporated and Discovery Laboratories, Inc, as well as several privately
held corporations. Dr. Rogers holds an M.D. from Downstate Medical Center and
an M.B.A. from The Wharton School of Business.
Michael Weiser, M.D., Ph.D. Dr. Weiser has served as a member of our board
of directors since June 2000 and as our Chief Medical Officer from our
inception until August, 2001. Dr. Weiser concurrently serves as the Director
of Research of Paramount Capital Asset Management. Dr. Weiser is also a member
of Orion Biomedical GP, LLC, and serves on the board of directors of several
privately held companies. Dr. Weiser holds an M.D. from New York University
School of Medicine and a Ph.D. in Molecular Neurobiology from Cornell
University Medical College. Dr. Weiser completed a Postdoctoral Fellowship in
the Department of Physiology and Neuroscience at New York University School of
Medicine and performed his post-graduate medical training in the Department of
Obstetrics and Gynecology and Primary Care at New York University Medical
Center.
Edward Miller, M.D. Dr. Miller has served as a member of our board of
directors since February 2001. He has served as the Dean and Chief Executive
Officer of the Johns Hopkins School of Medicine since January 1997. From July
1986 until June 1994, he was Professor and Chairman of the Department of
Anaesthesiology at Columbia Presbyterian Medical Center. From July 1994 to May
1999, Dr. Miller served as Professor and Chairman of the Department of
Anesthesiology and Critical Care Medicine at Johns Hopkins University. Dr.
Miller holds an M.D. from the University of Rochester School of Medicine. He
was a resident in anesthesiology at the Peter Bent Brigham Hospital and
completed post-doctoral training in physiology at Harvard Medical School.
Mark S. Siegel. Mr. Siegel has served as a member of our board of directors
since September 2000. He has served as the President of Remy Investors &
Consultants Inc., a private investment and financial management company, since
1993. He also serves as Chairman of the board of directors of Patterson-UTI
Energy, Inc., and Chairman of the board of directors of Variflex, Inc., and as
a member of the board of directors of Discovery Laboratories, Inc. Mr. Siegel
holds a J.D. from the University of California at Berkeley (Boalt Hall) School
of Law.
Peter M. Kash. Mr. Kash has served as a member of our board of directors
since February 2001. He has served as vice chairman of Keryx
BioPharmaceuticals, Inc. and as a member of its board of directors since
February 2001 and as a director of Paramount Capital Asset Management and
Senior Managing Director of Paramount Capital since September 1991. In
addition, Mr. Kash has served as an Adjunct Professor at The Wharton School of
Business since 1996 and is currently a Visiting Professor. Mr. Kash also
serves as a director of The Aries Master Fund, The Aries Master Fund II and
Aries Select, Ltd., for each of which Paramount Capital Asset Management
serves as general partner, and Gemini Management Partners, LLC. Mr. Kash is
also a member of Orion Biomedical GP, LLC. Mr. Kash holds an M.B.A. in Finance
and Banking from Pace University.
Douglas G. Watson. Mr. Watson has been appointed to our board of directors
effective April 1, 2002. He is the Chief Executive Officer of Pittencrieff Glen
Associates, a consulting company, which Mr. Watson founded in June 1999. From
January 1997 to June 1999, Mr. Watson served as President, Chief Executive
Officer and a director of Novartis Corporation, the U.S. subsidiary of Novartis
A.G. Mr. Watson
52
serves as a director of Engelhard Corporation and Dendreon Corporation as well
as several privately held companies. Mr. Watson is a member of the Fleet Bank-
New Jersey Advisory Board and serves on the President's Advisory Council of
Drew University. Mr. Watson holds an M.A. in Mathematics from Churchill
College, Cambridge University. He is also a member of the Chartered Institute
of Management Accountants.
Scientific Advisory Board
We have established a Scientific Advisory Board consisting of recognized
scholars in the fields of chemistry, molecular biology, pharmacology and
preclinical development. Our scientific advisors consult on matters relating to
the development of our product candidates. Our scientific advisors are
reimbursed for their reasonable expenses. Our scientific advisors are:
Daniel B. Carr M.D. Dr. Carr is the Saltonstall Professor of Pain Research
at New England Medical Center, and Professor of Anesthesiology and Medicine at
Tufts University School of Medicine. He is also the Medical Director of the
Pain Management Program at the New England Medical Center. Dr. Carr was a
founder of the Pain Center at the Massachusetts General Hospital, and served
as Special Consultant to the U.S. Department of Health and Human Services and
Co-Chair of the Agency for Health Care Policy and Research's Clinical Practice
Guidelines on Acute and Cancer Pain Management. He is Editor-in-Chief of Pain:
Clinical Updates published by the International Association for the Study of
Pain (IASP), and has served as a Director of the American Pain Society and the
IASP.
Richard Traystman, Ph.D. Dr. Traystman is Distinguished Research Professor of
Anesthesiology and Critical Care Medicine, Professor of Medicine, and Professor
of Environmental Health Sciences, Division of Environmental Physiology, Johns
Hopkins University School of Medicine. He is world-renowned for his
contributions to understanding the responses of the brain and its circulation to
stroke and cardiac arrest, and has served as Principal Investigator of numerous,
distinguished, National Institutes of Health Program Projects on these topics.
Dr. Traystman's research achievements have been recognized by the
Pharmacia--Upjohn Distinguished Lectureship; the Stuart Cullen Medal and
Distinguished Professorship; the American Society of Anesthesiologists
Excellence in Research Award; the Robert M. Berne-American Physiological
Society's Distinguished Lectureship; and the Asmund Laerdal Prize from the
Society of Critical Care Medicine.
Paul Waymack M.D., D.Sc. Dr. Waymack previously served as Medical Reviewer
and subsequently, Special Consultant to the U.S. Food and Drug
Administration's Center for Drug Evaluation and Research. Dr. Waymack is an
experienced clinical surgeon and former Chairman of the Pharmacy and
Therapeutics Committee at UMDNJ. He currently heads an independent drug
development consulting practice, and is on the faculty of the Pharmaceutical
Education and Research Institute, Inc. in Washington, D.C.
Lawrence Penkler M. Pharm, Ph.D. Dr. Penkler is Managing Director of
Shimoda Biotech (Proprietary) Ltd. of South Africa, and a recognized expert in
the use of cyclodextrins to improve drug formulations. He was appointed Group
Executive, International Scientific Affairs, by Aspen Pharmacare Holding in
March 2000. Dr. Penkler received a masters degree in Pharmaceutical Chemistry
in 1988 and a doctorate in Chemistry in 1992 from the University of Pretoria.
53
Clinical Advisors
We have established relationships with recognized scholars who consult on
matters relating to clinical trial design, marketing and regulatory issues. Our
clinical advisors are reimbursed for their reasonable expenses. Our clinical
advisors are:
Advisor Title Affiliation
- ------- ----- -----------
Najib Babul, Pharm. D.................. Clinical and Regulatory Consultant TheraQuest Biosciences, LLC
Ray Dionne, M.D........................ Clinical and Regulatory Consultant Jean Brown Associates
William Kramer, Ph.D................... PK/PD Consultant Kramer Consulting, LLC
Donald R. Mehlisch, M.D., D.D.S........ Clinical and Regulatory Consultant SCIREX Corp., Inc. D.R. Mehlisch &
Associates
Peter S. Staats, M.D................... Associate Professor, Dept. of Anesthesiology Johns Hopkins Hospital
and Critical Care
Board Composition
Currently we have eight members on our board of directors. Each of our
directors was elected in accordance with provisions of our certificate of
incorporation and bylaws.
Board Committees
We have established an audit committee composed of independent directors to
review and supervise our financial controls, including the selection of our
auditors, review our books and accounts, meet with our officers regarding our
financial controls, act upon recommendations of our auditors and take further
actions as our audit committee deems necessary to complete an audit of our books
and accounts. Our audit committee also performs other duties as may from time to
time be determined. Our audit committee currently consists of two directors, Dr.
Miller and Mr. Siegel. Mr. Watson has been appointed to our audit committee
effective April 1, 2002.
We have also established a compensation committee that reviews and approves
the compensation and benefits for our executive officers, administers our
compensation and stock plans, makes recommendations to the board of directors
regarding these matters and performs other duties as may from time to time be
determined by the board. Our compensation committee currently consists of four
directors, Drs. Rogers, Firestone, Mermelstein and Miller.
Compensation Committee Interlocks and Insider Participation
One of our compensation committee members, Dr. Firestone, is our Chief
Executive Officer and Chief Medical Officer. Another of our compensation
committee members, Dr. Mermelstein, is our President and Secretary. None of our
executive officers serves on the board of directors or compensation committee of
any entity that has one or more executive officers serving as a member of our
board or our compensation committee.
Director Compensation
We currently do not compensate any non-employee member of our board of
directors for serving as a board member, except through the grant of stock
options. Non-employee directors shall receive an option to purchase 12,500
shares of our common stock upon their initial election or appointment, except in
the case of our chairman who shall receive an option to purchase 25,000 shares,
and an option to purchase an additional 12,500 or 25,000 shares, as applicable,
on the date of our annual stockholders meeting each year after we become a
public company under our 2000 Omnibus Stock Incentive Plan. Directors who are
also employees do not receive additional compensation for serving as directors.
In February 2002, our directors were each granted options to purchase 50,807
shares of our common stock at an exercise price of $5.46 per share.
54
Executive Compensation
The following table summarizes the total compensation earned by our Chief
Executive Officer and each of our most highly compensated executive officers,
other than the Chief Executive Officer, who earned more than $100,000 during the
fiscal year ended December 31, 2001.
Annual compensation of an executive officer listed in the following table
excludes other compensation in the form of perquisites and other personal
benefits that constitute the lesser of $50,000 or 10% of the total annual salary
and bonus for that officer in the applicable year. The options listed in the
following table were granted outside our 2000 Omnibus Stock Incentive Plan.
55
Summary Compensation Table
Long-Term
Compensation
------------
Other Securities
Annual Underlying All Other
Annual Compensation Compensation Options (#) Compensation
-------------------- ------------ ----------- -------------
Name and Principal Position Year Salary ($) Bonus ($)
- --------------------------- ---- ---------- ---------
Leonard L. Firestone, M.D.(1) .................... 2001 -- -- -- -- $335,096
Chief Executive Officer and
Chief Medical Officer
Fred H. Mermelstein, Ph.D. ....................... 2001 $165,000 $16,500 -- -- --
President
Douglas A. Hamilton .............................. 2001 $135,000 $25,000 -- -- --
Chief Operating Officer and
Chief Financial Officer
Randi Albin, Ph.D. ............................... 2001 $110,000 $11,100 -- -- --
Chief Scientific Officer
- ---------------
(1) Compensation paid to Dr. Firestone was paid to a consulting company,
Experimed LLC, with which we contracted for Dr. Firestone's services.
Compensation will be paid directly to Dr. Firestone upon the consummation of
the offering.
Option Grants During the Year Ended December 31, 2001
The following table contains information concerning stock options granted in
2001 to each of the executive officers named in the summary compensation table.
The potential realizable value is calculated assuming the fair market value of
the common stock appreciates at the indicated rate for the entire term of the
option and that the option is exercised and sold on the last day of its term at
the appreciated price. These gains are based on assumed rates of appreciation
compounded annually from the dates the respective options were granted to their
expiration date based on an assumed initial public offering price of $9.00,
minus the applicable per share exercise price. Annual rates of stock price
appreciation of 5% and 10% from the initial public offering price is assumed
pursuant to the rules of the Securities and Exchange Commission. We can give no
assurance that the actual stock price will appreciate over the term of the
options at the assumed 5% and 10% levels or any other defined level. Actual
gains, if any, on exercised stock options will depend on the future performance
of our common stock.
Individual Grants
---------------------------------------------------
Potential Realizable
Value at Assumed
Percentage Annual Rates of Stock
Number of of Total Price Appreciation
Securities Options for
Underlying Granted to Exercise Option Term
Options Employees Price Expiration ---------------------
Name Granted in 2001 (per share) Date 5% 10%
- ---- ---------- ---------- ----------- ---------- --------- ---------
Leonard L. Firestone, M.D........ 355,650 100% 3.94 01/2011 $3,812,586 $6,900,920
Fred H. Mermelstein, Ph.D........ -- -- -- --
Douglas A. Hamilton.............. -- -- -- --
Randi Albin, Ph.D................ -- -- -- --
56
The following table contains information concerning stock options to purchase
common stock held as of December 31, 2001 by each of the officers named in the
summary compensation table who have stock options.
Value of Unexercised
In-The-Money
Number of Securities Options at
Underlying Unexercised Fiscal Year-End
Shares Options at Fiscal Year End
Acquired on Value --------------------------- ---------------------------
Name Exercise (#) Realized ($) Exercisable Unexercisable Exercisable Unexercisable
- ---- ------------ ------------ ----------- ------------- ----------- -------------
Leonard L. Firestone, M.D. ........... -- -- 355,650 -- $1,799,589 --
Fred H. Mermelstein, Ph.D. ........... -- -- 33,871 67,743 $ 171,387 --
Douglas A. Hamilton .................. -- -- 50,807 101,615 $ 257,083 --
Randi Albin, Ph.D. ................... -- -- 50,807 101,615 $ 257,083 --
Employee Benefit Plans
2000 Omnibus Stock Incentive Plan. Our 2000 Omnibus Stock Incentive Plan
was adopted by our board of directors on February 5, 2001 and approved by our
stockholders on February 15, 2001. Our plan was subsequently amended by our
board of directors on March 12, 2002 and approved by our stockholders on
.
We have reserved 4,200,000 shares of our common stock for issuance under our
stock incentive plan. The number of shares of common stock reserved for issuance
under our stock incentive plan will automatically increase on the first trading
day in January of each calendar year, beginning in calendar year 2003, by an
amount equal to 5% of the total number of shares of our common stock outstanding
on the last trading day in December of the preceding calendar year, but in no
event will any annual increase exceed shares. No participant in our stock
incentive plan may be granted awards with respect to more than 1,000,000 shares
of our common stock per calendar year.
The individuals eligible to participate in our stock incentive plan include
our officers and other employees, our non-employee board members and any
consultants we hire. Our stock incentive plan provides for the grant of stock
options, stock appreciation rights, or SARs, and direct stock grants. Stock
options are the right to purchase shares of our common stock at a specified
price, which may be less than, equal to or greater than the fair market value
per share on the date of grant. SARs may be granted alone or in connection with
another award, such as a stock option or grant of restricted stock, and provide
for an appreciation distribution from us equal to the increase in the fair
market value per share of common stock from a price specified on the grant date.
If granted in connection with another award, exercise of the SAR will generally
require the surrender of the related award. This appreciation distribution may
be made in cash or in shares of common stock. Direct stock grants include the
grant of performance shares which are distributable to the holder based on the
achievement of specified performance targets, stock which may be purchased at a
price less than, equal to or greater than the fair market value on the date of
purchase, and grants of bonus stock which do not require purchase by the award
recipient. Any of the direct stock grants may be restricted stock, which is
subject to forfeiture by the holder (or repurchase by us) upon the occurrence of
specified events, such as the holder's cessation of service prior to a specified
date.
The stock incentive plan includes an automatic option grant program for non-
employee directors, under which option grants will automatically be made at
periodic intervals to our non-employee board members to purchase shares of
common stock at an exercise price equal to 100% of the fair market value of
those shares on the grant date.
The stock incentive plan will be administered by the compensation committee,
except for automatic option grants. This committee will determine which eligible
individuals are to receive option grants, SARs or stock issuances, the time or
times when such awards are to be made, the number of shares subject to each such
award, the status of any granted option as either an incentive stock option or a
non-statutory stock option under the federal tax laws, the vesting schedule to
be in effect for the award and the maximum term for which any award is to remain
outstanding.
57
The exercise price for the shares of the common stock subject to option
grants made under our stock incentive plan may be paid in cash or, with approval
of the committee, in shares of common stock, including restricted shares, valued
at the fair market value on the exercise date; however, such shares must have
been held for at least six months prior to the date of exercise, valued at fair
market value. The option may also be exercised through a same-day sale program
without any cash outlay by the optionee. In addition, the plan administrator may
provide financial assistance to one or more optionees in the exercise of their
outstanding options or the purchase of their unvested shares by allowing the
individuals to deliver a full-recourse, interest-bearing promissory note in
payment of the exercise price and any associated withholding taxes incurred in
connection with the exercise or purchase.
The compensation committee will have the authority to cancel outstanding
options under the stock incentive plan in return for the grant of new options
for the same or a different number of option shares with an exercise price per
share based upon the fair market value of our common stock on the new grant
date.
In the event that we are acquired by merger or an asset sale in which we will
not be the surviving entity or in which we will survive as a wholly owned
subsidiary of another entity, each outstanding option will be assumed by the
successor corporation unless the compensation committee determines that the
options will accelerate and vest in full prior to such transaction.
Alternatively, the committee may cancel the options and pay each holder cash or
securities equal, for each cancelled option share, to the per share
consideration received by our stockholders in the transaction less the exercise
price of the option share. The compensation committee will have complete
discretion to structure one or more awards so those awards will vest in full or
in part in connection with such a transaction, upon the holder's cessation of
service within a specified period following such a transaction or under other
circumstances as determined by the compensation committee in its discretion.
The compensation committee may also grant awards subject to accelerated
vesting in connection with a successful tender offer for more than 50% of our
outstanding voting stock or a change in the majority of our board through one or
more contested elections for board membership. Such accelerated vesting may
occur either at the time of such transaction or upon the subsequent termination
of the individual's service.
Under the automatic option grant program, each individual who first becomes a
non-employee board member at any time after the closing of this offering will
automatically receive an option grant for 12,500 shares of our common stock on
the date such individual joins the board, if such individual has not been in our
prior employ, except for our chairman who shall receive an option grant for
25,000 shares of our common stock. In addition, on the date of each annual
stockholders meeting held after the closing of this offering, each non-employee
board member who is to continue to serve as a non-employee board member,
including each of our current non-employee board members, will automatically be
granted an option to purchase 12,500 shares of our common stock, except for our
chairman who shall receive an option grant for 25,000 shares of our common
stock, if such individual has served on our board for at least six months.
Each automatic grant will have an exercise price per share equal to the fair
market value per share of our common stock on the grant date and will have a
term of ten years, subject to earlier termination following the optionee's
cessation of board service. The option will be immediately exercisable for all
of the option shares; however, we may repurchase, at the lower of the exercise
price paid per share and the fair market value at the time of repurchase, any
shares purchased under the option which are not vested at the time of the
optionee's cessation of board service. The shares subject to each initial 12,500
or 25,000 share automatic option grant, as applicable, will vest in a series of
four successive annual installments upon the optionee's completion of each year
of board service over the four-year period measured from the grant date. The
shares subject to each annual share automatic option grant will vest upon the
optionee's completion of one year of board service measured from the grant date.
However, the shares subject to each automatic option grant will immediately vest
in full upon certain changes in control or ownership or upon the optionee's
death or disability while a board member.
The board may amend or modify the stock incentive plan at any time, subject
to any required stockholder approval. The stock incentive plan will terminate no
later than February 4, 2011.
58
Employee Stock Purchase Plan. Our Employee Stock Purchase Plan was adopted by
our board of directors on March 12, 2002 and approved by the stockholders on
, 2002. The plan will become effective immediately upon the signing
of the underwriting agreement for this offering. The plan is designed to allow
our eligible employees and the eligible employees of our participating
subsidiaries, if any, to purchase shares of our common stock, at semi-annual
intervals, with their accumulated payroll deductions.
We will initially reserve 500,000 shares of our common stock for issuance
under the plan. The reserve will automatically increase on the first trading day
in January of each calendar year, beginning in calendar year 2003, by an amount
equal to 0.05% of the total number of shares of our common stock outstanding on
the last trading day in December in the prior calendar year. In no event will
any such annual increase exceed 200,000 shares.
The plan will have a series of successive overlapping offering periods, with
a new offering period beginning on the first business day of May and November of
each year. Each offering period will have a duration of 24 months, unless
otherwise determined by the compensation committee. However, the initial
offering period may have a duration in excess of 24 months and will start on the
date the underwriting agreement for this offering is signed and will end on the
last business day in October 2002. The next offering period will start on the
first business day in May 2002 and will also end on the last business day of
October 2002.
Individuals scheduled to work more than eight hours per week for more than
five calendar months per year may join an offering period on the start date of
that period. However, employees may participate in only one offering period at a
time.
A participant may contribute up to 15% of his or her cash earnings through
payroll deductions, and the accumulated deductions will be applied to the
purchase of shares on each semi-annual purchase date. The purchase price per
share will be equal to 85% of the fair market value per share on the start date
of the offering period in which the participant is enrolled or, if lower, 85% of
the fair market value per share on the semi-annual purchase date. Semi-annual
purchase dates will occur on the last business day of April and October of each
year. However, a participant may not purchase more than 5,000 shares on any
purchase date, and not more than 150,000 shares may be purchased in total by all
participants on any purchase date. Our compensation committee will have the
authority to change these limitations for any subsequent offering period.
If the fair market value per share of our common stock on any semi-annual
purchase date within a particular offering period is less than the fair market
value per share on the start date of that offering period, then the participants
in that offering period will automatically be transferred and enrolled in the
new two-year offering period which will begin on the next business day following
such purchase date.
If we are acquired by merger or a sale of substantially all of our assets or
more than 50% of our outstanding voting securities, then all outstanding
purchase rights will automatically be exercised immediately prior to the
effective date of the acquisition. The purchase price in effect for each
participant will be equal to 85% of the market value per share on the start date
of the offering period in which the participant is enrolled at the time the
acquisition occurs or, if lower, 85% of the fair market value per share
immediately prior to the acquisition.
The plan will terminate no later than the last business day of ,
200 .
The board may at any time amend, suspend or discontinue the plan. However,
certain amendments may require stockholder approval.
Employment Agreements
In December 2001, we entered into an employment agreement with Dr. Leonard L.
Firestone, our Chief Executive Officer, which will commence upon the closing of
this offering. The employment agreement has an initial term of three years,
subject to automatic two-year renewal terms, unless terminated by us at least
six months prior to the end of the then-current term. Dr. Firestone will receive
an initial annual base salary of $400,000, subject to appropriate increases at
the discretion of our board of directors. During the term, Dr.
59
Firestone is entitled to receive a discretionary bonus amount of up to 150% of
his base salary then in effect and option grants to purchase an annual maximum
of 500,000 shares of our common stock, based on the achievement of certain
performance objectives. In addition, concurrently with the closing of this
offering, Dr. Firestone will be granted an option to purchase 750,000 shares of
our common stock at an exercise price equal to the initial public offering
price. These options vest with respect to one-third of the shares on the date of
the grant and then in two equal installments on the first and second annual
anniversaries of the date of grant, as long as he remains employed with us.
The employment agreement for Dr. Firestone provides that, if he dies, becomes
disabled or is terminated by us for "cause," we will pay to him any salary
accrued and unpaid to the date of such termination. In the case of death or
disability, Dr. Firestone or his legal representative will also receive any
bonus or incentives earned through the date of death or disability. If we
terminate Dr. Firestone without "cause," we are required to continue to pay Dr.
Firestone's salary for 12 months or until the expiration of the agreement,
whichever is longer, any bonuses and incentives accrued but unpaid prior to the
date his employment is terminated, his health benefits for 12 months and
accelerate the vesting of all his unvested stock options. Dr. Firestone may
terminate his employment upon one month's written notice to us. If he terminates
his employment with us, we will pay to Dr. Firestone any salary accrued and
unpaid to the date of such termination. In the event of a change of control, Dr.
Firestone may terminate his employment and we will be obligated to continue to
pay to Dr. Firestone his salary for 18 months and any accrued but unpaid bonuses
and incentives and accelerate the vesting of all his unvested options. In the
event that we desire to continue Dr. Firestone's employment, his employment may
be continued for up to 18 months, and upon the expiration of the term he will be
entitled to the same payments set forth in the preceding sentence.
None of our other executive officers has entered into employment agreements
with us.
60
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
We believe that we have executed all of the transactions set forth below on
terms no less favorable to us than we could have obtained from unaffiliated
third parties. Our intention is to ensure that all future transactions,
including loans, between us and our officers, directors and principal
stockholders and their affiliates, are approved by a majority of our board of
directors, including a majority of the independent and disinterested members of
the board of directors, and are on terms no less favorable to us than those that
we could obtain from unaffiliated third parties.
Office Space and Administrative Services
We presently maintain our executive offices on a rent-free basis in premises
of approximately 2,500 square feet that we share with Paramount Capital
Investments, LLC. We do not have a lease agreement with Paramount Capital
Investments and consequently our use of this space may be terminated at any
time. We believe we can obtain suitable alternative space without any material
disruption of our business and that such space will be available to us in the
future on commercially reasonable terms.
In addition, Paramount Capital Investments provides us with back office and
financial support and management services free of charge. We do not have a
management services agreement with Paramount Capital Investments and
consequently our use of their services may be terminated at any time. For the
year ended December 31, 2001, the estimated fair value of the financial
assistance Paramount has provided to us totaled $481,299, which has been
reflected in the accompanying financial statements as an expense in that period
with a corresponding deemed capital contribution. We anticipate receiving
similar support in the year 2002.
Private Placement of Securities
In April and July 1999, our predecessor corporation, Pain Management, Inc.,
issued promissory notes to purchasers in the total principal amount of
$1,040,000 bearing interest at a rate of 12% per annum for the first year in
which they were outstanding and 15% per annum thereafter. It also issued
warrants to purchase a total of 260,000 shares of its common stock at an
exercise price of $0.01, exercisable on or prior to September 22, 2005.
Immediately upon the closing of our series A convertible preferred stock, the
principal amount and the accrued interest on the notes became due and payable.
We repaid the notes in full, and, following the merger, the warrants to purchase
shares of Pain Management were converted into warrants to purchase an aggregate
of 231,859 shares of our common stock.
In September and October 2000, we issued a total of 4,014,125 shares of our
series A convertible preferred stock at a purchase price of $4.00 per share and
warrants to purchase 407,893 shares of our common stock at an exercise price of
$3.94 per share. Paramount Capital, Inc., an NASD member broker-dealer, acted
as our finder in connection with our sale of our series A convertible preferred
stock. In connection with the financing, Paramount Capital's designees received
a cash commission plus expenses equal to $1,157,572. In addition, Paramount
Capital's designees received warrants to purchase, in the aggregate, 40,218
shares of our common stock and 395,788 shares of series A convertible preferred
stock, convertible into 402,177 shares of common stock. Mark S. Siegel, one of
our directors, is the President of Remy Investors & Consultants, which purchased
500,000 shares of our series A convertible preferred stock in the offering.
In September 2000, in connection with our merger with Pain Management, we
issued an aggregate of 4,648,220 shares of our common stock, or 0.89174482
shares of common stock for each outstanding share of common stock of Pain
Management. We also exchanged warrants to purchase 485,000 shares of Pain
Management common stock with a weighted average exercise price of $0.01 with
warrants to purchase 432,496 shares of our common stock with a weighted average
exercise price of approximately $0.01.
In December 2001, we issued a total of 989,991 shares of series B convertible
preferred stock at a purchase price of approximately $5.55 per share. Paramount
Capital and Wells Fargo Securities, LLC, both NASD member broker-dealers, acted
as our placement agents in connection with the sale of our series B convertible
preferred stock. In connection with the financing, Paramount Capital's designees
received a cash commission equal to $222,586, Wells Fargo's designees received a
cash commission of $155,369 and we have paid other expenses which are currently
expected to be approximately $36,000. Wells Fargo is one of the managing
underwriters in this offering.
61
Stockholders Agreement
In February 1998, Pain Management entered into a stockholders agreement with
Dr. Lindsay A. Rosenwald, Dr. Stuart Weg, Herbert Brotspies and Calgar &
Associates. We assumed the obligations under the stockholders agreement upon the
closing of our merger with Pain Management. The stockholders agreement provides
the parties with two piggyback registrations any time we file a registration
statement after our initial public offering. These registration rights will
terminate on February 25, 2003.
Transactions with Directors and Executive Officers
We have entered into an employment agreement with Dr. Leonard L. Firestone,
our Chief Executive Officer and Chief Medical Officer. The employment agreement
is effective upon the consummation of our initial public offering and provides
for salary, bonus, benefits and incentives.
We have included in our certificate of incorporation and bylaws provisions to
eliminate the personal liability of our directors for monetary damages resulting
from breaches of their fiduciary duty to the fullest extent permitted by the
Delaware General Corporation Law and indemnify our directors and officers to the
fullest extent permitted by Section 145 of the Delaware General Corporation Law,
including circumstances in which indemnification is otherwise discretionary. We
believe that these provisions are necessary to attract and retain qualified
persons as directors and officers.
Relationship with Paramount
Dr. Lindsay A. Rosenwald, one of our principal stockholders, is also the
chairman of Paramount Capital, Paramount Capital Asset Management, Inc. and
Paramount Capital Investments. Dr. Rosenwald has in the past guaranteed
certain of our bank loans and the obligations securing these guarantees have
been fulfilled.
Dr. Mark C. Rogers, Chairman of our board of directors, is also the
president of Paramount Capital, Paramount Capital Asset Management and
Paramount Capital Investments.
Mr. Peter M. Kash, a member of our board of directors, is also a Senior
Managing Director of Paramount Capital and a director of Paramount Capital Asset
Management. He also serves as a director to The Aries Master Fund, The Aries
Master Fund II and Aries Select, Ltd., each a Cayman Island company for which
Paramount Capital Asset Management serves as general partner.
Dr. Michael Weiser, a member of our board of directors, is also Director of
Research of Paramount Capital Asset Management.
Dr. Fred H. Mermelstein, our President and Secretary and a member of our
board of directors, is also the Director of Venture Capital of Paramount Capital
Investments.
In June 2001, we entered into a consulting agreement with Dr. Elizabeth
Rogers, the wife of Dr. Mark C. Rogers, our chairman. Under the consulting
agreement, Dr. E. Rogers provides 10% of her professional time to our clinical
product development team. In consideration for these services, we have agreed
to pay to Dr. E. Rogers a consulting fee equal to $30,000 per year, payable in
equal bi-monthly installments. In addition, we have agreed to reimburse Dr. E.
Rogers for all pre-approved, out-of-pocket expenses incurred on our behalf.
Concurrently with the consummation of this offering, Dr. E. Rogers will be
granted options to purchase 75,000 shares of our common stock at an exercise
price equal to the price of common stock in this initial public offering.
License Agreement Guarantee
In August 2000, we entered into a license agreement with West Pharmaceutical
under which we received certain worldwide-exclusive rights to develop and
commercialize products including intranasal morphine and intranasal fentanyl
under patents held by West Pharmaceutical. The agreement required us to pay West
Pharmaceutical up-front license fees, milestone payments upon the successful
completion of certain defined events, a portion of any up-front license fees
that we may receive from our sub-licensees, a royalty based upon our or our
sub-licensees' sales of products and minimum annual royalty payments for each
licensed product that receives regulatory approval. Paramount Capital
Investments guaranteed our ability to pay the up-front license fees to West
Pharmaceutical. The guarantee expired upon the payments by us of the amounts we
owed to West Pharmaceutical.
62
PRINCIPAL STOCKHOLDERS
Except as otherwise set forth below, the following table sets forth certain
information regarding beneficial ownership of our common stock as of March 12,
2002, and as adjusted to reflect the sale of shares offered hereby, by:
o each person (or group of affiliated persons) who is known by us to own more
than five percent of the outstanding shares of our common stock,
o each of our directors,
o executive officers named in the summary compensation table, and
o all of our executive officers and directors as a group.
Beneficial ownership is determined in accordance with the rules of the
Securities and Exchange Commission and generally includes voting or investment
power with respect to securities. The principal address of each of the
stockholders listed below is c/o Innovative Drug Delivery Systems, Inc., 787
Seventh Avenue, 48th Floor, New York, New York 10019. We believe that all
persons named in the table have sole voting and sole investment power with
respect to all shares beneficially owned by them. All figures include shares of
common stock issuable upon the exercise of options or warrants exercisable
within 60 days of March 12, 2002 and, which are deemed to be outstanding and to
be beneficially owned by the person holding those options or warrants for the
purpose of computing the percentage ownership of that person, but are not deemed
to be outstanding for the purpose of computing the percentage ownership of any
other person. All figures also assume conversion of all outstanding shares of
our series A and series B convertible preferred stock.
Number of Percent of Shares
Shares Outstanding
Beneficially ----------------------
Owned Before Before the After the
5% Beneficial Owners, Directors, Named Officers Before the Offering the Offering Offering Offering
- ------------------------------------------------------------------- ------------ ---------- ---------
Lindsay A. Rosenwald(1).................................................................. 3,890,503 25.9% 18.8%
Mark C. Rogers(2)........................................................................ 1,630,685 10.8% 7.9%
Leonard L. Firestone(3).................................................................. 372,586 2.4% 1.8%
Stuart Weg(4)............................................................................ 757,983 5.0% 3.7%
Fred H. Mermelstein(5)................................................................... 527,779 3.5% 2.6%
Peter M. Kash(6)......................................................................... 525,007 3.4% 2.5%
Douglas A. Hamilton(7)................................................................... 432,688 2.9% 2.1%
Randi Albin(8)........................................................................... 305,670 2.0% 1.5%
Michael Weiser(9)........................................................................ 387,366 2.6% 1.9%
Mark S. Siegel(10)....................................................................... 525,007 3.4% 2.5%
Edward Miller(11)........................................................................ 16,936 * *
Douglas G. Watson........................................................................ -- * *
All directors and executive officers as a group (9 persons).............................. 4,723,725 28.6% 21.3%
- ---------------
* less than one percent
(1) Includes 486,313 shares of common stock owned by each of Donni Rosenwald,
Joshi Rosenwald, David Rosenwald and Demi Rosenwald, affiliates of
Lindsay A. Rosenwald. Dr. Rosenwald disclaims beneficial ownership of
these shares except to the extent of his pecuniary interest therein.
(2) Includes a unit purchase option to acquire 16,665 shares of series A
convertible preferred stock (convertible into 16,935 shares of common
stock) and warrants to purchase 1,693 shares of common stock and 93,147
shares of common stock obtainable upon exercise of stock options
exercisable within 60 days of December 31, 2001. Excludes 75,000 shares of
common stock obtainable upon exercise of stock options not currently
exercisable within 60 days of March 12, 2002 to be granted to Dr. Elizabeth
Rogers, an affiliate of Dr. Rogers. Also excludes 33,871 shares of common
stock obtainable upon exercise of stock options not currently exercisable
within 60 days of March 12, 2002
63
and 95,394 shares of common stock owned by each of Bradley Rogers and
Merideth Rogers, Dr. Rogers' adult children who do not reside with Dr.
Rogers.
(3) Includes 372,586 shares of common stock obtainable upon exercise of stock
options exercisable within 60 days of March 12, 2002. Excludes 783,871
shares of common stock obtainable upon exercise of stock options to be
granted upon the consummation of this offering.
(4) Excludes 189,495 shares of common stock held in escrow over which Dr. Weg
exercises no voting or dispositive control.
(5) Includes 50,807 shares of common stock obtainable upon exercise of stock
options exercisable within 60 days of March 12, 2002. Excludes 101,614
shares of common stock obtainable upon exercise of stock options not
currently exercisable within 60 days of March 12, 2002.
(6) Includes, in the aggregate, 60,969 shares, 15,252 shares of which are owned
by each of Shantal Kash, Colby Kash, Jared Kash and the Kash Family Trust,
affiliates of Peter Kash, a unit purchase option to acquire 164,655 shares
of series A convertible preferred stock (convertible into 167,313 shares of
common stock) and warrants to purchase 16,732 shares of common stock and
102,477 shares of common stock obtainable upon exercise of stock options
exercisable within 60 days of March 12, 2002. Mr. Kash disclaims
beneficial ownership of the shares held by Shantal Kash, Colby Kash, Jared
Kash and the Kash Family Trust except to the extent of his pecuniary
interest therein. Excludes 33,871 shares of common stock obtainable upon
exercise of stock options not currently exercisable within 60 days of
March 12, 2002.
(7) Includes 50,807 shares of common stock obtainable upon exercise of stock
options exercisable within 60 days of March 12, 2002. Excludes 101,614
shares of common stock obtainable upon exercise of stock options not
currently exercisable within 60 days of March 12, 2002.
(8) Includes 50,807 shares of common stock obtainable upon exercise of stock
options exercisable within 60 days of March 12, 2002. Excludes 101,614
shares of common stock obtainable upon exercise of stock options not
currently exercisable within 60 days of March 12, 2002.
(9) Includes a unit purchase option to acquire 3,000 shares of series A
convertible preferred stock (convertible into 3,049 shares of common stock)
and warrants to purchase 305 shares of common stock and 16,936 shares of
common stock obtainable upon exercise of stock options exercisable within
60 days of March 12, 2002. Excludes 33,871 shares of common stock
obtainable upon exercise of stock options not currently exercisable within
60 days of March 12, 2002.
(10) Includes 500,000 shares of series A convertible preferred stock
(convertible into 508,072 shares of common stock) owned by Remy Investors &
Consultants, Inc., of which Mr. Siegel is the President and 16,936 shares
of common stock obtainable upon exercise of stock options exercisable
within 60 days of March 12, 2002. Mr. Siegel disclaims beneficial
ownership of such shares except to the extent of his pecuniary interest
therein. Excludes 33,871 shares of common stock obtainable upon exercise of
stock options not currently exercisable within 60 days of March 12, 2002.
(11) Includes 16,936 shares of common stock obtainable upon exercise of stock
options exercisable within 60 days of March 12, 2002. Excludes 33,871
shares of common stock obtainable upon exercise of stock options not
currently exercisable within 60 days of March 12, 2002.
64
DESCRIPTION OF CAPITAL STOCK
General
The following summary assumes the amendment and restatement of our
certificate of incorporation and bylaws to read in their entirety as provided in
the forms of amended and restated certificate of incorporation and bylaws filed
as exhibits to the registration statement of which this prospectus forms a part.
It also reflects changes to our capital structure that will become effective
immediately prior to or upon the closing of this offering.
The following description of our capital stock does not purport to be
complete and is subject to, and qualified in its entirety by, our amended and
restated certificate of incorporation and amended and restated bylaws, which we
have included as exhibits to the registration statement of which this prospectus
forms a part. Upon the closing of this offering, our authorized capital stock
will consist of 60,000,000 shares of common stock, $0.001 par value, and
5,000,000 shares of undesignated preferred stock, $0.001 par value. As of
December 31, 2001, there were approximately 194 holders of record of our capital
stock.
Common Stock
Dividends and Voting. The holders of our common stock are entitled to such
dividends as our board of directors may declare from legally available funds,
subject to the preferences that may be applicable to any shares of preferred
stock then outstanding. The holders of our common stock are entitled to one vote
per share on any matter to be voted upon by stockholders. Our amended and
restated certificate of incorporation does not provide for cumulative voting. No
holder of our common stock will have any preemptive right under the Delaware
General Corporation Law, our certificate of incorporation or our bylaws to
subscribe for any shares of capital stock issued in the future.
Other Rights. Upon any voluntary or involuntary liquidation, dissolution, or
winding up of our affairs, the holders of our common stock will be entitled to
share ratably in all assets remaining after payment of creditors and subject to
prior distribution rights of our preferred stock. All of the outstanding shares
of common stock are, and the shares offered by us in this offering will be,
fully paid and non-assessable.
Preferred Stock
As of the closing of this offering, no shares of our preferred stock will be
outstanding. Our certificate of incorporation provides that our board of
directors may by resolution, without further stockholder approval, establish and
issue one or more classes or series of preferred stock, up to an aggregate of
5,000,000 shares, having the relative voting rights, designations, dividend
rates, liquidation, and other rights, preferences, and limitations as our board
of directors may fix. The holders of our preferred stock may be entitled to
preferences over common stockholders with respect to dividends, liquidation,
dissolution or our winding up in such amounts as our board of directors may
establish.
The issuance of our preferred stock may have the effect of delaying,
deferring or preventing a change in control of us without further action by the
holders and may adversely affect voting and other rights of holders of our
common stock. In addition, issuance of preferred stock, while providing
desirable flexibility in connection with possible acquisitions and other
corporate purposes, could make it more difficult for a third party to acquire a
majority of the outstanding shares of voting stock. At present, we have no plans
to issue any shares of preferred stock.
Options
As of February 25, 2002, options to purchase a total of 1,773,557 shares of
common stock were outstanding at a weighted average exercise price of $4.28.
Options to purchase a total of 3,150,046 shares of common stock are reserved
under our 2000 Omnibus Stock Incentive Plan for future grants. Since we intend
to file a registration statement on Form S-8 as soon as practicable following
the closing of this offering, any shares issued upon exercise of these options
will be immediately available for sale in the public market, subject to the
terms of lock-up agreements with the underwriters.
65
Warrants
As of February 25, 2002, there were warrants outstanding to purchase 216,253
shares of our common stock exercisable for approximately $0.01 per share, which
expire in September 2005, and warrants to purchase 407,893 shares of our common
stock exercisable for $3.94 per share, which expire in October 2005. In
addition, 442,395 shares of common stock are issuable upon the exercise and
assumed conversion of 15.83 Unit Purchase Options. The units entitle the holders
to purchase an aggregate of 395,788 shares of our series A convertible preferred
stock (convertible into 402,177 shares of common stock) at $4.40 per share and
40,218 shares of our common stock at $3.94 per share.
Registration Rights
Upon the closing of this offering, the holders of approximately 6,646,635
shares of common stock and warrants to purchase up to approximately 635,090
shares of our common stock will have registration rights with respect to their
shares. These rights are provided under the terms of agreements between us and
the holders of these securities. If we propose to register any of our securities
under the Securities Act, other than in connection with this offering, either
for our own account or for the account of other security holders exercising
registration rights, these holders will be entitled to notice of the
registration and are entitled to include shares of common stock in the
registration. The rights are subject to conditions and limitations, among them
the right of the underwriters of an offering to limit the number of shares
included in the registration. In the event West Pharmaceutical elects to receive
all or part of its milestone payments in shares of our common stock, at any time
commencing 30 days following the attainment of certain milestones, West
Pharmaceutical may require us to file up to three registration statements under
the Securities Act at our expense with respect to their shares of our common
stock, and we are required to use our best efforts to effect the registrations,
subject to conditions and limitations. At any time following 180 days after the
date of this prospectus, the holders of certain shares may require us to file up
to one registration statement under the Securities Act at our expense with
respect to their shares of our common stock, and we are required to use our best
efforts to effect the registration, subject to conditions and limitations.
Anti-takeover Provisions of the Certificate of Incorporation, Bylaws and
Delaware Law
Some provisions of our amended and restated certificate of incorporation and
our bylaws could discourage potential acquisition proposals and could delay or
prevent a change in control. These provisions also may have the effect of
preventing changes in our management. Our amended and restated certificate of
incorporation authorizes our board to establish one or more series of
undesignated preferred stock, the terms of which can be determined by our board
at the time of issuance. Our amended and restated certificate of incorporation
also provides that all stockholder action must be effected at a duly called
meeting of stockholders and not by written consent. In addition, our amended and
restated certificate of incorporation and bylaws do not permit our stockholders
to call a special meeting of stockholders. Only our Chief Executive Officer,
President, Chairman of the Board or a majority of the board of directors may be
permitted to call a special meeting of stockholders. Our amended and restated
certificate of incorporation also provides for the board of directors to be
divided into three classes, with each director assigned to a class with a term
of three years, and for the total number of directors to be determined only by
the board of directors. Our bylaws require that stockholders give advance notice
to our secretary of any nominations for director or other business to be brought
by stockholders at any stockholders' meeting, and permit the chairman of the
board to adjourn any meeting called by the stockholders. Our bylaws also require
a supermajority vote of members of the board of directors and stockholders to
amend some bylaw provisions.
We are subject to Section 203 of the Delaware General Corporation Law, which
regulates acquisitions of Delaware corporations. In general, Section 203
prohibits a publicly-held Delaware corporation from engaging in a business
combination with an interested stockholder for a period of three years following
the date the person becomes an interested stockholder, unless:
o our board of directors approved the business combination or the transaction
in which the person became an interested stockholder prior to the date the
person attained this status,
66
o upon consummation of the transaction that resulted in the person becoming
an interested stockholder, the person owned at least 85% of the voting
stock of the corporation outstanding at the time the transaction commenced,
excluding shares owned by persons who are directors and also officers, or
o on or subsequent to the date the person became an interested stockholder,
our board of directors approved the business combination and the
stockholders other than the interested stockholder authorized the
transaction at an annual or special meeting of stockholders.
Section 203 defines a "business combination" to include:
o any merger or consolidation involving the corporation and the interested
stockholder,
o any sale, transfer, pledge or other disposition involving the interested
stockholder of 10% or more of the assets of the corporation,
o in general, any transaction that results in the issuance or transfer by
the corporation of any stock of the corporation to the interested
stockholder, or
o the receipt by the interested stockholder of the benefit of any loans,
advances, guarantees, pledges or other financial benefits provided by or
through the corporation.
In general, Section 203 defines an "interested stockholder" as any person
who, together with the person's affiliates and associates, owns, or within three
years prior to the determination of interested stockholder status did own, 15%
or more of a corporation's voting stock.
Number of Directors; Removal; Filling Vacancies
Our board consists of eight directors and is divided into three classes of
directors serving staggered three-year terms. As a result, approximately one-
third of our board will be elected each year. These provisions, when coupled
with the provision of our amended and restated certificate of incorporation
authorizing the board to fill vacant directorships or increase the size of the
board may deter a stockholder from removing incumbent directors and
simultaneously gaining control of the board.
Bylaws
Our bylaws are subject to adoption, amendment, alteration, repeal, or
rescission either by our Board of Directors by a vote of a majority of all
directors in office, without the assent or vote of our stockholders, or by the
affirmative vote of the holders of a majority of the outstanding shares of
voting securities.
Transfer Agent
Our Transfer Agent and Registrar is American Stock Transfer & Trust Company.
Its telephone number is 212-936-5100.
67
SHARES ELIGIBLE FOR FUTURE SALE
Prior to this offering, there has been no public market for our common stock.
Future sales of substantial amounts of our common stock in the public market
could reduce prevailing market prices. Sales of substantial amounts of our
common stock in the public market after any restrictions on sale lapse could
adversely affect the prevailing market price of the common stock and impair our
ability to raise equity in the future.
Upon the closing of this offering, we will have 20,645,327 outstanding shares
of common stock. Of these shares, the 5.6 million shares sold in this offering
will be freely transferable without restriction or further registration under
the Securities Act, except for any shares purchased by an affiliate of us. The
remaining 15,045,327 shares of common stock held by existing stockholders are
restricted securities. Restricted securities may be sold in the public market
only if registered or if they qualify for exemption from registration described
below under Rule 144, 144(k) or 701 promulgated under the Securities Act.
As a result of contractual restrictions described below and the provisions of
Rules 144, 144(k) and 701, the restricted shares will be available for sale in
the public market as follows:
o 5,600,000 shares will be eligible for sale immediately following this
offering, and
o 15,045,327 shares will be eligible for sale upon the expiration of the
lock-up agreements, described below, beginning 180 days after the date of
this prospectus and when permitted under Rule 144, 144(k) or 701
promulgated under the Securities Act.
Lock-Up Agreements
All of our directors, officers, employees and the holders of substantially
all of our securities have entered into lock-up agreements in connection with
this offering. These lock-up agreements generally provide that these holders
will not offer, sell, contract to sell, grant any option to purchase or
otherwise dispose of our common stock or any securities exercisable for or
convertible into our common stock owned by them for a period of 180 days after
the date of this prospectus without the prior written consent of Thomas Weisel
Partners LLC. Notwithstanding possible earlier eligibility for sale under the
provisions of Rules 144, 144(k) and 701, shares subject to lock-up agreements
may not be sold until these agreements expire or are waived by Thomas Weisel
Partners LLC. Holders of approximately 91.28% percent of our stock outstanding
immediately prior to this offering have entered into lock-up agreements.
Rule 144
In general, under Rule 144 as currently in effect, after the expiration of
the lock-up agreements, a person who has beneficially owned restricted
securities for at least one year would be entitled to sell within any three-
month period a number of shares that does not exceed the greater of:
o 1% of the number of shares of common stock then outstanding, which will
equal approximately 206,453 shares immediately after this offering, and
o the average reported weekly trading volume of our common stock during the
four calendar weeks preceding the sale by such person.
Sales under Rule 144 are also subject to requirements with respect to manner
of sale, notice and the availability of current public information about us.
Rule 144(k)
Under Rule 144(k), a person who is not deemed to have been our affiliate at
any time during the three months preceding a sale, and who has beneficially
owned the shares proposed to be sold for at least two years, may sell these
shares without complying with the manner of sale, public information, volume
limitation or notice requirements of Rule 144.
68
Rule 701
Rule 701 permits our employees, officers, directors or consultants who
purchased shares pursuant to a written compensatory plan or contract to resell
such shares in reliance upon Rule 144, but without compliance with certain
restrictions. Rule 701 provides that affiliates may sell their Rule 701 shares
under Rule 144 90 days after effectiveness of this registration statement
without complying with the holding period requirement and that non-affiliates
may sell such shares in reliance on Rule 144 90 days after effectiveness of this
registration statement without complying with the holding period, public
information, volume limitation or notice requirements of Rule 144.
Registration Rights
Upon the closing of this offering, the holders of approximately 7,281,725
shares of common stock and warrants to purchase common stock, or their
transferees, will be entitled to rights with respect to the registration of
their shares under the Securities Act. Registration of their shares under the
Securities Act would result in these shares becoming freely tradeable without
restriction under the Securities Act, except for shares purchased by affiliates,
immediately upon the effectiveness of such registration.
Stock Options
We intend to file a registration statement under the Securities Act after the
closing of this offering to register shares to be issued pursuant to our 2000
Omnibus Stock Incentive Plan and our Employee Stock Purchase Plan. As a result,
shares of our common stock obtained through the exercise of any options or
rights granted under our 2000 Omnibus Stock Incentive Plan will also be freely
tradable in the public market. However, shares held by affiliates will still be
subject to the volume limitation, manner of sale, notice and public information
requirements of Rule 144, unless otherwise resalable under Rule 701.
69
UNITED STATES FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS
The following summary describes the material United States federal income and
estate tax consequences of the ownership of common stock by a non-U.S. holder as
of the date hereof. This discussion does not address all aspects of United
States federal income and estate taxes that may be relevant to a non-U.S.
holder of common stock. For example, in the case of a non-U.S. holder that is a
partnership, the United States tax consequences of holding and disposing of our
common stock may be affected by determinations made at the partner level. This
discussion also does not address foreign, state and local tax consequences.
Special rules may apply to certain non-U.S. holders, such as insurance
companies, tax-exempt organizations, banks, financial institutions, dealers in
securities, holders of securities held as part of a "straddle," "hedge" or
"conversion transaction," "controlled foreign corporations," "passive foreign
investment companies," "foreign personal holding companies" and corporations
that accumulate earnings to avoid United States federal income tax, that are
subject to special treatment under the Internal Revenue Code of 1986, as
amended, or the Code. Such persons should consult their own tax advisors to
determine the United States federal, state, local and other tax consequences
that may be relevant to them. Furthermore, the discussion below is based upon
the provisions of the Code, and regulations, rulings and judicial decisions
thereunder as of the date hereof, and these authorities may be repealed, revoked
or modified with retroactive effect so as to result in United States federal
income tax consequences different from those discussed below.
Persons considering the purchase, ownership or disposition of common stock
should consult their own tax advisors concerning the United States federal
income tax consequences in light of their particular situations as well as any
consequences arising under the laws of any other taxing jurisdiction.
As used in this section, a "U.S. holder" of common stock means a holder that
is (1) a citizen or resident of the United States, (2) a corporation or
partnership created or organized in or under the laws of the United States or of
any state thereof or in the District of Columbia, unless in the case of a
partnership, United States Treasury regulations provide otherwise, (3) an estate
the income of which is subject to United States federal income taxation
regardless of its source and (4) a trust (A) if a court within the United States
is able to exercise primary supervision over the administration of the trust and
one or more United States persons has the authority to control all substantial
decisions of the trust or (B) that has a valid election in effect under
applicable United States Treasury regulations to be treated as a United States
person. A "non-U.S. holder" is a holder that is not a U.S. holder.
Dividends
Dividends paid to a non-U.S. holder of common stock generally will be subject
to withholding of United States federal income tax at a 30% rate or such lower
rate as may be specified by an applicable income tax treaty. However, dividends
that are effectively connected with the conduct of a trade or business by the
non-U.S. holder within the United States and, generally, where a tax treaty
applies, are attributable to a United States permanent establishment of the
non-U.S. holder, are not subject to withholding tax, but instead are subject to
United States federal income tax on a net income basis at applicable graduated
individual or corporate rates. Certain certification and disclosure requirements
must be complied with in order for effectively connected income to be exempt
from withholding. Any such effectively connected dividends received by a foreign
corporation may be subject to an additional "branch profits tax" at a 30% rate
or such lower rate as may be specified by an applicable income tax treaty. A
non-U.S. holder of common stock who wishes to claim the benefit of an applicable
treaty rate (and avoid back-up withholding as discussed below) for dividends
paid will be required to satisfy applicable certification and other requirements
and may be required to obtain a United States taxpayer identification number.
A non-U.S. holder of common stock eligible for a reduced rate of United
States withholding tax may obtain a refund of any excess amounts withheld by
filing an appropriate claim for refund with the Internal Revenue Service, or the
IRS.
70
Gain on Disposition of Common Stock
A non-U.S. holder generally will not be subject to United States federal
income tax with respect to gain recognized on a sale or other disposition of
common stock unless (1) the gain is effectively connected with a trade or
business of the non-U.S. holder in the United States and, generally, where a tax
treaty applies, is attributable to a United States permanent establishment of
the non-U.S. holder, (2) in the case of a non-U.S. holder who is an individual
and holds the common stock as a capital asset, such holder is present in the
United States for 183 or more days in the taxable year of the sale or other
disposition and certain other conditions are met or (3) we are or have been a
"U.S. real property holding corporation" for United States federal income tax
purposes.
A non-U.S. holder described in clause (1) above will be subject to tax on the
net gain derived from the sale under regular graduated United States federal
income tax rates and, if it is a corporation, may be subject to the branch
profits tax at a rate equal to 30% of its effectively connected earnings and
profits or at such lower rate as may be specified by an applicable income tax
treaty. An individual non-U.S. holder described in clause (2) above will be
subject to a flat 30% tax on the gain derived from the sale, which may be offset
by United States source capital losses (even though the individual is not
considered a resident of the United States).
We believe we are not and do not anticipate becoming a "U.S. real property
holding corporation" for United States federal income tax purposes.
Federal Estate Tax
Common stock held by an individual non-U.S. holder at the time of death will
be included in such holder's gross estate for United States federal estate tax
purposes, unless an applicable estate tax treaty provides otherwise.
Information Reporting and Backup Withholding
We must report annually to the IRS and to each non-U.S. holder the amount of
dividends paid to such holder and the tax withheld with respect to such
dividends, regardless of whether withholding was required. Copies of the
information returns reporting such dividends and withholding may also be made
available to the tax authorities in the country in which the non-U.S. holder
resides under the provisions of an applicable income tax treaty.
A non-U.S. holder may be subject to back-up withholding unless applicable
certification requirements are met.
Payment of the proceeds of a sale of common stock within the United States or
conducted through certain United States related financial intermediaries is
subject to both backup withholding and information reporting unless the
beneficial owner certifies under penalties of perjury that it is a non-U.S.
holder (and the payor does not have actual knowledge or reason to know that the
beneficial owner is a United States person) or the holder otherwise establishes
an exemption.
Any amounts withheld under the backup withholding rules may be allowed as a
refund or a credit against such holder's United States federal income tax
liability provided the required information is furnished to the IRS.
71
UNDERWRITING
Subject to the terms and conditions set forth in an agreement among the
underwriters and us, each of the underwriters named below, through their
representatives, Thomas Weisel Partners LLC, Wells Fargo Securities, LLC and
Jefferies & Company, Inc. has severally agreed to purchase from us the aggregate
number of shares of common stock set forth opposite its name below:
Number
Underwriters of Shares
------------ ---------
Thomas Weisel Partners LLC.........................................
Wells Fargo Securities, LLC........................................
Jefferies & Company, Inc...........................................
---------
Total.............................................................. 5,600,000
=========
The underwriting agreement provides that the obligations of the several
underwriters are subject to various conditions. The nature of the underwriters'
obligations commits them to purchase and pay for all of the shares of common
stock listed above if any are purchased.
Thomas Weisel Partners LLC expects to deliver the shares of common stock to
purchasers on , 2002.
Over-Allotment Option
We have granted a 30-day over-allotment option to the underwriters to
purchase up to a total of 280,000 additional shares of our common stock from us
at the initial public offering price, less the underwriting discount payable by
us, as set forth on the cover page of this prospectus. If the underwriters
exercise this option in whole or in part, then each of the underwriters will be
separately committed, subject to conditions described in the underwriting
agreement, to purchase the additional shares of our common stock in proportion
to their respective commitments set forth in the table above.
Determination of Offering Price
Prior to this offering, there has been no public market for our common stock.
The initial public offering price will be determined through negotiations
between us and the representatives. In addition to prevailing market conditions,
the factors to be considered in determining the initial public offering price
will include:
o the valuation multiples of publicly-traded companies that the
representatives believe are comparable to us,
o our financial information,
o our history and prospects and the outlook for our industry,
o an assessment of our management, our past and present operations, and the
prospects for, and timing of, our future revenues,
o the present state of our development and the progress of our business
plan, and
o the above factors in relation to market values and various valuation
measures of other companies engaged in activities similar to ours.
An active or orderly trading market may never develop for our common stock,
and our common stock may not trade in the public markets subsequent to this
offering at or above the initial offering price.
Commissions and Discounts
The underwriters propose to offer the shares of common stock directly to the
public at the public offering price set forth on the cover page of this
prospectus, and at this price less a concession not in excess of $ per share of
common stock to other dealers specified in a master agreement among underwriters
who are members of the National Association of Securities Dealers, Inc. The
underwriters may
72
allow, and the other dealers specified may reallow, concessions, not in excess
of $ per share of common stock to these other dealers. After this offering,
the offering price, concessions and other selling terms may be changed by the
underwriters. Our common stock is offered subject to receipt and acceptance by
the underwriters and to other conditions, including the right to reject orders
in whole or in part.
The following table summarizes the compensation to be paid to the
underwriters by us and the proceeds to us before estimated expenses payable by
us of $2,000,000:
Total
--------------------------------------------
Without With
Per Share Over-Allotment Over-Allotment
--------- -------------- --------------
Public offering price ................................. $ $ $
Underwriting discount ................................. $ $ $
Proceeds, before expenses, to us ...................... $ $ $
Indemnification of the Underwriters
We will indemnify the underwriters against some civil liabilities, including
liabilities under the Securities Act of 1933 and liabilities arising from
breaches of our representations and warranties contained in the underwriting
agreement. If we are unable to provide this indemnification, we will contribute
to payments the underwriters may be required to make in respect of those
liabilities.
Reserved Shares
The underwriters, at our request, have reserved for sale at the initial
public offering price up to 280,000 shares of common stock to be sold in this
offering for sale to our employees and other persons designated by us. The
number of shares available for sale to the general public will be reduced to the
extent that any reserved shares are purchased. Any reserved shares not purchased
in this manner will be offered by the underwriters to the public on the same
basis as the other shares offered in this offering.
No Sales of Similar Securities
Our directors, officers and stockholders holding substantially all of the
outstanding shares of our capital stock prior to this offering have agreed,
subject to specified exceptions, not to offer, pledge, sell, contract to sell,
sell any option or contract to purchase, purchase any option or contract to
sell, grant any option, right or warrant to purchase, lend or otherwise transfer
or dispose of directly or indirectly, any shares of common stock or enter into
any swap or other arrangement that transfers to another, in whole or in part,
any of the economic consequences of ownership of our common stock or any
securities convertible into or exchangeable for shares of our common stock
without the prior written consent of Thomas Weisel Partners LLC for a period of
180 days after the date of this prospectus.
We have agreed that for a period of 180 days after the date of this
prospectus we will not, without the prior written consent of Thomas Weisel
Partners LLC, offer, sell, or otherwise dispose of any shares of common stock,
except for the shares of common stock offered in this offering and the shares of
common stock issuable upon exercise of outstanding options and warrants on the
date of this prospectus.
Information Regarding Thomas Weisel Partners LLC
Thomas Weisel Partners LLC, one of the representatives of the underwriters,
was organized and registered as a broker-dealer in December 1998. Since December
1998, Thomas Weisel Partners LLC has been named as a lead or co-manager on
numerous public offerings of equity securities. Thomas Weisel Partners LLC does
not have any material relationship with us or any of our officers, directors or
other controlling persons, except with respect to its contractual relationship
with us under the underwriting agreement entered into in connection with this
offering and as described below.
73
Nasdaq National Market Listing
We have applied to have our common stock approved for quotation on the Nasdaq
National Market under the symbol "IDDS."
Discretionary Accounts
The underwriters do not expect sales of shares of our common stock offered by
this prospectus to any accounts over which they exercise discretionary authority
to exceed five percent of the shares offered.
Short Sales, Stabilizing Transactions and Penalty Bids
In order to facilitate this offering, persons participating in this offering
may engage in transactions that stabilize, maintain or otherwise affect the
price of our common stock during and after this offering. Specifically, the
underwriters may engage in the following activities in accordance with the rules
of the Securities and Exchange Commission.
Short Sales. Short sales involve the sale by the underwriters of a greater
number of shares than they are required to purchase in the offering. "Covered"
short sales are sales made in an amount not greater than the underwriters'
option to purchase additional shares from the issuer in the offering. The
underwriters may close out any covered short position by either exercising their
option to purchase shares or purchasing shares in the open market. In
determining the source of shares to close out the covered short position, the
underwriters will consider, among other things, the price of shares available
for purchase in the open market as compared to the price at which they may
purchase shares through the over-allotment option. "Naked" short sales are any
sales in excess of such over-allotment option. The underwriters must close out
any naked short position by purchasing shares in the open market. A naked short
position is more likely to be created if the underwriters are concerned that
there may be downward pressure on the price of the common stock in the open
market after pricing that could adversely affect investors who purchase in the
offering.
Stabilizing Transactions. The underwriters may make bids for or purchases of
the shares for the purpose of pegging, fixing or maintaining the price of the
shares, so long as stabilizing bids do not exceed a specified maximum.
Penalty Bids. If the underwriters purchase shares in the open market in a
stabilizing transaction or syndicate covering transaction, they may reclaim a
selling concession from the underwriters and selling group members who sold
those shares as part of this offering. Stabilization and syndicate covering
transactions may cause the price of the shares to be higher than it would be in
the absence of these transactions. The imposition of a penalty bid might also
have an effect on the price of the shares if it discourages resales of the
shares.
Any of these activities may have the effect of preventing or retarding a
decline in the market price of our common stock. They may also cause the price
of our common stock to be higher than the price that would otherwise exist in
the open market in the absence of these activities. The transactions above may
occur on the Nasdaq National Market or otherwise. Neither we nor the
underwriters make any representation or prediction as to the effect that the
transactions described above may have on the price of our common stock. If these
transactions are commenced, they may be discontinued without notice at any time.
Other Relationships
In December 2001, Wells Fargo Securities, LLC, one of the representatives of
the underwriters, acted as our placement agent in connection with the private
placement of our series B convertible preferred stock for which it received
customary compensation and reimbursement of expenses. In addition, certain
individuals associated with Thomas Weisel Partners LLC and Wells Fargo
Securities, LLC purchased an aggregate of shares of our series B convertible
preferred stock, which upon the closing of this offering will automatically
convert into an aggregate of 54,009 shares of our common stock. Under the NASD's
Conduct Rules, these shares of our series B convertible preferred stock could be
deemed to be underwriting compensation received in connection with this
offering. Accordingly, these individuals have agreed, for a period of one year,
not to sell, transfer, assign, pledge or hypothecate the shares of our common
stock that they will receive upon
74
conversion of this preferred stock, other than to any NASD member participating
in this offering or an officer or partner of that NASD member. The underwriters
and their affiliates may, from time to time, engage in transactions with and
perform services for us in the ordinary course of our business.
LEGAL MATTERS
The validity of the common stock offered will be passed upon for us by
Brobeck, Phleger & Harrison LLP, New York, New York. The validity of the common
stock offered will be passed upon for the underwriters by Pillsbury Winthrop
LLP, New York, New York.
EXPERTS
The financial statements as of December 31, 2000 and 2001 and for each of the
three years in the period ended December 31, 2001 and the cumulative period from
February 23, 1998 (inception) to December 31, 2001 included in this prospectus
have been so included in reliance on the report of PricewaterhouseCoopers LLP,
independent accounts, given on the authority of said firm as experts in auditing
and accounting.
WHERE YOU CAN FIND MORE INFORMATION
We have filed with the Securities and Exchange Commission, or SEC, a
registration statement on Form S-1 under the Securities Act for the registration
of our common stock offered hereby. This prospectus does not contain all of the
information included in the registration statement and the exhibits and
schedules to the registration statement. For further information on us and our
common stock, you should refer to the registration statement and the exhibits
and schedules filed as a part of the registration statement. Statements
contained in this prospectus as to any contract or any other document are not
necessarily complete. Where the contract or other document is an exhibit to the
registration statement, each statement is qualified by the provisions of that
exhibit. You may inspect the registration statement, including exhibits and
schedules thereto, included without charge at the Commission's principal office
in Washington, D.C., and copies of all or any part thereof may be obtained from
the Public Reference Room of the SEC, 450 Fifth Street, N.W., Washington, D.C.
20549 and after payment of fees prescribed by the SEC. You may call the SEC at
1-800-732-0330 for further information about the operation of the public
reference room. The SEC also maintains a World Wide Web site, which provides
online access to reports, proxy and information statements and other information
regarding registrants that file electronically with the SEC at the address
http://www.sec.gov.
75
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Index to Financial Statements
Page
----
Report of Independent Accountants ....................................... F-2
Financial Statements:
Balance Sheets as of December 31, 2000 and 2001 ......................... F-3
Statements of Operations for the years ended December 31, 1999, 2000 and
2001, and the cumulative period from February 23, 1998 (inception) to
December 31, 2001...................................................... F-4
Statements of Redeemable Convertible Preferred Stock and Stockholders'
Deficit for the period from February 23, 1998 (inception) to December
31, 2001, including the period from February 23, 1998 (inception) to
December 31, 1998, and the years ended December 31, 1999, 2000
and 2001 .............................................................. F-5
Statements of Cash Flows for the years ended December 31, 1999, 2000,
and 2001 and the cumulative period from from February 23, 1998
(inception) to December 31, 2001....................................... F-6
Notes to Financial Statements ........................................... F-7
F-1
Report of Independent Accountants
To the Board of Directors and Stockholders of
Innovative Drug Delivery Systems, Inc.:
The stock dividend described in Note 1 to the financial statements has not
been consummated at March 13, 2002. When it has been consummated, we will be in
a position to furnish the following report:
"In our opinion, the accompanying balance sheets and the related statements
of operations, of redeemable preferred stock and stockholders' deficit and of
cash flows present fairly, in all material respects, the financial position of
Innovative Drug Delivery Systems, Inc. (the "Company") (a development stage
enterprise) at December 31, 2000 and 2001, and the results of its operations and
its cash flows for each of the three years in the period ended December 31, 2001
and the cumulative period from February 23, 1998 (inception) to December 31,
2001 in conformity with accounting principles generally accepted in the United
States of America. These financial statements are the responsibility of the
Company's management; our responsibility is to express an opinion on these
financial statements based on our audits. We conducted our audits of these
statements in accordance with auditing standards generally accepted in the
United States of America which require that we plan and perform the audits to
obtain reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements, assessing
the accounting principles used and significant estimates made by management, and
evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion."
PricewaterhouseCoopers LLP
New York, New York
January 30, 2002, except for
Note 9 as to which the date
is February 25, 2002 and Note 1,
as to which the date is March 12, 2002
F-2
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Balance Sheets
December 31, Pro forma
--------------------------- December 31,
2000 2001 2001
------------ ----------- ------------
(unaudited)
See Note 2
ASSETS
Current assets:
Cash and cash equivalents..............................................$ 10,083,611 $ 7,743,840 $ 7,743,840
Grant receivable....................................................... 306,035 194,990 194,990
Prepaid expenses and other current assets.............................. 64,000 57,912 57,912
------------ ------------ ------------
Total current assets ................................................ 10,453,646 7,996,742 7,996,742
Fixed assets, at cost, net of accumulated depreciation .................. 4,003 11,420 11,420
Restricted cash ......................................................... 40,000 60,000 60,000
Prepaid offering costs .................................................. 776,819 776,819
------------ ------------ ------------
Total assets ........................................................$ 10,497,649 $ 8,844,981 $ 8,844,981
============ ============ ============
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK
AND STOCKHOLDERS' (DEFICIT) EQUITY
Current liabilities:
Accounts payable and accrued expenses..................................$ 256,214 $ 1,153,325 $ 1,153,325
Due to affiliates...................................................... 22,574 38,450 38,450
------------ ------------ ------------
Total current liabilities ........................................... 278,788 1,191,775 1,191,775
------------ ------------ ------------
Commitments and contingencies
Redeemable convertible preferred stock, 6,500,000 shares authorized;
Series A convertible preferred stock, $0.001 par value; 4,500,000
shares designated; 4,014,125 shares issued and outstanding at
December 31, 2000 and 2001; and no pro forma shares issued and
outstanding (liquidation value $16,056,500 in 2000 and 2001).......... 13,774,952 13,774,952
Series B convertible preferred stock, $0.001 par value; 1,351,350
shares designated; no shares issued and outstanding at December 31,
2000, 989,991 shares issued and outstanding at December 31, 2001; no
pro forma shares issued and outstanding (liquidation value
$5,494,450) .......................................................... 5,020,032
------------ ------------ ------------
Total redeemable convertible preferred stock ........................ 13,774,952 18,794,984
------------ ------------ ------------
Stockholders' (deficit) equity
Common stock, $0.001 par value; 21,500,000 shares authorized; 9,929,579
and 9,960,427 shares issued and outstanding at December 31, 2000 and
2001 respectively and pro forma 15,045,327 shares issued and
outstanding .......................................................... 9,930 9,960 15,045
Additional paid in capital............................................. 21,134,234 21,615,672 40,405,571
Subscription receivable................................................ (654) (110) (110)
Deficit accumulated during the development stage....................... (24,699,601) (32,767,300) (32,767,300)
------------ ------------ ------------
Total stockholders' (deficit) equity ................................ (3,556,091) (11,141,778) 7,653,206
------------ ------------ ------------
Total liabilities, redeemable convertible preferred stock and
stockholders' (deficit) equity.....................................$ 10,497,649 $ 8,844,981 $ 8,844,981
============ ============ ============
The accompanying notes are an integral part of the financial statements.
F-3
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Statements of Operations
Year Ended Cumulative from
December 31, February 23, 1998
------------------------------------------ (inception) to
1999 2000 2001 December 31, 2001
----------- ------------ ------------ -----------------
Revenues:
Government grants.......................................... $ 306,035 $ 882,358 $ 1,188,393
------------ ------------ ------------
Operating expenses:
Research and development................................... $ 664,636 21,832,641 7,009,543 29,713,438
General and administrative................................. 312,079 1,353,445 2,285,779 4,208,283
Depreciation and amortization.............................. 324 748 3,210 4,282
----------- ------------ ------------ ------------
Total operating expenses................................. 977,039 23,186,834 9,298,532 33,926,003
----------- ------------ ------------ ------------
Operating loss............................................. (977,039) (22,880,799) (8,416,174) (32,737,610)
----------- ------------ ------------ ------------
Other income (expense):
Interest expense........................................... (239,092) (320,533) (566,227)
Interest income............................................ 10,572 177,490 348,475 536,537
----------- ------------ ------------ ------------
(228,520) (143,043) 348,475 (29,690)
----------- ------------ ------------ ------------
Net loss................................................. (1,205,559) (23,023,842) (8,067,699) (32,767,300)
Deemed dividend related to beneficial conversion feature of
Series B redeemable convertible preferred stock........... (3,559,305) (3,559,305)
----------- ------------ ------------ ------------
Net loss attributable to common stockholders............... $(1,205,559) $(23,023,842) $(11,627,004) $(36,326,605)
=========== ============ ============ ============
Net loss per share attributable to common stockholders
Basic and diluted........................................ $ (0.28) $ (3.93) $ (1.20)
=========== ============ ============
Weighted average shares.................................. 4,309,510 5,859,105 9,725,376
=========== ============ ============
Pro forma net loss per share attributable to common
stockholders (unaudited) (see Note 2)
Basic and diluted........................................ $ (0.84)
============
Weighted average shares.................................. 13,807,058
============
The accompanying notes are an integral part of the financial statements.
F-4
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Statements of Redeemable Preferred Stock and Stockholders' Deficit
For the period from February 23, 1998 (inception) to December 31,
2001, including the period from February 23, 1998
(inception) to December 31, 1998 and the years ended
December 31, 1999, 2000, and 2001
Stockholders'
Deficit
------------------
Series A Series B
Redeemable Redeemable
Preferred Stock Preferred Stock Common Stock
----------------------- -------------------- ------------------
Shares Amount Shares Amount Shares Amount
--------- ----------- ------- ---------- --------- ------
Sale of Common Stock to founders at
inception for cash ($0.001 per share)... 4,458,724 $4,459
Fair value of services provided by an
affiliate (see Note 11).................
Net loss for the period February 23, 1998
(inception) to December 31, 1998........
--------- ------
Balance at December 31, 1998 ......... 4,458,724 4,459
Issuance of 231,859 warrants in June in
connection with bridge financing (see
Note 6).................................
Issuance of Common Stock to consultant in
June for services (see Note 5).......... 189,496 189
Issuance of 200,642 warrants to
consultants in August for services
(see Note 6)............................
Fair value of services provided by an
affiliate (see Note 11).................
Net loss for the year ended December 31,
1999....................................
--------- ------
Balance at December 31, 1999 ......... 4,648,220 4,648
Issuance of 15,242 warrants to an advisor
for services in connection with the sale
of Series A redeemable preferred stock
in August (see Note 5).................. $ (55,790)
Exercise of warrants by consultants ...... 200,642 201
Issuance of Common Stock in connection
with acquisition of a license in
September (see Note 1).................. 5,080,717 5,081
Sale of 160.565 Units for cash in
September ($100,000 per Unit), net of
offering expenses of $1,157,572
(see Note 5)............................ 4,014,125 14,898,928
Issuance of Preferred A warrants in
September (see Note 5).................. (960,361)
Issuance of Preferred A Finders Units for
services in September (see Note 5)...... (107,825)
Payment of stock subscription receivable .
Non-cash compensation in connection with
issuance of stock options to non-
employees in August and November (see
Note 9).................................
Fair value of services provided by an
affiliate (see Note 11).................
Net loss for the year ended December 31,
2000....................................
--------- ----------- ------- ---------- --------- ------
Balance at December 31, 2000 ......... 4,014,125 13,774,952 9,929,579 9,930
Sale of 10.9887 Units with beneficial
conversion feature for cash in December
($500,000 per Unit) (see Note 5)........ 989,991 1,935,044
Expenses in connection with sale of
Series B stock.......................... $ (474,317)
Deemed dividend related to beneficial
conversion feature of Series B stock
(see Note 5)............................ 3,559,305
Payment of stock subscription receivable .
Exercise of warrants by a consultant ..... 15,242 15
Exercise of bridge warrants .............. 15,606 15
Fair value of services provided by an
affiliate (see Note 11).................
Net loss for the year ended December 31,
2001....................................
--------- ----------- ------- ---------- --------- ------
Balance at December 31, 2001 ......... 4,014,125 $13,774,952 989,991 $5,020,032 9,960,427 $9,960
========= =========== ======= ========== ========= ======
Stockholders' Deficit
----------------------------------------------------------
Deficit
Accumulated
Additional Stock during the Total
Paid-in Subscription Development Stockholders'
Capital Receivable Stage Deficit
----------- ------------ ------------ -------------
Sale of Common Stock to founders at
inception for cash ($0.001 per share)... $ 539 $(3,749) $ 1,249
Fair value of services provided by an
affiliate (see Note 11)................. 89,531 89,531
Net loss for the period February 23, 1998
(inception) to December 31, 1998........ $ (470,200) (470,200)
----------- ------- ------------ ------------
Balance at December 31, 1998 ......... 90,070 (3,749) (470,200) (379,420)
Issuance of 231,859 warrants in June in
connection with bridge financing (see
Note 6)................................. 101,564 101,564
Issuance of Common Stock to consultant in
June for services (see Note 5).......... 93,267 (106) 93,350
Issuance of 200,642 warrants to
consultants in August for services
(see Note 6)............................ 98,598 98,598
Fair value of services provided by an
affiliate (see Note 11)................. 155,917 155,917
Net loss for the year ended December 31,
1999.................................... (1,205,559) (1,205,559)
----------- ------- ------------ ------------
Balance at December 31, 1999 ......... 539,416 (3,855) (1,675,759) (1,135,550)
Issuance of 15,242 warrants to an advisor
for services in connection with the sale
of Series A redeemable preferred stock
in August (see Note 5).................. 55,790 55,790
Exercise of warrants by consultants ...... (3) 198
Issuance of Common Stock in connection
with acquisition of a license in
September (see Note 1).................. 18,599,919 18,605,000
Sale of 160.565 Units for cash in
September ($100,000 per Unit), net of
offering expenses of $1,157,572
(see Note 5)............................ --
Issuance of Preferred A warrants in
September (see Note 5).................. 960,361 960,361
Issuance of Preferred A Finders Units for
services in September (see Note 5)...... 107,825 107,825
Payment of stock subscription receivable . 3,201 3,201
Non-cash compensation in connection with
issuance of stock options to non-
employees in August and November (see
Note 9)................................. 707,550 707,550
Fair value of services provided by an
affiliate (see Note 11)................. 163,376 163,376
Net loss for the year ended December 31,
2000.................................... (23,023,842) (23,023,842)
----------- ------- ------------ ------------
Balance at December 31, 2000 ......... 21,134,234 (654) (24,699,601) (3,556,091)
Sale of 10.9887 Units with beneficial
conversion feature for cash in December
($500,000 per Unit) (see Note 5)........ 3,559,305 3,559,305
Expenses in connection with sale of
Series B stock..........................
Deemed dividend related to beneficial
conversion feature of Series B stock
(see Note 5)............................ (3,559,305) (3,559,305)
Payment of stock subscription receivable . 544 544
Exercise of warrants by a consultant ..... 15
Exercise of bridge warrants .............. 139 154
Fair value of services provided by an
affiliate (see Note 11)................. 481,299 481,299
Net loss for the year ended December 31,
2001.................................... (8,067,699) (8,067,699)
----------- ------- ------------ ------------
Balance at December 31, 2001 ......... $21,615.672 $ (110) $(32,767,300) $(11,141,778)
=========== ======= ============ ============
Securities issued in connection with services or financings were valued based
upon the estimate of fair value of the securities issued as determined by the
Company's Management.
The accompanying notes are an integral part of the financial statements.
F-5
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Statements of Cash Flows
Cumulative from
Year Ended December 31, February 23, 1998
----------------------------------------- (inception) to
1999 2000 2001 December 31, 2001
----------- ------------ ----------- -----------------
Cash flows from operating activities:
Net loss........................................................ $(1,205,559) $(23,023,842) $(8,067,699) $(32,767,300)
Adjustments to reconcile net loss to net cash used in operating
activities:
Depreciation................................................... 324 748 3,210 4,282
Amortization of deferred financing costs....................... 96,314 131,003 227,317
Amortization of original issue discount........................ 41,820 59,744 101,564
Issuance of Common Stock in connection with acquisition of a
license ...................................................... 18,600,000 18,600,000
Stock and warrants issued in consideration for services
rendered ..................................................... 93,350 707,550 800,900
Non-cash expense contributed by affiliate...................... 155,917 163,376 481,299 890,123
Changes in assets and liabilities:
(Increase) decrease in grant receivable ...................... (306,035) 111,045 194,990
(Increase) decrease in prepaid expenses, other current assets
and other assets............................................ (12,565) (51,435) 6,088 (57,912)
Increase (decrease) in accounts payable, accrued expenses and
due to affiliates........................................... 124,973 (49,796) 912,987 1,191,775
----------- ------------ ----------- ------------
Net cash used in operating activities.......................... (705,426) (3,768,687) (6,553,070) (11,204,241)
----------- ------------ ----------- ------------
Cash flows from investing activities:
Capital expenditures............................................ (1,825) (3,250) (10,627) (15,702)
Restricted cash................................................. -- (40,000) (20,000) (60,000)
----------- ------------ ----------- ------------
Net cash used in investing activities.......................... (1,825) (43,250) (30,627) (75,702)
----------- ------------ ----------- ------------
Cash flows from financing activities:
Proceeds from exercise of warrants.............................. 198 544 742
Proceeds from sale of common stock.............................. 8,201 169 9,619
Proceeds from sale of Preferred Stock........................... 16,056,500 5,494,349 21,550,849
Expenses associated with sale of Preferred Stock................ (1,157,572) (474,317) (1,631,889)
(Increase) in prepaid offering costs............................ (776,819) (776,819)
Proceeds from notes payable..................................... 1,040,000 250,000 1,515,000
Expenses associated with notes payable.......................... (128,719) (128,719)
Repayment of notes payable...................................... (1,515,000) (1,515,000)
----------- ------------ ----------- ------------
Net cash provided by financing activities...................... 911,281 13,642,327 4,243,926 19,023,783
----------- ------------ ----------- ------------
Net increase (decrease) in cash and
cash equivalents ............................................. 204,030 9,830,390 (2,339,771) 7,743,840
Cash and cash equivalents at beginning of period ................. 49,191 253,221 10,083,611 --
----------- ------------ ----------- ------------
Cash and cash equivalents at end of period ....................... $ 253,221 $ 10,083,611 $ 7,743,840 $ 7,743,840
=========== ============ =========== ============
Supplemental disclosures:
Cash paid for interest.......................................... $ 16,003 $ 215,542 $ -- $ 237,346
=========== ============ =========== ============
Supplemental disclosure of noncash investing and financing
activities:
Original issue discount on note payable .......................... $ 101,564 $ 101,564
Options and warrants issued for services
and financings.................................................. $ 98,598 $ 1,123,976 $ 1,222,574
The accompanying notes are an integral part of the financial statements.
F-6
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Notes to Financial Statements
(1) Organization, Business and Basis of Presentation
Innovative Drug Delivery Systems, Inc. (the "Company" or "IDDS") is a
development stage enterprise engaged in the research, development and
commercialization of innovative treatments for the relief of acute and chronic
moderate to severe pain. The Company is incorporated in the State of Delaware
with operations in a single segment in the United States of America.
On March 12, 2002, the Company's Board of Directors approved a 1.0161-for-
one split of the outstanding shares of common stock which will be effectuated as
a stock dividend immediately prior to the consummation of this offering. All
common share and per share data included herein have been adjusted as if the
stock dividend had occurred at inception.
As a development stage enterprise, the Company's primary efforts, to date,
have been devoted to raising capital, forming collaborations for research and
development and recruiting staff. The Company has limited capital resources and
revenues and has experienced net operating losses and negative cash flows from
operations since inception and expects these conditions to continue for the
foreseeable future. At December 31, 2001, the Company had approximately $7.7
million in cash and cash equivalents. Management believes that cash and cash
equivalents on hand at December 31, 2001 will be sufficient to fund operations
beyond one year. The Company will be required to raise additional funds to meet
long-term planned goals. The Company believes that it will be able to obtain
additional financing through public or private equity financings, or other
arrangements to fund operations. There can be no assurance that such additional
financing, if at all available, can be obtained on terms acceptable to the
Company. If the Company is unable to obtain such additional financing, future
operations will need to be scaled back or discontinued. On December 31, 2001,
the Company closed a private financing raising net proceeds of approximately
$5.0 million through the sale of 989,991 shares of Series B redeemable
convertible Preferred Stock (Series B stock) (see Note 5).
In addition, to the normal risks associated with a new business venture,
there can be no assurance that the Company's research and development will be
successfully completed or that any approved product will be commercially viable.
In addition, the Company operates in an environment of rapid change in
technology, and is dependent upon the services of its employees, collaborators
and consultants. The Company is solely dependent upon a supplier to supply a key
component in connection with the Company's clinical trials of morphine.
Pain Management, Inc. (the "Predecessor Company") was incorporated in the
State of Delaware on February 23, 1998. On August 14, 2000, the Predecessor
Company agreed to merge with IDDS. The terms of the merger provided for each
share of the Predecessor Company's common stock to convert into approximately
.892 share of IDDS common stock as adjusted for a 0.0161-for-one stock dividend
on March 12, 2002. Accordingly, the stockholders of the Predecessor Company
exchanged 5,212,500 shares of the Predecessor Company's common stock for
4,648,220 shares of IDDS common stock. Prior to the merger, IDDS had outstanding
5,080,717 shares of common stock. At the time the merger closed on September 22,
2000, the only asset held by IDDS was a licensing agreement with West
Pharmaceutical Services, Inc. (see Note 7) executed on August 25, 2000. IDDS was
incorporated on April 8, 1999, however, it remained dormant until executing the
merger and licensing agreements noted above. The Predecessor Company's Board of
Directors and management assumed similar roles in the Company after the merger
closed. For financial reporting purposes, the merger was accounted for as the
acquisition of a licensing agreement by the Predecessor Company and a
reorganization with the Company becoming the surviving entity. Consequently, the
assets, liabilities and historic operating results of the Company prior to the
merger are those of the Predecessor Company. The fair value of the licensing
agreement was determined to be approximately $18.6 million based on the fair
value of the common stock issued. The rights obtained under the licensing
agreement related to an unproven technology that would require significant
research and development effort to commercialize a product. There is also a
significant uncertainty as to whether the research and
F-7
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Notes to Financial Statements -- (Continued)
development effort will be successful. Since the licensed technology has no
alternative future use, the fair value of the consideration issued to obtain the
licensing agreement was expensed as research and development at the time the
merger closed.
(2) Summary of Significant Accounting Policies
Revenue Recognition
The Company has been awarded government grants from the Department of Defense
(the "DoD") and the National Institutes of Health (the "NIH"), which are used to
subsidize the Company's research and development projects ("Projects"). DoD and
NIH revenue is recognized as subsidized Project costs for each period are
incurred. For the years ended December 31, 2000 and 2001, all of the Company's
research grant revenue came from the DoD and the NIH.
Interest income is recognized as earned.
Research and Development Costs
The Company expenses all research and development costs as incurred for which
there is no alternative future use. Such expenses include licensing and upfront
fees paid in connection with collaborative agreements.
Concentrations of Credit Risk
Financial instruments which potentially subject the Company to concentrations
of credit risk consist of cash, cash equivalents, and receivables from the DoD
and the NIH. The Company has established guidelines that relate to credit
quality and diversification and that limit exposure to any one issue of
securities.
Fixed Assets
Furniture and fixtures, and computer equipment are stated at cost. Furniture,
fixtures, and computer equipment are depreciated on a straight-line basis over
their estimated useful lives. Expenditures for maintenance and repairs which do
not materially extend the useful lives of the assets are charged to expense as
incurred. The cost and accumulated depreciation of assets retired or sold are
removed from the respective accounts and any gain or loss is recognized in
operations. The estimated useful lives of fixed assets are as follows:
Furniture and fixtures........... 5 years
Computer equipment............... 3 years
Patents
As a result of research and development efforts conducted by the Company, it
has applied, or is applying, for a number of patents to protect proprietary
inventions. All costs associated with patents are expensed as incurred.
Cash and Cash Equivalents
The Company considers all highly liquid investments which have maturities of
three months or less, when acquired, to be cash equivalents. The carrying amount
reported in the balance sheet for cash and cash equivalents approximates its
fair value. Cash and cash equivalents subject the Company to concentrations of
F-8
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Notes to Financial Statements -- (Continued)
credit risk. At December 31, 2001 and 2000, the Company had invested
approximately $7.7 million and $10.1 million, respectively, in funds with a
single commercial bank.
Net Loss Per Share
The Company prepares its per share data in accordance with Statement of
Financial Accounting Standards No. 128, "Earnings Per Share" ("SFAS No. 128").
Basic net loss per share is computed on the basis of net loss for the period
divided by the weighted average number of shares of common stock outstanding
during the period. Since the Company has incurred net losses since inception,
diluted net loss per share does not include the number of shares issuable upon
exercise of outstanding options and warrants and the conversion of preferred
stock since such inclusion would be anti-dilutive. Disclosures required by SFAS
No. 128 have been included in Note 8.
Pro Forma Financial Information (unaudited)
As discussed further in Note 5, all outstanding shares of Series A redeemable
convertible preferred stock ("Series A stock") and Series B stock will
automatically convert into 5,084,900 shares of common stock upon the closing of
an initial public offering of the Company's common stock as defined. The pro
forma balance sheet at December 31, 2001, assumes that the historical balance
sheet is adjusted to reflect the conversion of Series A stock and Series B stock
into common stock as if it had occurred on December 31, 2001. The pro forma net
loss per share data presented within the Statement of Operations for the year
ended December 31, 2001 assumes that the historical per share data computed in
accordance with SFAS No. 128 is adjusted to reflect the conversion of all
outstanding shares of Series A stock and Series B stock, on a weighted average
basis, as if such conversion had occurred on the dates of issuance (September
22, 2000 and December 31, 2001, respectively). Pro forma net loss per share data
for the years ended December 31, 1999 and 2000 have been intentionally omitted.
Deferred Financing Costs
Costs incurred in connection with issuance of notes payable are deferred and
amortized using the interest method, which approximates the straight-line
method, as interest expense over the term of the debt instrument.
Income Taxes
The Company accounts for income taxes in accordance with the provisions of
Statement of Financial Accounting Standards No. 109, "Accounting for Income
Taxes" ("SFAS No. 109"). SFAS No. 109 requires that the Company recognize
deferred tax liabilities and assets for the expected future tax consequences of
events that have been included in the financial statements or tax returns. Under
this method, deferred tax liabilities and assets are determined on the basis of
the difference between the tax basis of assets and liabilities and their
respective financial reporting amounts ("temporary differences") at enacted tax
rates in effect for the years in which the temporary differences are expected to
reverse.
Comprehensive Loss
Statement of Financial Accounting Standards No. 130, "Reporting Comprehensive
Income", established standards for reporting and display of comprehensive loss
and its components in the financial statements. Implementation of this statement
has not had an impact on the Company's financial statements as the Company has
no other comprehensive items to report other than net loss.
F-9
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Notes to Financial Statements -- (Continued)
Impairment of Long-Lived Assets
In accordance with the provisions of Statement of Financial Accounting
Standards No. 121, "Accounting for Impairment of Long-Lived Assets and Long
Lived Assets to be Disposed Of" ("SFAS 121") long-lived assets are reviewed for
impairment whenever events or changes in circumstances indicate that the
carrying amount may not be recoverable. If the sum of the expected future
undiscounted cash flows is less that the carrying amount of the asset, a loss is
recognized for the difference between the fair value and carrying value of the
asset. For all periods presented there have been no impairment losses incurred.
Equity Issuance Costs
Costs associated with the issuance of the Company's common or preferred stock
are initially recorded as prepaid offering costs. Upon issuance of the
securities, those costs are reclassified as a reduction of the offering
proceeds. In the event that the offering is not completed, those costs would be
expensed in the period the offering is determined to be unsuccessful.
Risks and Uncertainties
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect the amounts reported in the financial statements and accompanying notes.
Significant estimates relate to the valuation of equity instruments issued for
services rendered, recoverability of fixed assets and deferred taxes. Actual
results could differ from those estimates.
Stock-Based Compensation
The Company accounts for stock-based compensation to employees in accordance
with APB Opinion No. 25, "Accounting for Stock Issued to Employees" ("APB No.
25"). Under APB No. 25, generally, no compensation expense is recognized in the
financial statements in connection with the awarding of stock option grants to
employees provided that, as of the grant date, all terms associated with the
award are fixed and the fair value of the Company's stock, as of the grant date,
is equal to or less than the amount an employee must pay to acquire the stock.
The Company will recognize compensation expense in situations where the terms of
an option grant are not fixed or where the fair value of the Company's common
stock on the grant date is greater than the amount an employee must pay to
acquire the stock.
Disclosures required by Statement of Financial Accounting Standards No. 123,
"Accounting for Stock-Based Compensation" ("SFAS No. 123"), including pro forma
operating results had the Company prepared its financial statements in
accordance with the fair-value-based method of accounting for stock-based
compensation, have been included in Note 9.
The fair value of options and warrants granted to non-employees for
financing, goods or services are included in the financial statements and
expensed over the life of the debt, as the goods are utilized or the services
performed, respectively. The fair value of options and warrants issued to non-
employees has been calculated using the Black-Scholes option pricing model,
based on the following assumptions: risk free interest rate of 6%; expected life
of 5 to 7 years; zero dividend yield; and volatility of 75%.
Impact of Future Adoption of Recently Issued Accounting Standards
The Financial Accounting Standards Board has recently issued Statement of
Financial Accounting Standards No. 141 (FAS 141), "Business Combinations" and
Statement of Financial Accounting Standards No. 142 (FAS 142), "Goodwill and
Other Intangible Assets". FAS 141 requires that all business combinations be
accounted for under the purchase method and that certain acquired intangible
assets in a
F-10
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Notes to Financial Statements -- (Continued)
business combination be recognized as assets apart from goodwill. FAS 142
requires that ratable amortization of goodwill and certain intangible assets be
replaced with periodic tests of the goodwill's impairment and that other
intangible assets be amortized over their useful lives. FAS 141 is effective for
all business combinations initiated after June 30, 2001. The provisions of FAS
142 will be effective for fiscal years beginning after December 15, 2001 and
will thus be adopted by the Company in fiscal year 2002.
In July 2001, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 143 (FAS 143), "Accounting for Obligations
Associated with the Retirement of Long-Lived Assets." The objective of FAS 143
is to provide accounting guidance for legal obligations associated with the
retirement of tangible long-lived assets. The retirement obligations included
within the scope of this project are those that an entity cannot avoid as a
result of either the acquisition, construction or normal operation of a long-
lived asset. Components of larger systems also fall under this project, as well
as tangible long-lived assets with indeterminable lives. FAS 143 is required to
be adopted on January 1, 2003.
The Financial Accounting Standards Board issued FASB Statement No. 144,
Accounting for the Impairment or Disposal of Long-Lived Assets. The objectives
of FAS 144 are to address significant issues relating to the implementation of
FASB Statement No. 121 (FAS 121), Accounting for the Impairment of Long-Lived
Assets and for Long-Lived Assets to Be Disposed Of, and to develop a single
accounting model, based on the framework established in FAS 121, for long-lived
assets to be disposed of by sale, whether previously held and used or newly
acquired. The provisions of FAS 144 are effective for financial statements
issued for fiscal years beginning after December 15, 2001.
Management believes that the future adoption of these accounting standards
will not have a material impact on the Company's financial statements.
(3) Fixed Assets
Fixed assets consist of the following:
December 31,
-----------------
2000 2001
------- -------
Office equipment and computers............................. $ 5,075 $15,702
Less, Accumulated depreciation............................. (1,072) (4,282)
------- -------
$ 4,003 $11,420
======= =======
(4) Accounts Payable and Accrued Expenses
Accounts payable and accrued expenses consist of the following:
December 31,
---------------------
2000 2001
-------- ----------
Accounts payable....................................... $100,706 $ 361,471
Accrued professional fees.............................. 47,794 573,935
Accrued research and development....................... 59,910 196,174
Accrued expenses....................................... 47,804 21,745
-------- ----------
$256,214 $1,153,325
======== ==========
The Company has agreements to spend approximately $4.7 million for future
clinical and development programs. However, such agreements may be cancelled
upon written notice to the other party.
F-11
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Notes to Financial Statements -- (Continued)
(5) Stockholders' (Deficit) Equity
The Company's Certificate of Incorporation, as amended, authorizes the
Company to issue 21.5 million shares of common stock (the "Common Stock"),
$0.001 par value, and 6.5 million shares of preferred stock (the "Preferred
Stock"), $0.001 par value. The Company's Board of Directors (the "Board") has
the authority to issue preferred stock, in series, with rights and privileges
determined by the Board. The Board designated 4.5 million shares of preferred
stock as Series A stock and approximately 1.4 million shares of Preferred Stock
as Series B stock. In September 2000 and December 2001, investors purchased
4,014,125 shares of Series A stock and 989,991 shares of Series B stock,
respectively.
Dividends may be declared and paid on Common Stock and Preferred Stock as
determined by the Board, provided that (i) concurrently with the declaration of
dividends on Common Stock, the Company declares and pays a dividend to the
holders of Preferred Stock equal to that which would be payable to them if their
Preferred Stock had been converted into Common Stock on the date of
determination of holders of Common Stock to receive such dividend and (ii)
dividends declared on Series A stock are subject to prior rights of holders of
any superior class of stock.
In the event of liquidation, dissolution or winding up of the Company,
holders of Series A stock will be entitled to be paid the greater of (i) $4.00
per share subject to adjustment for stock dividends, stock splits, mergers or
other recapitalization, as defined, plus all dividends accrued or declared but
unpaid, out of the assets of the Company (the "Liquidation Amount") or (ii) the
Shared Allocation Amount. The Shared Allocation Amount is that portion of the
Company's assets available for distribution to stockholders allocated based on
percentage of outstanding shares held by that class of stockholders. The order
of preference of payments will be to holders of Series A Stock and then Common
Stock.
Each share of Series A stock is convertible into the number of shares of
Common Stock determined by dividing the Series A Conversion Price into $4.00.
The Series A Conversion Price of the Series A stock is initially $3.94 per share
adjusted for certain dilutive events, as defined. Accrued but unpaid dividends
are forfeited upon conversion of Series A stock. As of December 31, 2000 and
2001, the Series A Conversion Price was $3.94 and the outstanding Series A stock
is convertible into 4,078,927 shares of Common Stock.
Shares of Series A stock will automatically convert into shares of Common
Stock based upon the Series A Conversion Price in effect at the time upon (i)
the closing of an initial public offering of the Company's Common Stock, within
defined terms or (ii) written election of the holders of a majority of Series A
stock.
In the event of consolidation, merger or other reorganization of the Company
in which the Company is not the surviving entity, the holders of Series A stock
will be entitled to be paid, out of the assets of the Company available for
distribution before any payment to holders of junior stock of the Company, the
greater of (i) the Liquidation Amount or (ii) the Shared Allocation Amount, as
defined. Such payment will be made by redemption of such shares by the Company
or by the surviving company. Accordingly, the Series A stock is presented as
redeemable preferred stock.
Holders of Series A stock have the number of votes equal to the number of
shares of Common Stock into which the shares of Series A stock convert into at
the date on which the vote is held. Holders of Common Stock have one vote per
share.
At the option of the Company, shares of Series A stock may be redeemed at a
redemption price per share of $4.00 plus dividends accrued or declared but
unpaid (the "Redemption Price") up to and including the redemption date. The
Redemption Price is subject to adjustment for stock dividends, stock splits,
mergers or recapitalizations, as defined.
In September 2000, the Company sold 160.565 units ("Units" or "Series A
Financing") to investors at a per Unit price of $100,000. Each Unit consisted of
25,000 shares of Series A stock (convertible into 25,404
F-12
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Notes to Financial Statements -- (Continued)
shares of common stock) and 2,540 warrants (the "A Preferred Warrants"). Each A
Preferred Warrant entitles the holder to purchase one share of Common Stock at
an exercise price of $3.94 per share. The A Preferred Warrants contain certain
antidilution provisions, as defined. The A Preferred Warrants expire in October
2005. The fair value of the A Preferred Warrants at issuance was $960,361. At
December 31, 2001, none of the A Preferred Warrants had been exercised (see Note
10).
As partial consideration for the sale of the Units, an option to purchase
15.83 units (the "Finders Units") was issued to members of the firm responsible
for obtaining the financing. Each Finders Unit entitles the holder to purchase
25,000 shares of Series A stock (convertible into 25,404 shares of common stock)
and 2,540 A Preferred warrants (the "Finders Warrants") for $110,000 per Finders
Unit. The fair value of the Series A stock, which was accounted for as a cost of
the Series A Financing, totaled $1,071,331. Each Finders Warrant entitles the
holder to purchase one share of Common Stock at a per share price of $3.94. The
Finders Warrants expire in September 2007. The fair value of the Finders
Warrants at the date of issue was $107,825.
During 1999, a consultant (the "Consultant") was issued 189,496 shares of
Common Stock for services rendered and a subscription receivable of $106. The
fair value of the Consultant shares was $93,244.
In 2000, another consultant, acting as an advisor to the Series A Financing,
received 15,242 warrants to purchase shares of Common Stock at an exercise price
of approximately $0.001 per share. The warrants expire in August, 2007. The fair
value of the warrants, which has been accounted for as a cost of the Series A
Financing, at the issuance date was $55,790. All of the warrants were exercised
in 2001.
In December, 2001, the Company's Board of Directors designated 1,351,350
shares of preferred stock, $0.001 par value, as Series B Convertible Preferred
Stock ("Series B stock"). The Company then closed a $5.5 million private
financing consisting of the sale of 10.9887 units of Series B stock (the "Series
B Unit") at $500,000 per Series B Unit. Each Series B Unit consists of 90,090
shares of Series B stock with a stated value of $5.55 per share, subject to
adjustment for stock dividends, stock splits, mergers and recapitalizations, as
defined. The preferences and rights of Series B stock are the same as those of
Series A stock regarding conversion, redemption, voting and liquidation of the
Company, except that the stated value and the conversion price used in
calculating those preferences is $5.55 and $5.46 for Series B stock,
respectively, rather than $4.00 and $3.94 for Series A stock respectively. As of
December 31, 2001, the Series B stock converts into 1,005,973 shares of common
stock. Series B stock is considered to be mandatorily redeemable preferred stock
since it is redeemable upon events of consolidation, merger or other
reorganization of the Company.
The Series B conversion price represented a discount from the estimated fair
value of the Common Stock at the time of issuance. Accordingly, the discount
amount is considered incremental yield ("the beneficial conversion feature") to
the preferred stockholders and has been accounted for as a deemed dividend to
preferred stockholders. Based on the conversion terms of the Series B stock, a
deemed dividend of approximately $3.6 million has been added to the net loss in
the calculation of net loss applicable to common stockholders in the year ended
December 31, 2001.
(6) Notes Payable
(a) During 1998, the Company issued two notes payable to two banks with
principal amounts of $145,000 and $80,000, respectively (the "Notes"). The Notes
were due in September 2000 and bear interest of 1% over the Eurodollar rate and
the bank's prime rate, respectively. The Notes were guaranteed by one of the
Company's investors. At December 31, 1999, the outstanding balances on the Notes
were $145,000 and $80,000, respectively, accrued interest totaled $1,400 and the
weighted average interest rate was 7.5%. During 2000, the $145,000 Note was
increased to $245,000. Both Notes were repaid in October 2000, following the
issuance of Series A stock (see Note 5).
F-13
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Notes to Financial Statements -- (Continued)
(b) During 1999, the Company raised $1.04 million by issuing notes payable
(the "Bridge Notes") and warrants (the "Bridge Warrants"). The Bridge Notes
accrued interest at 12% per annum for the first twelve months and 15% per annum
for up to an additional year. At December 31, 1999, accrued interest on the
Bridge Notes was approximately $86,000. At December 31, 1999, the fair value of
the Bridge Notes approximated their face value. In November, 2000, after
issuance of Series A stock, the principal plus accrued interest totaling
approximately $1,238,000 was repaid.
In connection with the Bridge Notes, 231,859 Bridge Warrants to purchase an
equal number of shares of Common Stock, with an exercise price of approximately
$0.01, were issued to the Bridge Noteholders. The Bridge warrants contain
anti-dilution provisions and expire in September, 2005. The fair value of the
Bridge Warrants at the date of issue was $101,564. Accordingly, the Bridge Notes
were recorded at an original issue discount of $101,564, which was amortized to
interest expense over the term of the Bridge Notes. At December 31, 1999, the
Bridge Notes were recorded at $980,256. During the year ended December 31, 2001,
Bridge Warrants to purchase 15,606 shares of common stock were exercised (see
Note 10).
Professional fees incurred in connection with the Bridge Notes, amounting to
$128,719, were accounted for as deferred financing costs.
In 1999, three consultants, who had arranged the sale of Bridge Notes
received a total of 200,642 warrants, exercise price of approximately $0.001, to
purchase shares of Common Stock. The warrants expire in August 2007. The fair
value of the warrants, which were accounted for as deferred financing costs, at
the issuance date was $98,598. All of the warrants were exercised in 2000.
(c) In July 2000, the Company entered into a note (the "Second Note") with a
commercial bank with principal amount of $150,000 and bearing interest, payable
monthly, based on the Eurodollar rate plus 1% due in July, 2001. The Second Note
was guaranteed by one of the Company's investors. In October 2000, following the
closing of the sale of Series A stock, the Second Note was repaid.
Notes payable transactions are summarized as follows:
Notes Bridge Note Second Note Total
--------- ----------- ----------- -----------
Issuance of Notes............................................. $ 145,000 $ 145,000
Issuance of Notes............................................. 80,000 80,000
--------- -----------
Balance at December 31, 1998.................................. 225,000 225,000
Issuance of Bridge Notes...................................... $ 1,040,000 1,040,000
Discount on Bridge Notes...................................... (101,564) (101,564)
Amortization of Discount...................................... 41,820 41,820
--------- ----------- -----------
Balance at December 31, 1999.................................. 225,000 980,256 1,205,256
Issuance of Notes............................................. 100,000 100,000
Issuance of Second Note....................................... $ 150,000 150,000
Amortization of Discount...................................... 59,744 59,744
Repayment..................................................... (325,000) (1,040,000) (150,000) (1,515,000)
--------- ----------- --------- -----------
Balance at December 31, 2000 and 2001......................... -- -- -- --
========= =========== ========= ===========
(7) Commitments and Contingencies
Research Collaboration, Licensing and Consulting Agreements
(a) As part of the formation of the Company, the Company entered into a
license agreement with Stuart Weg, M.D. The license granted the Company
exclusive worldwide rights, including the right to grant
F-14
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Notes to Financial Statements -- (Continued)
sublicenses, for the intellectual property surrounding transnasal ketamine. In
connection therewith, the Company made an upfront payment to Dr. Weg, Herbert
Brotspies, and Calgar & Associates (collectively the "Founders") and issued the
Founders shares of Common Stock, of which a portion is held in escrow and will
be released to the Founders, if at all, upon the successful completion of the
Phase III trial. The issuance of the shares from escrow is not contingent on the
Founders' performance. The Company also reimbursed the Founders for patent and
other costs. The Company will pay semi-annual royalty payments to the Founders
based on a percentage of net sales of transnasal ketamine by the Company or its
sublicensees. In addition, the Company shall pay the Founders a defined
percentage of all sublicensing fees or other lump sum payments. The Company is
also obligated to make aggregate future payments of approximately $1.3 million
upon the earlier of certain defined dates ranging from August 2003 to November
2004 or satisfaction of certain clinical and regulatory milestones, which
includes the filing of a New Drug Application ("NDA") with the Food & Drug
Administration ("FDA"), the approval of an NDA by the FDA and the first
commmercial sale of a licensed product. A defined percentage of such milestone
payments shall be creditable against royalties earned; provided, however, that
in no event shall royalties earned be reduced by more than a certain percentage
in any applicable semi-annual period. The Company may satisfy a portion of the
milestone payments through the issuance of shares of Common Stock of the
Company; provided that the Company is publicly traded at the time such milestone
payment accrues.
In connection with the above license agreement, in February 1998 the Company
entered into a three year Consulting Agreement, renewable upon mutual consent,
with each of Dr. Weg and Herbert Gary. Pursuant to such Consulting Agreements,
both Dr. Weg and Mr. Gary will provide the Company with such consulting services
as the Company may reasonably request. In consideration for such services the
Company has agreed to pay to each of Dr. Weg and Mr. Gary a consulting fee equal
to $75,000 per year, payable in equal monthly installments. These agreements
expired March 2001 and were not renewed.
(b) On August 25, 2000, the Company entered into a license agreement with
West Pharmaceutical Services, Inc. ("West") for rights to develop and
commercialize intranasal morphine, fentanyl and other products. Under the terms
of the agreement, the Company was granted an exclusive, worldwide, royalty
bearing license, including the right to grant sublicenses, for the rights to the
intellectual property covering these products. The license agreement will expire
with the last to expire of the license patents in 2016. In consideration of the
license, the Company paid and expensed on September 22, 2000 an up front fee. In
addition, under the license agreement for morphine, fentanyl and other products
the Company is obligated to make royalty payments to West based upon net sales
of products by the Company or its sublicensees, if any, as defined. The Company
is also obligated to pay West a minimum annual royalty for each licensed product
that receives approval by a regulatory agency to be marketed in any major market
country, as defined. The Company is also obligated to pay West a defined amount
of any up-front license fees in the event that the Company sublicenses any
rights to any third party. In addition, under a Development Milestone and Option
Agreement entered into by the Company and West in connection with the license
agreement, the Company is obligated to make aggregate future payments totaling
$5.0 million upon reaching certain defined development milestones, which
includes the filing of an NDA with the FDA, the approval of an NDA by the FDA of
a licensed product. Milestone payments can be paid in cash or equity upon the
satisfaction of certain clinical and regulatory milestones and provided that the
Company is publicly traded at the time such milestone payment accrues. The
Company's ability to pay the upfront payment for the license agreement and the
M-6-G fee (see below) was guaranteed by an affiliate of the Company. The
guarantee expired upon the payments by the Company of amounts owed to West. In
addition, the Company granted West the right of first refusal to enter into a
clinical manufacturing agreement for nasal morphine (see c. (i), below).
The license agreement and related agreements (see c. (i) to c. (iv) below)
may be terminated by mutual consent of the parties at any time or by either
party upon written notice of default, including non-performance, by the other
party that is not cured within 30 days.
F-15
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Notes to Financial Statements -- (Continued)
(c) In connection with the West license agreement, the Company entered into
the following additional agreements:
(i) A clinical manufacturing agreement, whereby the Company will buy from
West 100% of the nasal morphine product required for conducting the clinical
trials subject to West's ability to supply 100% of the required product. West
will manufacture and package the clinical product for the Company. This
agreement will be in effect until the earlier of (a) a period of 2 years or
(b) the last to occur launch date after the clinical product has been
launched in all major market countries.
(ii) An option agreement, whereby the Company was granted an option to
include morphine -6- glucuronide ("M-6-G") as an identified compound under
the license agreement. The Company paid and expensed a non-refundable fee in
consideration of the option, which expired unexercised on December 22, 2000.
(iii) On October 24, 2000, the Company expanded its license agreement to
include an additional development agreement with West for rights to develop
and commercialize intranasal fentanyl. The Company will undertake a
development program for intranasal fentanyl with West. The parties will
endeavor to complete the development program within the defined time table.
However, the Company can use other suppliers should West be unable to either
provide competitive cost bids or complete the program within a reasonable
timeframe. In addition, under the development agreement, the Company is
obligated to make aggregate future payments totaling $6.3 million upon
reaching certain defined development milestones, which includes completion of
proof-of-principle studies, successful completion of a phase I/II clinical
trial, commencement of a phase III clinical trial, filing of an NDA with the
FDA and the approval of an NDA by the FDA of a licensed product. These
milestone payments can be paid in cash or equity upon the satisfaction of
certain clinical and regulatory milestones and provided that the Company is
publicly traded at the time such milestone payment accrues.
(iv) On November 17, 2000, the Company entered into a clinical
manufacturing agreement with West to manufacture, package, purchase and sell
to the Company nasal ketamine clinical product according to agreed upon
clinical product specifications and price schedule. The agreement terminated
in November 2001.
(d) On December 14, 2001 (the "Effective Date"), the Company entered into an
agreement (the "Shimoda Agreement") with Shimoda Biotech (Proprietary) Ltd. and
certain affiliated entities ("Shimoda"), for an exclusive worldwide license to
commercialize formulations of pharmaceutical products containing diclofenac. The
Company will pay: (i) a license fee to Shimoda and reimbursement for expenses,
if certain defined events occur; (ii) two percent of the net proceeds, as
defined, of the Company's initial public offering to Shimoda, but not less than
$1 million or in excess of $2 million; (iii) aggregate future milestone payments
of $6.0 million payable upon the satisfaction of certain clinical and regulatory
milestones which includes submission of an NDA with the FDA, approval of an NDA
by the FDA and one year following the date of first sale of a licensed product;
and (iv) royalty payments to Shimoda based upon the sales of products by the
Company or its sublicensees, if any, as defined. Upon achievement of a
milestone, Shimoda has the option to receive payment in cash or shares of common
stock. In the event Shimoda elects to receive common stock, the number of shares
to be issued is based on a formula whereby the defined milestone payment is
divided by the per share price of the Company's common stock in an initial
public offering as defined. Should common stock be issued in satisfaction of
milestones, the Company will record a non-cash charge based on the fair value of
the consideration paid at the date the milestone is achieved. Such charge could
be material and could result in a material dilution to per share amounts. The
Shimoda Agreement may be terminated (i) by either party due to breach by the
other party that is not cured within 60 days of written notice; (ii) by Shimoda
in the event of default by the Company for non-payment of amounts due that is
not cured with 60 days of written notice; (iii) by the Company, if certain
defined initial activities are not
F-16
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Notes to Financial Statements -- (Continued)
completed by Shimoda within 90 days of the Effective Date, in which case all
payments to Shimoda other than the initial payment will be refunded to the
Company or (iv) by the Company at any time by giving 90 days written notice to
Shimoda.
(8) Net Loss per Share
The Company's basic net loss per share amounts have been computed by dividing
net loss by the weighted-average number of common shares outstanding during the
period. For all periods presented, the Company reported a net loss and,
therefore, common stock equivalents were not included since such inclusion would
have been anti-dilutive. In addition, for all periods presented, 222,937 shares
of Common Stock were held in escrow and have been excluded from the calculation
of basic and diluted earnings per share.
The calculation of net loss per share, basic and diluted, is as follows:
Weighted
Average
Common
Net Loss Shares Per Share
(Numerator) (Denominator) Amount
------------ ------------- ---------
The year ended December 31, 2001
Basic and diluted................................................................. $(11,627,004) 9,725,376 $(1.20)
============ ======
Adjustment to reflect weighted average effect of conversion of Series A and
Series B redeemable convertible preferred stock as if such conversion
occurred on the dates of issuance (September 22, 2000 and December 31, 2001,
respectively) (unaudited)......................................................... 4,081,682
----------
Pro forma basic and diluted (unaudited)............................................ $(11,627,004) 13,807,058 $(0.84)
============ ========== ======
The year ended December 31, 2000
Basic and diluted................................................................. $(23,023,842) 5,859,105 $(3.93)
============ ========== ======
The year ended December 31, 1999
Basic and diluted................................................................. $ (1,205,559) 4,309,510 $(0.28)
============ ========== ======
For all periods presented common stock equivalents which have been excluded
from diluted per share amounts because their effect would have been anti-
dilutive, include the following:
For the Years Ended December 31,
-------------------------------------------------------------------
1999 2000 2001
------------------- -------------------- --------------------
Weighted Weighted Weighted
Weighted Average Weighted Average Weighted Average
Average Exercise Average Exercise Average Exercise
Number Price Number Price Number Price
-------- -------- --------- -------- --------- --------
Options .................................................... -- 127,744 $3.93 1,365,152 $3.94
Warrants ................................................... 209,966 $0.006 616,040 $1.56 1,078,656 $3.25
Convertible Preferred Stock ................................ -- 1,117,514 4,081,682
------- --------- ---------
Total ................................................... 209,966 1,861,298 6,525,490
======= ========= =========
(9) Stock Incentive Plan
In February 2001, the Board and stockholders approved the adoption of the
2000 Omnibus Stock Incentive Plan (the "Plan"). Under the Plan, subject to Board
and stockholder approval of certain amendments, the Plan will provide for the
issuance of 3,556,502 shares of Common Stock to be awarded to
F-17
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Notes to Financial Statements -- (Continued)
employees, consultants, directors and other individuals who render services to
the Company (collectively, "Awardees"). The number of shares of common stock
reserved for issuance under the Plan will automatically increase on the first
trading day in January of each calendar year, beginning in calendar year 2003,
by an amount equal to 5% of the total number of shares of Common Stock
outstanding on the last trading day in December of the preceding calendar year,
but in no event will any annual increase exceed a defined number of shares.
Awards include options, restricted shares, bonus shares, stock appreciation
rights and performance shares (the "Awards"). The Plan contains certain
anti-dilution provisions in the event of a stock split, stock dividend or other
capital adjustment, as defined. The Plan includes an automatic option grant
program for non-employee directors, under which option grants will automatically
be made at periodic intervals to non-employee board members to purchase shares
of common stock as defined. The Plan provides for a Committee of the Board of
Directors (the "Committee") to grant Awards to Awardees and to determine the
exercise price, vesting term, expiration date and all other terms and conditions
of the Awards, including acceleration of the vesting of an Award at any time.
All options granted under the Plan are intended to be non-qualified ("NQO")
unless specified by the Committee to be incentive stock options ("ISO"), as
defined by the Internal Revenue Code. NQO's may be granted to employees,
consultants or other individuals at an exercise price, equal to, below or above
the fair value of the Common Stock on the date of grant. ISO's may only be
granted to employees of the Company and may not be granted at exercise prices
below fair value of the Common Stock on the date of grant (110% of fair value
for employees who own 10% or more of the Company). The period during which an
option may be exercised may not exceed ten years from the date of grant (five
years for grants of ISO's to employees who own 10% or more of the Company).
Under the Plan, for a period of one year following the termination of an
Awardee's employment or active involvement with the Company, the Company has the
right, should certain contingent events occur, to repurchase any or all shares
of Common Stock acquired upon exercise of an Award held by the Awardee at a
purchase price defined by the Plan. The Plan will terminate at the earliest of
(i) its termination by the Committee, (ii) February 4, 2011 or (iii) the date on
which all of the shares of Common Stock available for issuance under the Plan
have been issued and all restrictions on such shares have lapsed. Awards granted
before termination of the Plan will continue under the Plan until exercised,
cancelled or expired.
As of December 31, 2001, no options have been granted under the Plan;
however, options to purchase 1,367,101 shares of the Company's common stock have
been granted outside of the Plan.
The following table summarizes non-plan stock option information for the
options as of December 31, 2001:
Options Outstanding Options Exercisable
-------------------------------------------------- ------------------------------
Weighted-Average Weighted-Average Weighted-Average
Range of Number Remaining Exercise Number Exercise
Exercise Prices Outstanding Contractual Life Price Exercisable Price
----------------- ----------- ---------------- ---------------- ----------- ----------------
$ 0.01 1,219 8.7 yrs. $0.01 1,219 $0.01
$ 3.94 1,365,882 8.9 yrs. $3.94 976,360 $3.94
--------- -------
$ 0.01- $3.94 1,367,101 8.9 yrs. $3.93 977,579 $3.93
F-18
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Notes to Financial Statements -- (Continued)
Transactions involving options during the years ended December 31, 2000 and
2001 are summarized as follows:
Number of Weighted-Average Number Weighted-Average
Shares Exercise Price Exercisable Exercise Price
--------- ---------------- ----------- ----------------
2000: Granted .............................. 1,011,451 $3.93
---------
Balance outstanding, December 31, 2000 ..... 1,011,451 $3.93 427,168 $3.93
2001: Granted (1) .......................... 355,650 $3.94
---------
Balance outstanding, December 31, 2001 ..... 1,367,101 $3.93 977,579 $3.93
=========
(1) In addition to the above, the Committee has or has agreed to grant: 850,000
options to three employees and 75,000 options to a related party consultant
with an exercise price equal to that of the Company's common stock at an
initial public offering. The Committee also agreed to grant 406,456 options
to the Company's directors. The Committee originally intended that the
measurement date of these options would be the date of the Company's initial
public offering and that the options' exercise price would be equal to the
initial public offering price. On February 25, 2002 the Committee granted
such options fixing the exercise price at $5.46 per share. The exercise
price is below the estimated fair value of the Company's common stock on the
date of grant and accordingly the Company will incur a non-cash expense.
The aggregate intrinsic value of the option grants to the directors at the
measurement date total approximately $1.4 million. Such amount will be
expensed over the vesting period with approximately $1.0 million recognized
during 2002 and the balance pro rata through February 2004.
Included in the options above, during the year ended December 31, 2000, the
Company granted 300,150 fully vested stock options to non-employees ("Non-
employee Options") with an average exercise price of $3.94, which are accounted
for in accordance with EITF 96-18. The estimated fair value of the Non-employee
Options on the grant date totaling $707,550 was recognized as compensation
expense in the year ended December 31, 2000.
The following table summarizes the pro forma operating results of the Company
had compensation costs for non-plan options been determined in accordance with
the fair value based method of accounting for stock based compensation as
prescribed by SFAS No. 123. Since option grants awarded during 2000 and 2001
vest over several years and additional awards are expected to be issued in the
future, the pro forma results shown below are not likely to be representative of
the effects on future years of the application of the fair value based method.
Since no stock options were granted prior to September 1, 2000, the pro forma
net loss and net loss per share for the year ended December 31, 1999 is equal to
the amount as presented in the Statement of Operations.
Year Ended December 31,
---------------------------
2000 2001
------------ ------------
Pro Forma Net Loss .............................. $(23,379,852) $(12,921,587)
============ ============
Pro Forma Net Loss per Share (Basic and Diluted) $ (3.99) $ (1.33)
============ ============
For the purpose of the above pro forma calculation, the fair value of each
option granted was estimated on the date of grant using the Black-Scholes option
pricing method. The weighted-average fair value of the options granted during
2000 and 2001 was $2.39. The following assumptions were used in computing the
fair value of option grants: expected volatility of 75%, expected life of 5
years; zero dividend yield and risk-free interest rate of 6.0%.
F-19
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Notes to Financial Statements -- (Continued)
The Company intends to adopt an employee stock purchase plan ("ESPP"), which
will become effective upon the completion of an initial public offering of the
Company's common stock. Under the ESPP, eligible employees may set aside up to
15% of their eligible compensation to be applied to the purchase of shares of
the Company's common stock. The per share price the employee must pay to acquire
each share of common stock will be equal to 85% of the lower of the quoted
market price of the Company's Common Stock at the start date of the offering
period or the semi-annual purchase date. The ESPP will be implemented in a
series of overlapping periods, each with a duration of 24 months. The initial
offering period will begin at the time of the initial public offering.
Subsequent offering periods will begin at 6-month intervals and each such
offering period will have 4 semi-annual purchase dates. The ESPP has been
designed to qualify as a non-compensatory plan under Section 423 of the Internal
Revenue Code. Upon completion of an initial public offering, the Company will
finalize various terms and conditions including the number of shares of common
stock available under the ESPP.
(10) Warrants and Units
The following table summarizes warrant and unit activity for the period from
February 23, 1998 (inception) to December 31, 2001:
Bridge Preferred A Consultants Finders
Warrants Warrants Warrants Units
-------- ----------- ----------- -------
Issuance of Bridge Warrants (see Note 6).......................... 231,859
Issuance of Consultants Warrants (see Note 6)..................... 200,642
------- ------- -------- -----
Balance outstanding, December 31, 1999............................ 231,859 -- 200,642 --
Issuance of Preferred A Warrants (see Note 5)..................... 407,893
Exercise of Consultants Warrants.................................. (200,642)
Issuance of Finders Units (see Note 5)............................ 15.83 (1)
Issuance of Consultants Warrants (see Note 5)..................... 15,242
------- ------- -------- -----
Balance outstanding, December 31, 2000............................ 231,859 407,893 15,242 15.83
Exercise of Bridge Warrant........................................ (15,606)
Exercise of Consultants Warrants.................................. (15,242)
------- ------- -------- -----
Balance outstanding, December 31, 2001............................ 216,253 407,893 -- 15.83
======= ======= ======== =====
- ---------------
(1) Each Finders Unit entitles the holder to purchase 25,000 shares of Series A
stock and 2,540 Preferred A Warrants. Total issuance entitles holders to
purchase 395,788 shares of Series A stock (convertible into 402,177 shares
of common stock) and 40,218 A Preferred Warrants.
(11) Related Party Transactions
The Company, since its inception, has received financial assistance from a
principal stockholder in the form of office space and management and legal
assistance provided at no cost. In accordance with the Securities and Exchange
Commission Staff Accounting Bulletin No. 79, the estimated fair value of such
assistance has been reflected in the accompanying financial statements as an
expense in the period benefited with a corresponding deemed capital
contribution. The estimated fair value of the financial assistance totaled
$155,917, $163,376 and $481,299 for the years ended December 31, 1999, 2000 and
2001, respectively, and $890,123 for the cumulative period from February 23,
1998 (inception) to December 31, 2001.
F-20
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
(A Development Stage Enterprise)
Notes to Financial Statements -- (Continued)
(12) Income Taxes
There is no provision (benefit) for federal or state income taxes for the
years ended December 31, 1999, 2000 and 2001 since the Company has incurred
operating losses and has established valuation allowances equal to the total
deferred tax asset due to the uncertainty with respect to achieving taxable
income in the future.
The tax effect of temporary differences and net operating losses as of
December 31, 2000 and 2001 are as follows:
December 31,
-------------------------
2000 2001
----------- -----------
Deferred tax assets and valuation allowance:
Net operating loss carry-forwards ..................................................... $ 2,229,328 $ 5,624,080
Deferred charges ...................................................................... 482 362
Valuation allowance ................................................................... (2,229,810) (5,624,442)
----------- -----------
$ -- $ --
=========== ===========
As of December 31, 2000 and 2001, the Company has available, for tax
purposes, unused net operating loss carryforwards of approximately $5.0 million
and $12.6 million which will expire between 2018 and 2021. As of December 31,
2001, the Company had aggregate permanent differences of $20.2 million including
$18.6 million for the license acquired in connection with the merger. Future
ownership changes may limit the Company's ability to utilize these net operating
loss carryforwards as defined by the federal and state tax codes.
F-21
PROSPECTUS , 2002
[LOGO]
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
5,600,000 Shares
Common Stock
Thomas Weisel Partners LLC
Wells Fargo Securities, LLC
Jefferies & Company, Inc.
- -------------------------------------------------------------------------------
Neither we nor any of the underwriters have authorized anyone to provide
information different from that contained in this prospectus. When you make a
decision about whether to invest in our common stock, you should not rely upon
any information other than the information in this prospectus. Neither the
delivery of this prospectus nor the sale of our common stock means that
information contained in this prospectus is correct after the date of this
prospectus. This prospectus is not an offer to sell or solicitation of an offer
to buy these shares of common stock in any circumstances under which the offer
or solicitation is unlawful.
Until , 2002 (25 days after commencement of this offering), all
dealers that buy, sell or trade these shares of common stock, whether or not
participating in this offering, may be required to deliver a prospectus. This is
in addition to the dealers' obligation to deliver a prospectus when acting as
underwriters and with respect to their unsold allotments or subscriptions.
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 13. Other Expenses of Issuance and Distribution
The following table sets forth the costs and expenses, other than
underwriting discounts and commissions, payable by IDDS in connection with the
sale of the common stock being registered hereby. All the amounts shown are
estimated, except the SEC registration fee, the NASD filing fee and the Nasdaq
National Market listing fee.
SEC Registration Fee .............................................. $ 16,491
NASD Filing Fee ................................................... 7,400
Nasdaq National Market Listing Fee ................................ 100,000
Printing Expenses ................................................. 350,000
Legal Fees and Expenses ........................................... 600,000
Accounting Fees and Expenses ...................................... 700,000
Blue Sky Expenses and Counsel Fees ................................ 10,000
Transfer Agent and Registrar Fees ................................. 15,000
Miscellaneous ..................................................... 201,109
Total ............................................................. $2,000,000
==========
Item 14. Indemnification of Directors and Officers
The Registrant's Amended and Restated Certificate of Incorporation in effect
as of the date hereof (the "Certificate") provides that, except to the extent
prohibited by the Delaware General Corporation Law, as amended (the "DGCL"), the
Registrant's directors shall not be personally liable to the Registrant or its
stockholders for monetary damages for any breach of fiduciary duty as directors
of the Registrant. Under the DGCL, the directors have a fiduciary duty to the
Registrant which is not eliminated by this provision of the Certificate and, in
appropriate circumstances, equitable remedies such as injunctive or other forms
of nonmonetary relief will remain available. In addition, each director will
continue to be subject to liability under the DGCL for breach of the director's
duty of loyalty to the Registrant, for acts or omissions which are found by a
court of competent jurisdiction to be not in good faith or involving intentional
misconduct, for knowing violations of law, for actions leading to improper
personal benefit to the director, and for payment of dividends or approval of
stock repurchases or redemptions that are prohibited by the DGCL. This provision
also does not affect the directors' responsibilities under any other laws, such
as the Federal securities laws or state or Federal environmental laws. The
Registrant has obtained liability insurance its officers and directors.
Section 145 of the DGCL empowers a corporation to indemnify its directors and
officers and to purchase insurance with respect to liability arising out of
their capacity or status as directors and officers, provided that this provision
shall not eliminate or limit the liability of a director: (i) for any breach of
the director's duty of loyalty to the corporation or its stockholders, (ii) for
acts or omissions not in good faith or which involve intentional misconduct or a
knowing violation of law, (iii) arising under Section 174 of the DGCL, or (iv)
for any transaction from which the director derived an improper personal
benefit. The DGCL provides further that the indemnification permitted thereunder
shall not be deemed exclusive of any other rights to which the directors and
officers may be entitled under the corporation's bylaws, any agreement, a vote
of stockholders or otherwise. The Certificate eliminates the personal liability
of directors to the fullest extent permitted by Section 102(b)(7) of the DGCL
and provides that the Registrant may fully indemnify any person who was or is a
party or is threatened to be made a party to any threatened, pending or
completed action, suit or proceeding (whether civil, criminal, administrative or
investigative) by reason of the fact that such person is or was a director or
officer of the Registrant, or is or was serving at the request of the Registrant
as a director or officer of another corporation, partnership, joint venture,
trust, employee benefit plan or other enterprise, against expenses (including
attorney's fees), judgments, fines and amounts paid in settlement actually and
reasonably incurred by such person in connection with such action, suit or
proceeding.
II-1
At present, there is no pending litigation or proceeding involving any
director, officer, employee or agent as to which indemnification will be
required or permitted under the Certificate. The Registrant is not aware of any
threatened litigation or proceeding that may result in a claim for such
indemnification.
Item 15. Recent Sales of Unregistered Securities
Since its inception, the Registrant, including its predecessor corporation
Pain Management, Inc., has issued and sold unregistered securities in the
amounts, at the times, and for the aggregate amounts of consideration listed as
follows:
1. In February 1998, Pain Management, Inc. issued to its founders
5,000,000 shares of common stock for an aggregate purchase price of
$5,000 pursuant to stock purchase agreements between Pain Management
and the founders.
2. In June 2000, the Registrant issued to its founders 5,080,717 shares
of common stock for an aggregate purchase price of $5,000 pursuant to
stock purchase agreements between the Registrant and the founders.
3. In September 1999, Pain Management raised approximately $1.04
million by issuing notes payable and warrants to investors. The
notes accrued interest at 12% per annum for the first twelve months
and 15% per annum thereafter. In connection with the notes, Pain
Management issued warrants to purchase 260,000 shares of common
stock at an exercise price of $0.01 per share to noteholders. In
November 2000, the principal and interest on the notes representing
approximately $1,238,000 was repaid.
4. In September 2000, in connection with a merger with Pain Management,
Inc., the Registrant issued 4,648,220 shares of common stock in
exchange for 5,000,000 shares of Pain Management. In addition, the
Registrant exchanged warrants to purchase 260,000 shares of Pain
Management common stock with warrants to purchase 231,859 shares of
the Registrant's common stock. In September 2001, warrants to purchase
15,606 shares of common stock were exercised.
5. During 1999, a consultant was issued 189,496 shares of the
Registrant's common stock for services rendered. Also in 1999, three
consultants received warrants to purchase a total of 200,642 shares
of the Registrant's common stock at an exercise price of
approximately $0.001. In 2000, warrants to purchase all of these
shares were exercised. In 2000, a consultant received warrants to
purchase 15,242 shares of the Registrant's common stock at an
exercise price of approximately $0.001. All of the warrants were
exercised in 2001.
6. In September 2000, the Registrant sold 160.565 units ("Units") to
investors at a per Unit price of $100,000. Each Unit consisted of
25,000 shares of series A convertible preferred stock (convertible
into 25,404 shares of common stock) and 2,540 warrants. Each warrant
entitles the holder to purchase one share of the Registrant's common
stock at an exercise price of $3.94 per share. The Registrant sold,
in the aggregate, 4,014,125 shares of series A convertible preferred
stock (convertible into 4,078,927 shares of common stock) and
warrants to purchase 407,893 shares of common stock for net proceeds
of $14,898,928.
7. As partial consideration for the sale of the Units, an option to
purchase 15.83 units was issued to members of the firm responsible for
obtaining the financing. Each Unit entitles the holder to purchase
25,000 shares of series A convertible preferred stock (convertible
into 25,404 shares of common stock) at a price of $4.40 per share and
warrants to purchase 2,540 shares of common stock at an exercise price
of $3.94 per share.
8. The Registrant granted stock options to purchase 1,365,882, 1,219 and
406,456 shares of common stock at exercise prices of $3.94,
approximately $0.01 and $5.46 respectively, per share to employees,
consultants and directors.
9. In December 2001, the Registrant sold 989,991 shares of series B
convertible preferred stock for net proceeds of $5,020,032.
No underwriters were engaged in connection with the foregoing sales of
securities. Such sales of common stock, Preferred Stock and warrants were made
in reliance upon the exemption from registration set forth in Section 4(2) of
the Securities Act of 1933 and Rule 506 of Regulation D promulgated thereunder
for
II-2
transactions not involving a public offering, and all purchasers were accredited
investors as such term is defined in Rule 501(a) of Regulation D. Issuances of
options to the Registrant's employees, directors and consultants were made
pursuant to Rule 701 promulgated under the Securities Act of 1933.
Item 16. Exhibits and Financial Statement Schedules
(a) Exhibit Index
No. Description
- ------ -----------
1.1 Underwriting Agreement*
2.1 Agreement and Plan of Merger between Innovative Drug Delivery Systems, Inc. and Pain Management, Inc. dated as of
August 14, 2000 (schedules and exhibits omitted)**
3.1 Form of Amended and Restated Certificate of Incorporation*
3.2 Form of Amended and Restated Bylaws*
4.1 Securities Issuance and Registration Rights Agreement, dated September 22, 2000, between Innovative Drug Delivery
Systems, Inc. and West Pharmaceutical Services, Inc.**
4.2 Stockholders Agreement, dated February 25, 1998, between Pain Management, Inc., Dr. Stuart Weg, Dr. Lindsay
Rosenwald, Herbert Brotspies and Calgar & Associates.**+
4.3 2000 Omnibus Stock Incentive Plan, as amended*
4.4 Employee Stock Purchase Plan*
4.5 Form of Common Stock Warrant for Innovative Drug Delivery Systems, Inc.**
4.6 Form of Common Stock Warrant for Pain Management, Inc.**
4.7 Form of Innovative Drug Delivery Systems, Inc. Stock Purchase Agreement**
4.8 Form of Series A Preferred Stock Subscription Agreement
4.9 Form of Series B Preferred Stock Subscription Agreement
4.10 Specimen Stock Certificate*
5.1 Opinion of Brobeck, Phleger & Harrison LLP*
10.1 Employment Agreement, dated December 26, 2001, between Innovative Drug Delivery Systems, Inc. and Dr. Leonard
Firestone
10.2 License Agreement, dated February 25, 1998, between Pain Management, Inc. and Dr. Stuart Weg+**
10.3 Confidentiality Agreement, dated August 24, 2000, between Innovative Drug Delivery Systems, Inc. and West
Pharmaceutical Services, Inc.**
10.4 License Agreement, dated August 25, 2000, between Innovative Drug Delivery Systems, Inc. and West Pharmaceutical
Services, Inc.+**
10.5 Letter Agreement, dated September 22, 2000, between Innovative Drug Delivery Systems, Inc. and West Pharmaceutical
Services, Inc.+**
10.6 Development Milestone and Option Agreement, dated September 22, 2000, between Innovative Drug Delivery Systems, Inc.
and West Pharmaceutical Services, Inc.+**
10.7 Clinical Manufacturing Agreement, dated September 22, 2000, between Innovative Drug Delivery Systems, Inc. and West
Pharmaceutical Services, Inc.+**
10.8 Research and Development and Option Agreement, dated October 24, 2000, between Innovative Drug Delivery Systems, Inc.
and West Pharmaceutical Services, Inc.+**
10.9 Option Agreement, dated September 22, 2000, between Innovative Drug Delivery Systems, Inc. and West Pharmaceutical
Services, Inc.+**
10.10 Letter Agreement, dated October 9, 2001, between Innovative Drug Delivery Systems, Inc. and West Pharmaceutical
Services, Inc.+**
10.11 License Agreement, dated December 14, 2001, among Innovative Drug Delivery Systems, Inc. and Shimoda Biotech
(Proprietary) Ltd., Farmarc N.A.N.V. (Netherlands Antilles) and Farmarc Netherlands B.V. (Registration No. 2807216)+
10.12 Services Agreement, dated December 31, 2001, among Paramount Capital Investments, LLC, Paramount Capital, Inc.,
Paramount Capital Asset Management, Inc. and Innovative Drug Delivery Systems
10.13 Intellectual Property Letter Agreement, dated December 31, 2001 among Paramount Capital Investments, LLC, Paramount
Capital, Inc., Paramount Capital Asset Management, Inc. and Innovative Drug Delivery Systems
23.1 Consent of Brobeck, Phleger & Harrison LLP (included in Exhibit 5.1)
23.2 Consent of PricewaterhouseCoopers LLP
24.1 Power of attorney (on signature page)
- ---------------
* To be filed by amendment.
** Previously filed.
+ Confidential treatment requested for certain portions of this agreement.
II-3
(b) Financial Statement Schedules. The following financial statement
schedules are filed herewith:
None.
All other schedules are omitted because they are not required or are not
applicable or the information is included in the financial statements or notes
thereto.
Item 17. Undertakings
The undersigned Registrant hereby undertakes to provide to the underwriters
at the closing specified in the underwriting agreement certificates in such
denominations and registered in such names as required by the underwriters to
permit prompt delivery to each purchaser.
Insofar as indemnification for liabilities arising under the Securities Act
of 1933 may be permitted to directors, officers and controlling persons of the
Registrant pursuant to the provisions described under Item 14 above, or
otherwise, the Registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as
expressed in the Securities Act of 1933, and is, therefore, unenforceable. In
the event that a claim for indemnification against such liabilities (other than
the payment by the Registrant of expenses incurred or paid by a director,
officer, or controlling person of the Registrant in the successful defense of
any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the
Registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction
the question of whether such indemnification by it is against public policy as
expressed in the Securities Act of 1933 and will be governed by the final
adjudication of such issue.
The undersigned Registrant hereby undertakes that:
(1) For purposes of determining any liability under the Securities Act of
1933, the information omitted from the form of prospectus filed as part of
this registration statement in reliance upon Rule 430A and contained in a
form of prospectus filed by the Registrant pursuant to Rule 424 (b) (1) or
(4) or 497 (h) under the Securities Act of 1933 shall be deemed to be part of
this registration statement as of the time it was declared effective.
(2) For the purpose of determining any liability under the Securities Act
of 1933, each post-effective amendment that contains a form of prospectus
shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be
deemed to be the initial bona fide offering thereof.
II-4
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the
Registrant has duly caused this Amendment No. 1 to the Registration Statement to
be signed on its behalf by the undersigned, thereunto duly authorized, in the
City of New York, State of New York, on March 12, 2002.
INNOVATIVE DRUG DELIVERY SYSTEMS, INC.
By: /s/ LEONARD L. FIRESTONE
----------------------------------------
Leonard L. Firestone
Chief Executive Officer and Director
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears
below hereby severally constitutes and appoints Leonard Firestone and Douglas
Hamilton and each of them individually, with full power of substitution and
resubstitution, his or her true and lawful attorney-in fact and agent, with full
powers to each of them to sign for us, in our names and in the capacities
indicated below, the Registration Statement on Form S-1 filed with the
Securities and Exchange Commission, and any and all amendments to said
Registration Statement (including post-effective amendments), and any
registration statement filed pursuant to Rule 462(b) under the Securities Act of
1933, as amended, in connection with the registration under the Securities Act
of 1933, as amended, of equity securities of the Registrant, and to file or
cause to be filed the same, with all exhibits thereto and other documents in
connection therewith, with the Securities and Exchange Commission, granting unto
said attorneys, and each of them, full power and authority to do and perform
each and every act and thing requisite and necessary to be done in connection
therewith, as fully to all intents and purposes as each of them might or could
do in person, and hereby ratifying and confirming all that said attorneys, and
each of them, or their substitute or substitutes, shall do or cause to be done
by virtue of this Power of Attorney. This power of attorney may be executed in
counterparts and all capacities to sign any and all amendments.
Pursuant to the requirements of the Securities Act of 1933, as amended, this
Amendment No. 1 to the Registration Statement has been signed below by the
following persons in the capacities and on the dates indicated.
Signature Title(s) Date
--------- -------- ----
/s/ LEONARD L. FIRESTONE Chief Executive Officer and Director (Principal March 12, 2002
- ------------------------ Executive Officer)
Leonard L. Firestone
/s/ DOUGLAS A. HAMILTON Chief Financial Officer, Secretary and Treasurer March 12, 2002
- ------------------------ (Principal Financial and Principal Accounting
Douglas A. Hamilton Officer)
* President and Director March 12, 2002
- ------------------------
Fred H. Mermelstein
* Chairman of the Board of Directors March 12, 2002
- ------------------------
Mark C. Rogers
* Director March 12, 2002
- ------------------------
Michael Weiser
II-5
Signature Title(s) Date
--------- -------- ----
* Director March 12, 2002
- ----------------------------
Edward Miller
* Director March 12, 2002
- ---------------------------
Mark S. Siegel
* Director March 12, 2002
- ---------------------------
Peter M. Kash
/s/ DOUGLAS G. WATSON Director Designee March 12, 2002
- ---------------------------
Douglas G. Watson
*By: /s/ LEONARD L. FIRESTONE
---------------------------------
Leonard L. Firestone
As Attorney-In-Fact
II-6
EXHIBIT INDEX
Exhibit
Number Description
- ------ -----------
1.1 Underwriting Agreement*
2.1 Agreement and Plan of Merger between Innovative Drug Delivery Systems, Inc. and Pain Management, Inc. dated as of
August 14, 2000 (schedules and exhibits omitted)**
3.1 Form of Amended and Restated Certificate of Incorporation*
3.2 Form of Amended and Restated Bylaws*
4.1 Securities Issuance and Registration Rights Agreement, dated September 22, 2000, between Innovative Drug Delivery
Systems, Inc. and West Pharmaceutical Services, Inc.**
4.2 Stockholders Agreement, dated February 25, 1998, between Pain Management, Inc., Dr. Stuart Weg, Dr. Lindsay
Rosenwald, Herbert Brotspies and Calgar & Associates.+**
4.3 2000 Omnibus Stock Incentive Plan, as amended*
4.4 Employee Stock Purchase Plan*
4.5 Form of Common Stock Warrant for Innovative Drug Delivery Systems, Inc.**
4.6 Form of Common Stock Warrant for Pain Management, Inc.**
4.7 Form of Innovative Drug Delivery Systems, Inc. Stock Purchase Agreement**
4.8 Form of Series A Preferred Stock Subscription Agreement
4.9 Form of Series B Preferred Stock Subscription Agreement
4.10 Specimen Stock Certificate*
5.1 Opinion of Brobeck, Phleger & Harrison LLP*
10.1 Employment Agreement, dated December 26, 2001, between Innovative Drug Delivery Systems, Inc. and Dr. Leonard
Firestone
10.2 License Agreement, dated February 25, 1998, between Pain Management, Inc. and Dr. Stuart Weg+**
10.3 Confidentiality Agreement, dated August 24, 2000, between Innovative Drug Delivery Systems, Inc. and West
Pharmaceutical Services, Inc.**
10.4 License Agreement, dated August 25, 2000, between Innovative Drug Delivery Systems, Inc. and West Pharmaceutical
Services, Inc.+**
10.5 Letter Agreement, dated September 22, 2000, between Innovative Drug Delivery Systems, Inc. and West Pharmaceutical
Services, Inc.+**
10.6 Development Milestone and Option Agreement, dated September 22, 2000, between Innovative Drug Delivery Systems, Inc.
and West Pharmaceutical Services, Inc.+**
10.7 Clinical Manufacturing Agreement, dated September 22, 2000, between Innovative Drug Delivery Systems, Inc. and West
Pharmaceutical Services, Inc.+**
10.8 Research and Development and Option Agreement, dated October 24, 2000, between Innovative Drug Delivery Systems, Inc.
and West Pharmaceutical Services, Inc.+**
10.9 Option Agreement, dated September 22, 2000, between Innovative Drug Delivery Systems, Inc. and West Pharmaceutical
Services, Inc.+**
10.10 Letter Agreement, dated October 9, 2001, between Innovative Drug Delivery Systems, Inc. and West Pharmaceutical
Services, Inc.+**
10.11 License Agreement, dated December 14, 2001, among Innovative Drug Delivery Systems, Inc. and Shimoda Biotech
(Proprietary) Ltd., Farmarc N.A.N.V. (Netherlands Antilles) and Farmarc Netherlands B.V. (Registration No. 2807216)+
10.12 Services Agreement, dated December 31, 2001, among Paramount Capital Investments, LLC, Paramount Capital, Inc.,
Paramount Capital Asset Management, Inc. and Innovative Drug Delivery Systems
10.13 Intellectual Property Letter Agreement, dated December 31, 2001 among Paramount Capital Investments, LLC, Paramount
Capital, Inc., Paramount Capital Asset Management, Inc. and Innovative Drug Delivery Systems
23.1 Consent of Brobeck, Phleger & Harrison LLP (included in Exhibit 5.1)
23.2 Consent of PricewaterhouseCoopers LLP
24.1 Power of attorney (on signature page)
- ---------------
* To be filed by amendment.
** Previously filed.
+ Confidential treatment requested for certain portions of this agreement.